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Hepcidin-25 is regarded as the master regulator of iron homeostasis. Three N-truncated 
isoforms of hepcidin-25 have been identified in human serum; hepcidin-20, -22, and -24, 
although information is scant as to the serum concentrations of these isoforms.  
A liquid chromatography-high resolution-mass spectrometry (LC-HR-MS) assay was 
developed for the simultaneous quantitation of hepcidin isoforms in human serum. Serum (200 
µL) was mixed with aqueous formic acid (600 µL), and the supernatant loaded onto a 96-well-
SPE-plate. Eluted sample (70 µL) was diluted with deionised water (60 µL) and analysed using 
LC–HR–MS. Samples previously analysed by a published LC-MS/MS assay were analysed for 
method comparison. All hepcidin isoforms were quantified in samples from healthy volunteers 
as controls, and patients with hereditary haemochromatosis (HH), non-alcoholic fatty liver 
disease (NAFLD), iron deficient anaemia (IDA), anaemia of chronic disease (ACD), and sickle 
cell anaemia (SCA). Samples were also analysed from individuals with chronic kidney disease 
(CKD) not requiring haemodialysis, and those pre- and post-haemodialysis.  
Intra-/inter-assay accuracy and precision were acceptable, calibration was linear (R2 > 
0.90, all analytes), and the LLoQ was 1 µg/L (all analytes). There was a good correlation for 
hepcidin-25 to a published LC-MS/MS assay (y = 0.85x -3.2, R2 = 0.96). Median (range) 
hepcidin-25 concentrations in controls, and individuals with IDA, SCA, HH, ACD and sepsis 
were: 8 (1–31), <1 (<1–2), <1 (<1–10), 2 (<1–15), 60 (10–213), and 92 (11–216) µg/L, 
respectively. Hepcidin-20, -22, or -24 were not detected in any control sample, but were 
detected in 30–100 % of all samples at 10–20 % of the hepcidin-25 concentration. Following 
haemodialysis, all hepcidin isoforms declined by some 35–50 %. Hepcidin-25 was most strongly 
correlated to hepcidin-24, and less so to hepcidin-22 and -20, in all disease states. 
The developed method was applicable for clinical use. However, further controlled 
studies are required to fully evaluate the role of hepcidin-20, -22, and -24 measurement in a 
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Iron is an essential element that is required for adequate erythropoietic function, oxidative 
metabolism, and cellular immune response. Even though iron is a vital element, free or ‘non-
protein bound’ iron can be extremely toxic, causing damage to cellular membranes, proteins, 
and DNA through the formation of reactive oxygen species via the Fenton reaction (von 
Drygalski & Adamson, 2013). Therefore, iron uptake, transport and storage are highly regulated. 
The regulation of iron metabolism is mediated by several complex pathways, and although the 
fundamental principles are well understood, the exact mechanisms of all pathways remain 
unsolved. In 2000, hepcidin-25, a peptide hormone, was identified in human serum (Krause et 
al., 2000) and urine (Park et al., 2001), and is now considered to be the master regulator of iron 
homeostasis. The identification and study of hepcidin-25 has greatly improved our 
understanding of the physiology and pathophysiology of iron homeostasis, in-part initially 
through the use of immunochemical based methods. A number of promising areas have been 
suggested for the measurement of hepcidin-25, these include screening for hereditary 
haemochromatosis (HH) and the treatment of iron deficiency or overload with hepcidin-25 
antagonists or agonists. The development of accurate, precise, and selective analytical 
methods for the measurement of hepcidin-25, however has been challenging (Kroot et al., 2009; 
Kroot et al., 2012; van der Vorm et al., 2016) but is crucial if hepcidin-25 measurement is to be 




Non-haem bound (NHB) iron is absorbed from the proximal duodenum. In this acidic 
environment, NHB iron is maintained in the ferric (Fe3+) state, but is reduced to ferrous iron 
(Fe2+) by the ferrireductase duodenal cytochrome B (DCYTB, Figure 1-1, McKie et al., 2001), 
where it is transported into the enterocyte via the divalent metal-ion transporter-1 (DMT-1) 
(Gunshin et al., 1997). Haem bound (HB) iron is transported across the apical membrane via 
haem carrier protein-1 (HCP-1) (Shayeghi et al., 2005). Once in the enterocyte NHB iron is 
either bound to ferritin - the primary iron storage protein that can store up to 4000 atoms of iron 
per molecule, or exported from the cell via ferroportin-1 (FP-1) (Donovan et al., 2000; McKie et 
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al., 2000). Once HB iron is within the cell, it is processed by haemoxygenase-1 (HO-1) to 
liberate Fe2+. This is then either bound to ferritin or transported across the basolateral 
membrane by FP-1. Iron released through FP-1 is re-oxidised to the ferric form by the 
membrane-bound ferroxidase; hephaestin (Fuqua et al., 2014; Vulpe et al., 1999). Once in the 
plasma, iron is transported by transferrin, a single chain polypeptide produced in the liver that 
can bind two molecules of ferric iron. 
 
 
Figure 1-1. Schematic showing absorption of haem and non-haem bound iron by 
enterocytes. (DMT-1: divalent metal-ion transporter-1; HCP-1: haem carrier protein 1; HO-



















1.2.2 Transport and Erythropoiesis 
Once in circulation, most iron bound transferrin is transported to the bone marrow for use in 
developing erythroid cells. At the cell membrane, the iron-transferrin complex binds to 
Transferrin Receptor-1 (TfR1), and enters the cell via clathrin-coated pits to form clathrin-coated 
endosomes (siderosomes). Within the cell, following the removal of clathrin, the siderosomes 
are acidified by an ATP-dependent proton pump (V-type ATPase). This change in pH alters the 
structure of transferrin and TfR1, releasing Fe3+. Ferric iron is then reduced to Fe2+ by the 
ferrireductase STEAP (six transmembrane epithelial antigen of the prostate) proteins and 
transported to the cytoplasm via DMT-1 (Dautry-Varsat et al., 1983, Ohgami et al., 2005, 2006). 
Once in the cytoplasm, the released iron is transported to mitochondria, where it is incorporated 
into haemoglobin. Once the erythrocyte is fully mature and ready for release into the circulation, 
the transferrin protein is released back into circulation, and TfR1 is released back to the cell 
membrane. At the cell membrane TfR1 is cleaved by proteases and is released into the plasma 
as soluble TFR1 protein (STfR) (Hentze et al., 2010). Therefore, the concentration of STfR in 
the plasma reflects the iron status of the patient, and total erythropoetic activity. 
 
1.2.3 Recycling and Storage 
Macrophages play an important role in iron recycling, as senescent erythrocytes are 
phagocytosed by macrophages present in the reticuloendothelial system. While in the 
macrophage, ferrous iron is released into the cytosol by HRG1 (Heme-responsive gene 1 
protein homolog) where haem catabolism takes place (White et al., 2013). Iron is then exported 
from macrophages to transferrin by FP-1 (Hentze et al., 2010). Macrophages are also an 
important store for iron. In the cell, iron can either be stored as ferritin in the cytosol, or as 
haemosiderin. When iron is stored within macrophages it is relatively inert, that is, reactive 
oxygen species are not formed and oxidative damage does not occur. Usually, storage of iron 
as haemosiderin within macrophages is minimal, but can increase dramatically during iron 
overload. The liver is also another main storage organ for iron, and during iron overload, 
reactive oxygen species are generated leading to lipid peroxidation, cell necrosis, and 





1.3.1 Synthesis and structure 
Hepcidin-25, is a 25 amino acid polypeptide that is primarily synthesised within the liver as an 
initial 84 amino acid ‘prepropeptide’ that is encoded by the hepcidin antimicrobial peptide gene 
(HAMP), also known as liver expressed antimicrobial peptide (LEAP). The first 24 amino acids 
contain an endoplasmic reticulum targeting signal, and cleavage of the 84 amino acid 
prepropeptide produces a 60 amino acid long ‘prohepcidin’. Prohepcidin is then further cleaved 
by prohormone convertase furin to produce hepcidin-25 (Figure 1-2; Macdougall et al., 2010; 




Figure 1-2. Amino acid sequence of hepcidin-25, with cysteine bonds indicated 
(1 = C-terminus, 25 = N-terminus). 
 
Loss of amino acids from the N-terminus of hepcidin-25 can result in the formation of hepcidin-
20 (20 amino acids), hepcidin-22 (22 amino acids) and hepcidin-24 (24 amino acids), all of 
which have been identified in human urine, plasma or serum (Addo et al., 2016; Campostrini et 
al., 2012; Laarakkers et al., 2013; Moe et al., 2013; Rochat et al., 2013). Other N-truncated 
isoforms; hepcidin-19 (19 amino acids), hepcidin-21 (21 amino acids), and hepcidin-23 (23 
amino acids) have also been reported in human serum (Moe et al., 2013). This finding, 
however, has not been substantiated by other investigators, and it remains to be ascertained 
whether these were an artefact of sample storage and/or preparation prior to analysis. 
Little is known as to the origin of the smaller N-truncated hepcidin isoforms. It has been 
suggested that calcium-independent tissue activity in pancreas extracts may lead to the N-
terminal processing of hepcidin-25 to hepcidin-22, and that dipeptidylpeptidase-4 maybe 





Ganz, 2008). However, evidence is scarce and these isoforms of hepcidin may be ex-vivo 
artefacts of hepcidin-25 degradation during storage or sample preparation. 
All hepcidins have a distorted beta-sheet with a hairpin loop that is stabilised by four 
disulphide bridges and hydrogen bonds (Figure 1-3). All hepcidins are weakly basic with an 
equal number of hydrophobic, hydrophilic and charged amino acids within their sequences 
(Table 1.1), giving rise to an amphipathic structure containing both hydrophilic and hydrophobic 
regions, with a tendency to adhere to laboratory glass/plastic ware, and for the peptide to 
aggregate (Malyszko, 2009).  
 
Figure 1-3. Molecular structure of hepcidin-25 [Distorted beta sheets (grey arrows), 
peptide sequence (grey), disulphide bonds (yellow), charged residues: positive (blue) 
and negative (red) (Jordan et al., 2009)].  
 
 
Table 1.1. Some physiochemical properties of hepcidin isoforms (isoelectric point data 






(% of sequence) 
Hydrophilic  
amino acids 
(% of sequence) 
Charged 
amino acids 
(% of sequence) 
Hepcidin-19 8.53 16 21 21 
Hepcidin-20 8.53 25 25 25 
Hepcidin-21 8.60 24 19 19 
Hepcidin-22 8.53 27 18 18 
Hepcidin-23 8.53 26 22 22 
Hepcidin-24 8.51 25 25 21 
Hepcidin-25 8.22 24 28 24 
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1.3.2 Function and Regulation 
Hepcidin-25 binds to, and causes the internalisation and proteolysis of FP-1 on the membranes 
of macrophages, enterocytes and hepatocytes (Nemeth et al., 2004). This causes increased 
intracellular iron stores, decreased dietary iron absorption, and hence decreased circulating iron 
concentrations (Kroot et al., 2011; Rizvi & Schoen, 2011). In-vitro studies have shown that 
hepcidin-20, -22 and hepcidin-24 have little, if any activity at the FP-1 receptor, and therefore 
are unlikely to have a significant effect on iron metabolism (Laarakkers et al., 2013; Nemeth et 
al., 2006). However, hepcidin-20, as well as hepcidin-25 have been shown to have bactericidal 
properties, although hepcidin-20 has a lower activity than hepcidin-25. The exact antibacterial 
mechanism is currently unknown, but may involve binding of copper within bacteria (Ho et al., 
2013; Lombardi et al., 2015; Maisetta et al., 2010). 
Several processes are involved in regulating plasma hepcidin-25 concentrations - 
separated into positive and negative regulators. Hepcidin-25 synthesis, and subsequent 
increases or decreases in plasma iron occur within a few hours of exposure to appropriate 
stimuli. Studies in mice have shown that following intraperitoneal injection of synthetic hepcidin-
25, serum iron concentrations declined by some 3-fold (Rivera et al., 2005). Positive regulators 
that increase hepcidin-25 plasma concentrations are primarily infection, inflammation and an 
increase in iron stores. During inflammation, the inflammatory cytokine IL-6 (interleukin-6) 
induces hepcidin synthesis via the janus kinase/signal transducer and activator of transcription-
3 pathway (Nemeth et al., 2004a). It has been suggested that this increase in plasma hepcidin-
25 in response to infection and inflammation may have evolved as a host response to infection, 
where low plasma iron could slow the growth of micro-organisms (Fung & Nemeth, 2013).  
A principal mechanism by which hepcidin-25 expression is stimulated is through the 
BMP-6-HJV-SMAD signalling pathway (Figure 1-4). With increasing iron stores, bone 
morphogenetic proteins (BMPs) form complexes with type I and II BMP receptors within 
hepatocytes, resulting in phosphorylation of SMAD proteins (Figure 1-4; Babitt et al., 2006; 
Babitt et al., 2007). The phosphorylated SMAD protein forms a complex with SMAD4, activating 
transcription of the HAMP gene. Other iron sensors such as transferrin receptors I and II (TFRI 
and II) are also involved in regulating hepcidin-25 in response to raised plasma iron, and the 
haemochromatosis protein (HFE) has been suggested to act as a shuttle between transferrin 
receptors, although the precise mechanism by which these proteins act is poorly understood 
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(Poli et al., 2014). Haemojuvelin (HJV) is a member of the repulsive guidance molecule family, 
encoded by the HFE-2 gene and exists in two forms, a cell membrane bound form and a soluble 
form (S-HJV). Membrane bound HJV is a co-receptor for BMP receptors and acts with BMP-6 to 
stimulate hepcidin-25 expression via the SMAD pathway within hepatocytes (Babitt et al., 2006; 
Casanovas et al., 2009). Conversely S-HJV, which is formed from the cleavage of HJV by 
transmembrane serine protease matriptase-2 encoded by the TMPRSS6 gene, binds to and 




Figure 1-4. Schematic showing proposed roles of iron stores in hepcidin regulation 
(adapted from Babitt and Lin, 2010). (Tf-Fe: transferrin-iron complex; S-HJV: soluble 
haemojuvelin; HJV: haemojuvelin; BMP: bone morphogenetic protein; TfR1/2: transferrin 
receptor 1/2; MAPK: mitogen-activated protein kinase).  
 
Down-regulation of hepcidin-25 synthesis causes a release of stored iron and an increase in 



















deficiency, and increased erythropoietic activity. Hypoxia is a potent inhibitor of hepcidin-25 
production and, although the exact mechanism has not been fully elucidated, it is thought to be 
related to the hypoxia inducing factor pathway (Liu et al., 2012). Regulation of hepcidin-25 
production during iron-deficiency occurs via the BMP-6-HJV-SMAD signalling pathway 
described above, although the mechanism by which erythropoiesis regulates hepcidin-25 
expression is poorly understood. However, recently erythroferrone, a member of the 
C1q/tumour necrosis factor-related protein family, which is expressed from erythroblasts in 
response to erythropoietin, has been suggested to be a key regulator (Kautz et al., 2014; 
Pasricha et al., 2016; Ganz et al., 2017). Other proteins such as growth/differentiation factor 15 
(GDF15) and Twisted Gastrulation BMP Signalling Modulator 1 (TWSG1) are also released 
from erythroid pre-cursors, and are thought to inhibit the BMP-6-HJV-SMAD signalling pathway 
by an unknown mechanism (Hentze et al., 2010). 
 
1.3.3 Hepcidin Kinetics 
Hepcidin-25 has been reported to bind to α-2-macroglobulin, and to a lesser extent albumin, 
with only 11 % of circulating hepcidin-25 non-protein bound (Peslova et al., 2009); although 
another study has reported that less than 3 % of circulating hepcidin is protein-bound (Itkonen 
et al., 2012). It is not clear whether binding of hepcidin-25 to plasma proteins affects its 
functional properties. The clearance of hepcidin-25 is thought to occur via degradation with FP-
1 at its site of action, followed by excretion via the kidneys. It is also thought that non-protein 
bound hepcidin-25 may be filtered at the glomerulus, although fractional excretion rates of only 
up to 5 % have been reported (Kroot et al., 2011). Nothing is known as to the degree of protein 
binding of the other hepcidin-25 isoforms, but hepcidin-20, -22, and -24 have all been identified 
in urine. 
Concentrations of hepcidin-25 in the plasma and serum of healthy individuals have 
been extensively studied. In one of the largest studies (Galesloot et al., 2011), median serum 
hepcidin-25 concentrations of 22 (95 % CI; 17–65) and 19 (95 % CI; 1–65) µg/L for males (N = 
1066) and females (N = 882), respectively, were reported. This study measured hepcidin-25 
using a competitive enzyme-linked immunosorbent assay (ELISA) and it should be borne in 
mind that there is considerable variability in the concentrations of hepcidin-25 measured 
depending on the methodology used (van der Vorm et al., 2016). Despite this, these ranges are 
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comparable to others that have been reported using immunochemical and mass spectrometric 
methods (Busbridge et al., 2009; Grebenchtchikov et al., 2009; Kroot et al., 2009a; Swinkels et 
al., 2008).  
Few studies have reported plasma or serum concentrations of other truncated isoforms 
of hepcidin-25. Mean serum hepcidin-20 concentrations in males (N = 706) and females (N = 
871) of 9.4 and 9.6 µg/L, respectively, from a general population using Surface Enhanced Laser 
Desorption Ionisation-Mass Spectrometry (SELDI-MS) have been reported (Campostrini et al., 
2012). However, hepcidin-20 was only detected (limit of detection: 1.6 µg/L) in some 50 % of 
samples. In 40 healthy volunteers, mean serum hepcidin-20, -22, and -24 concentrations of 2.6, 
0.97, and 12.4 µg/L, respectively, have been reported (Addo et al., 2016). Plasma and serum 
are in general used interchangeably, and broadly have shown to be comparable for hepcidin-25 
(Butterfield et al., 2010, Kobold et al., 2008), although a bias of some 24 % for hepcidin-25 
between human EDTA plasma and human serum has been reported (Lefebvre et al., 2015). 
Nothing has been reported as to the comparability of plasma and serum for other isoforms of 
hepcidin. 
 
1.4 Disorders of Iron Metabolism 
Disorders of iron metabolism can be broadly divided into two main groups; (i) disorders of iron 
deficiency (which can be functional or absolute), and (ii) disorders of iron storage. Both groups 
of which are associated with either hepcidin-25 deficiency or excess.  
 
1.4.1 Anaemia 
It has been estimated that some 25 % of the population has anaemia, defined as a haemoglobin 
concentration < 13, and < 12 g/dL in males and females, respectively (McLean et al., 2009). 
There are several causes of anaemia, but in infants and women of child bearing age, iron-
deficiency (ID) is the most frequent cause and occurs in 2–3 %, and 5 % of individuals in these 
groups, respectively (Vermeulen & Vermeersch, 2012). After iron deficient anaemia (IDA), 
anaemia of chronic disease (ACD) is the second most prevalent form of anaemia, and is very 
common in hospitalised patients (Weiss & Goodnough, 2005). In one hospital review, 65 % of 
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patients developed anaemia and of these, ACD accounted for 57 % (Wong & Intragumtornchai, 
2006).  
Treatment of IDA and ACD is very different, and hence requires appropriate diagnosis. 
In patients with IDA, addressing the underlying cause of iron deficiency and treatment with iron 
supplements is the usual course of action. However, in patients with ACD, oral iron is poorly 
absorbed and treating the underlying cause of the infection is the priority. In individuals with 
ACD, hepcidin-25 is raised, primarily due to increased inflammatory cytokines (in-particular IL-
6), preventing the absorption of dietary iron and cellular release. Individuals with ACD will have 
normal to raised ferritin concentrations, with appropriate iron stores, but low circulating plasma 
iron, and therefore reduced erythropoiesis. In contrast, in IDA, there are inadequate iron stores, 
for example caused by poor dietary intake, or excessive blood loss. These individuals would 
have low plasma hepcidin-25 concentrations. There are, however, individuals that have ACD 
with concomitant iron deficiency, and a suggested algorithm for the diagnosis of IDA, ACD/ID, 
and ACD is given in Figure 1-5. Anaemia is also common in patients with chronic kidney 
disease (CKD), in part due to reduced erythropoietin production, but also poor absorption of 
dietary iron and release from macrophages. This is thought to occur due to raised hepcidin-25 
concentrations present from infection and inflammation, which is common in this group of 




Figure 1-5. Suggested algorithm for the diagnosis of IDA, ACD/IDA, and ACD (modified 






(males < 13 g/dL, females < 12 g/dL) 
Transferrin saturation < 20 % 
Ferritin < 30 µg/L  












ACD & IDA ACD 
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Another group of anaemias are the ‘congenital iron-loading anaemias’. These include sickle cell 
anaemia (SCA), β-thalassemia, and congenital dyserythropoietic anaemia (CDA). In these 
anaemias, the diseased erythron dysregulates iron homeostasis via reduced hepcidin synthesis. 
SCA is relatively common in individuals of African descent, and is characterised by 
mutations in the gene encoding for the β-globulin sub-unit of haemoglobin (HBB). SCA is when 
an individual has 2 copies of haemoglobin S (HbS), whereas individuals with HbS and 
haemoglobin C (HbC) have a milder form of SCA. During a ‘sickle cell crisis’, erythrocytes 
become sickle shaped and haemolyse, therefore individuals with SCA are characterised by a 
chronic haemolytic anaemia, increased erythropoiesis, and a chronic inflammatory state (Kroot 
et al., 2009b). 
CDA is a rare disorder characterised by morphological abnormalities in erythroid pre-
cursor cells. There are 3 main types, of which CDA II is the most common with approximately 
370 cases identified worldwide (Iolascon et al., 2012). CDA II is caused by a mutation in the 
SEC23B gene, which encodes the coat protein complex II protein, causing bi- and multi-
nucleated erythroblasts, and therefore ineffective erythropoiesis, anaemia, and subsequent iron 
overload (Schwarz et al., 2009; Casanovas et al., 2011). 
 
1.4.2 Iron overload and haemochromatosis 
Iron overload can be caused by a number of factors one of which is liver disease such as 
alcoholic fatty liver disease or non-alcoholic fatty liver disease (NAFLD). In some populations 
(e.g. Asian) up to 40 % of all cases of iron overload have been attributed to non- 
haemochromatic causes (McDonald et al., 2013), and NAFLD is one of the most common 
causes of liver disease in the USA where it has been estimated that some 75 % of all chronic 
liver disease cases are due to NAFLD (Hassan et al., 2014). There are 4 main stages to 
NAFLD; (i) simple fatty liver (steatosis), (ii) non-alcoholic steatohepatitis (NASH), (iii) fibrosis, 
and (iv) cirrhosis. Individuals that are obese, have type 2 diabetes, high blood pressure, raised 
cholesterol, or smoke, are at increased risk of developing NAFLD. Individuals commonly 
present with fatigue together with metabolic syndrome (combination of diabetes, high blood 
pressure, and obesity), and increased hepatic iron is present - this is known as dysmetabolic 
iron overload syndrome (DIOS). Iron overload is associated with later stages of NAFLD, 
although the mechanism by which iron overload occurs is not clear (Britton et al., 2016). 
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Hepcidin-25 has been reported to be raised in these individuals in response to the iron overload 
present (Boga et al., 2015).   
Hereditary haemochromatosis (HH) is a common cause of iron overload in caucasian 
populations. Most individuals with HH have defects in the genes that encode proteins involved 
in the regulation of hepcidin-25 (i.e. HFE, TfR2, HJV). These individuals usually suffer from mild 
to moderate iron overload, and become symptomatic (and diagnosed) in adult-hood. However, 
in some rare forms of HH there are defects in the genes that directly encode for either FP-1 
(SLC40A1) or hepcidin-25 (HAMP). When mutations in the FP-1 gene are present, it is known 
as ‘ferroportin disease’. Individuals with mutations in this gene have severe iron overload that 
occurs at an earlier age than those individuals with mutations in the HFE gene, and are 
diagnosed in child hood or early adult-hood (20-30 years of age).  
The most common form of HH is HFE-related, particularly a G to A transition at 
nucleoside 845 which leads to a cysteine to tyrosine substitution at amino acid position 282 
(C282Y). Another common mutation is a C to G translation at nucleoside 187, leading to a 
histidine to aspartic acid substitution at amino acid position 63 (H63D). The substitution of 
cysteine to tyrosine at amino acid position 282 disrupts the interaction between HFE and β2-
microglobulin, causing intracellular sequestration of HFE. Individuals with this genotype are 
partially responsive to acute/chronic iron loading, but have markedly reduced synthesis of 
hepcidin-25, which is inappropriate to the overload of iron present. Conversely, the C to G 
transition at nucleoside 187 (H63D) does not disrupt binding of HFE with β2-microglobulin 
(Feder et al. 1997). Therefore, this mutation has little clinical significance with regards to iron 
overload.  
The prevalence of C282Y homozygosity has been suggested to be 1 in 200 individuals, 
although the penetrance of this genotype is only 5 % (Pietrangelo, 2015; Rossi & Jeffrey, 2004). 
C282Y heterozygosity alone is rarely associated with iron overload and other factors, such as 
diabetes, liver diseases, and alcohol abuse have been proposed as potential causes of iron 
overload in individuals with this genotype, although this is controversial (Aguilar-Martinez et al., 
2011). The H63D polymorphism is much more prevalent (1 in 7 individuals) than C282Y 
homozygosity but it has little clinical penetrance, and is usually associated with other conditions 




1.5 Clinical Applications of Hepcidin Measurement 
Several potential diagnostic and therapeutic applications for hepcidin-25 measurement have 
been suggested, although it is not yet clear whether there is any clinical rationale for the 
measurement of hepcidin-20, -22, or -24. 
One area that shows promise for hepcidin-25 measurement is the differential diagnosis 
of IDA from ACD since hepcidin-25 is low in IDA but inappropriately raised in ACD (van Santen 
et al., 2011). Currently there is no single laboratory test that can be used to differentiate 
between these two conditions, instead the results from a number of biochemical tests (e.g. 
ferritin, transferrin saturation) are reviewed in combination to aid diagnosis.  
Another promising application for hepcidin-25 measurement is in the treatment of 
anaemia in patients with CKD. In this group of patient’s anaemia is common, partly due to 
inadequate production of EPO, and therefore patients are commonly treated with erythropoietin 
stimulating agents (ESAs) or iron supplementation. However, some of these patients do not 
respond to treatment with iron, which in part maybe due to raised plasma hepcidin-25 
concentrations (most likely due to chronic inflammation) inhibiting duodenal iron uptake and iron 
release from cellular stores (Konz et al., 2014). Clinically, measurement of hepcidin-25 in these 
patients would help identify those that would respond from oral iron supplementation.  
As regards to therapeutic applications, there are a number of agents that are being 
developed that manipulate the mechanisms involved in hepcidin-25 production (Boyce et al., 
2016; Liu et al., 2016; Poli et al., 2014,). In this situation measurement of plasma hepcidin-25 
could be of use to assess the effectiveness of these agents. 
 
1.6 Methodology 
1.6.1 Mass spectrometry 
Mass spectrometry (MS) is the gas phase separation of ionized atomic or molecular species 
according to their mass-to-charge ratio (m/z). Following ionisation of an analyte, a characteristic 
ion that represents the intact atom/molecule or a group of ions that represent fragments of the 
ionized species are formed. These ions are then separated by manipulating magnetic or 
electrostatic fields in a high vacuum, and detected using an electron multiplier tube. The plot of 
their relative abundance against the m/z of each ion is a mass spectrum.  
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The basic components of a mass spectrometer are: (i) sample introduction system, (ii) 
an ion source, (iii) mass analyser, (iv) a detector (typically an electron multiplier tube), and (v) a 
data collection system (Flanagan et al., 2007). There are a number of different types of mass 
analysers available, primarily; (i) sector/double focusing, (ii) time of flight (TOF), (iii) quadrupole, 
(iv) quadrupole ion trap, (v) fourier-transform ion cyclotron resonance, and (vi) the recently 
introduced Orbitrap mass analyser. Two important parameters used in mass spectrometry that 
define instrument, and method related performance are ‘resolving power’ and ‘resolution’, 
respectively. Resolving power is the ability to distinguish two adjacent ions of equal intensity, 
and the IUPAC definition (Murray et al., 2013) is – 
 
“For two peaks of equal height with masses m1 and m2, when there is overlap between the two peaks to a stated 
percentage of either peak height (10 % is recommended), then the resolving power is defined as: m1/ (m1 – m2)” 
 
Whereas resolution is a function of both the ion width and mass being measured, and the 
IUPAC definition (Murray et al., 2013) is – 
 
“For a single peak made up of singly charged ions at mass m in a mass spectrum, the resolution may be expressed as: 
m/ ∆m. Where ∆m is the width of the peak at a height which is a specified fraction of the maximum peak height (for 
example, 50 %).” 
 
Resolving power is important as the greater the resolving power, the greater the ability to 
differentiate two ions of similar mass, and therefore improve selectivity. Typically, quadrupole 
instruments have a resolving power of broadly 2000 FWHM (at m/z 200) and an ion peak width 
of 0.6 atomic mass units (amu), hence such instruments are referred to as ‘low resolution’ (LR-
MS). TOF instruments typically have a resolving power of around 15,000 FWHM (at m/z 400), 
and Orbitrap instruments of 140,000 FWHM (at m/z 200), and are known as ‘high resolution’ 
(0.1 ≥ amu, HR-MS, Rochat et al., 2012). 
 
1.6.2 Hepcidin methodology 
Since the discovery of hepcidin-25, several methods have been published for its quantitation in 
plasma, serum and urine. These methods broadly fall into two categories, (i) immunochemical, 
and (ii) mass spectrometric. There is no ‘gold-standard’ assay for the quantitation of hepcidin-25 
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or N-truncated analogues, nor any external quality assurance scheme or external quality control 
material commercially available. Therefore, much variability between mass spectrometry and 
immunochemical based methods has been reported, and even much variability within each 
technique (Kroot et al., 2009; Kroot et al., 2012; van der Vorm et al., 2016). The introduction of 
a commercially available isotopically labelled hepcidin-25 for use as an internal standard has 
the potential to greatly improve the accuracy and precision of mass spectrometric hepcidin-25 
assays. Of course, this still depends on the sample preparation and detection conditions being 
fully optimised, and the accurate preparation of calibration solutions. 
 
1.6.2.1 Immunochemical assays 
Immunochemical assays are widely used in routine clinical laboratories as they can be easily 
automated and do not require highly trained staff. For hepcidin-25, competitive enzyme linked 
immunosorbent assays (cELISA, Kroot et al., 2010; Ganz et al., 2008; Koliaraki et al., 2009; 
Schwarz et al., 2011), competitive radioimmunoassays (cRIA, Busbridge et al., 2009; 
Grebenchtchikov et al., 2009) and a 2-site ELISA have been reported (Butterfiled et al., 2010). 
However, the development of a reliable immunochemical method for the measurement of 
hepcidin-25 has been complicated by difficulties in generating specific hepcidin-25 antibodies in 
animals such as rabbits. It is likely that currently available immunochemical assays will detect all 
known isoforms of hepcidin (e.g. hepcidin-20, -22, and -24) to some degree, and not just 
hepcidin-25. 
 
1.6.2.2 Matrix Assisted and Surface Enhanced Laser Desorption Ionisation 
In Matrix Assisted Laser Desorption Ionisation (MALDI) the sample is mixed with an organic 
compound (e.g. 2-mercapto-nezothiazole) in a suitable solvent. This mixture is then spotted 
onto a sample planchet, where the solvent is evaporated leaving a crystalised matrix. A UV 
laser, most typically based on nitrogen, is focused onto the sample in short bursts, which 
induces desorption and ionization of the analyte and matrix. The ions formed are then analysed 
using a time of flight mass spectrometer (TOF-MS). MALDI-TOF-MS is a ‘soft’ ionization 
technique with little, if any fragmentation of the protonated molecule (Watson and Sparkman, 
2007), which makes it a useful technique for determining the molecular mass of peptides, 
proteins or polymers. Therefore, it is widely used for qualitative analysis, although it has been 
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used for the quantification of hepcidin-25 in serum or plasma (Anderson et al., 2011; Kroot et 
al., 2010) and in urine (Anderson et al., 2010; Bansal et al., 2009a; Gay et al., 2010).  
Surface Enhanced Laser Desorption/Ionisation (SELDI) is a variant of MALDI where the 
analyte is bound to a surface that has incorporated chemistry, i.e. hydrophobic, cationic, 
anionic, metal ion presenting or hydrophilic surfaces. Once the sample has been dispensed 
onto the surface it is incubated after a washing step where any proteins or contaminants are 
that are not retained by the surface chemistry are removed. One advantage of this approach is 
that components such as salts or detergents that may interfere with analysis are removed 
during the washing step (Seibert et al., 2004). SELDI-TOF was the first MS based method 
described for the semi-quantitative measurement of hepcidin-25 in human urine and plasma 
(Tomosugi et al., 2006). Several fully quantitative SELDI-MS methods have since been reported 
for the measurement of hepcidin-25 in serum (Swinkels et al., 2008; Ward et al., 2008) and 
urine (Bozzini et al., 2008; Swinkels et al., 2008; Altamura et al., 2009).  
 A partial disadvantage of TOF mass spectrometers is that they operate at a constant 
resolving power. This means that smaller differences between two m/z values can be separated 
at the low end of the instruments range (e.g. m/z 200) than at the high end (e.g. m/z 1,000), and 
importantly, resolution increases with increasing m/z values. Therefore, when analysing 
peptides that typically have a high m/z it may not be possible to completely resolve ions of 
different masses or isotopes. Thereby, there is potential for accurate and precise quantitation to 
be compromised, should the assay not be fully optimised and validated. Furthermore, together 
with limited sample pre-treatment opportunities, and no LC, prior to analysis by MS, analyte 
specificity maybe compromised (Anderson et al., 2010). 
 
1.6.2.3 Liquid Chromatography-Mass Spectrometry [LC-MS(/MS)] 
An increasing number of methods have been reported for the measurement of hepcidin-25 
using liquid chromatography-mass spectrometry (LC-MS). Most reported methods use LC 
coupled with a triple quadrupole mass spectrometer (TQMS), and the data acquired using 
selected/multiple reaction monitoring (S/MRM). In this technique, following appropriate sample 
preparation, analytes are separated by liquid chromatography and a pre-selected precursor ion 
undergoes collision induced dissociation under controlled conditions, and the formation of 
defined product ion(s) is monitored. The first liquid chromatography tandem mass spectrometry 
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(LC-MS/MS) based method for hepcidin-25 analysis to be reported was by Murphy et al., 
(2007). This method used calcitonin gene-related peptide as an internal standard, which is not 
ideal due to its different physiochemical properties to that of hepcidin-25. Despite this, a lower 
limit of quantitation of 1 µg/L was reported, and accuracy and precision were deemed 
acceptable. Several other LC-MS/MS based methods using a TQMS for the quantification of 
hepcidin-25 in either serum (Murao et al., 2007; Kobold et al., 2008; Li et al., 2009; Hwang et 
al., 2011; Wolff et al., 2013; Delaby et al., 2014, Lefebvre et al., 2015) or urine (Hwang et al., 
2011; Wolff et al., 2013) have been since been published. 
 One concern in using TQMS for peptide analysis is that usually a product ion(s) of one 
charge state, and one isotope is monitored, however there maybe sample-to-sample variability 
in the isotope and charge state distribution, thereby compromising accurate quantitation. 
Furthermore, in LC-MS/MS, the analyte should fragment appropriately (i.e. to a few but not too 
many ions).  An LC-MS/MS method for the measurement of hepcidin-25 in plasma has also 
been reported using an ion-trap MS (Bansal et al., 2010). 
Traditionally high resolution-mass spectrometry (HR-MS) has been used predominantly 
for qualitative analysis, such as drug metabolite identification, and proteomics. However, in 
recent years with the introduction of Orbitrap mass analysers from ThermoFisher Scientific in 
2005, HR-MS is being increasingly used for quantitative analysis in clinical settings. Orbitrap 
instruments have high resolution capabilities, and maximal resolving powers of up to 280,000 
FWHM (m/z 200) in the most advanced model currently available (Q-Exactive Plus, 
ThermoFisher Scientific). Furthermore, they have an extended mass range of up to 6000 m/z. 
Instruments are now available that include a quadrupole as well as an Orbitrap (Q-Exactive), 
that allow data to be collected not only in full scan mode, but also for ions to be fragmented and 
all products collected (parallel reaction monitoring). HR-MS has several advantages compared 
to LR-MS, for example: (i) if data is acquired in full scan mode, the collision energy for each 
analyte does not have to be optimised as with LC-MS/MS, (ii) HR-MS allows full scan data to be 
acquired, and for all charge states and isotopes to be monitored, (iii) when data is acquired in 
full-scan mode it can be retrospectively audited for compounds not initially targeted, and (iv) 
almost all pre-cursor ions entering the instrument can be spectrometrically resolved (depending 
on resolving power used). To date, two methods have been published for the measurement of 
hepcidin-25 using HR-MS. The first was reported by Rochat et al., (2013) where an Exactive 
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Plus Orbitrap (ThermoFisher Scientific) was used to acquire data in full scan mode using a 
single charge state for quantitation, but only the 3 most abundant isotopes of that charge state 
were monitored. Li et al., (2014) reported a method for the measurement of hepcidin-25 in mice 
and cynomolgus monkey serum using a Q-Exactive Orbitrap (ThermoFisher Scientific), with 
data acquired in parallel reaction monitoring (PRM) mode, but again only a single charge state 
was used for quantitation.  
Regarding sample preparation prior to detection with LC-MS(MS), solid phase 
extraction (SPE) is most widely used for hepcidin-25 measurement (Murphy et al., 2007; Li et 
al., 2009; Wolff et al., 2013; Li et al., 2014; Lefebvre et al., 2015). Other sample preparation 
techniques that have been used include protein precipitation (PPT), ultrafiltration, and the use of 
magnetic nanoparticles prior to LC-MS/MS. The preference for using SPE is, in part, because 
SPE allows concentration of the analyte onto the sorbent, and by introducing wash steps of the 
SPE cartridge with appropriate solvents, compounds that may interfere with accurate 
quantification can be removed prior to elution of the desired analyte. Furthermore, 96-well 
plates are available, thereby allowing relatively high throughput. 
 
1.6.2.4 Inductively Coupled Plasma mass spectrometry (ICP-MS) 
Inductively Coupled Plasma-Mass Spectrometry, unlike LC-MS/MS, is an inorganic technique. 
The advantage of this technique is that ion-suppression is less of a concern compared to LC-
MS(/MS) analysis, and that calibration solutions containing the specific analyte are not required, 
instead solutions containing the element to be monitored at known concentrations are used. 
Hepcidin-25 is composed of 9 amino acids that contain sulphur (8 cysteines and 1 methionine), 
and with this in mind a method has been published for the measurement of hepcidin-25 in 
human urine monitoring 32S (Konz et al., 2011). In this method samples were extracted using 
SPE and then analysed by capillary liquid chromatography coupled to ICP-MS. A solution of 34S 
was continuously pumped and mixed with the column effluent prior to being introduced into the 
ICP-MS as an internal standard. The ratio of 32S:34S was used to quantify 32S. The reported limit 
of detection was 7 µg/L for 32S, which corresponded to 70 µg/L of hepcidin-25; however, this 
was insufficient to measure hepcidin-25 in urine samples from healthy volunteers. Konz et al. 
(2012) exploited the binding of Cu2+ions at the N-terminus of hepcidin-25 for the measurement 
of hepcidin-25 in human serum. In this technique serum samples from healthy volunteers and 
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those with Parkinson’s disease were incubated with a solution of copper in 10 mM ammonium 
acetate. Samples were analysed by liquid chromatography coupled to ICP-MS with a solution of 
65Cu introduced post-column. The 63Cu:65Cu ratio was used to quantify 63Cu as a surrogate for 
hepcidin-25, and an LLoQ of 1.8 µg/L for hepcidin-25 was achieved.  
The use of ICP-MS for the quantitation of hepcidin-25 is not practical in a clinical setting 
because these instruments are infrequently used in routine clinical laboratories, except for those 
that offer a trace elements/metals service. 
 
1.7 Aim and objectives of thesis 
The aim of this work will be to define what role measurement of hepcidin isoforms have in a 
clinical setting, and the hypothesis that hepcidin-25 measurement has a clinical role. The 
objectives undertaken to achieve this will be: (i) develop a LC-HR-MS based method for serum 
hepcidin-20, -22, -24, and -25; (ii) validate the method, including a method comparison with 
samples analysed by existing immunoassay and LC-MS/MS assays; (iii) define a method based 
reference range for all hepcidin isoforms using samples from healthy volunteers; (iv) investigate 
analyte stability in different matrices under a range of storage conditions (i.e. room temperature, 
2-8 °C, and -20 °C); (v) investigate hepcidin isoform concentrations in patients with various 
stages of CKD, in those undergoing dialysis as well as those not requiring haemodialysis, 
correlating hepcidin concentrations with traditional markers of iron status (e.g. ferritin, transferrin 
saturation); and (vi) investigate concentrations of hepcidin isoforms in patients with iron 




















When developing any method for the measurement of a given analyte, optimisation of the 
sample preparation technique and detection method is essential in order to ensure optimum 
sensitivity, and accurate/precise quantitation is achieved. This can be time consuming and is 
influenced by the chemical and physical properties of the analyte(s). In general, when 
developing an LC-MS based method, the MS parameters (detection) are broadly optimised first, 
followed by the LC conditions (chromatographic separation), and then finally suitable sample 
preparation techniques are investigated. 
 The method development undertaken here will use a Q-Exactive MS, and once 
developed, this instrument will continue to be used. This is because: (i) it has high resolution 
capabilities (ii), can be operated in full-scan mode, allowing acquisition of all charge states and 
isotopes for post-acquisition data processing (iii), it has a quadrupole as well as an orbitrap 
mass analyser, therefore allowing parallel reaction monitoring if required and (iv), this 
instrument is not routinely used within the laboratory. 
 
The aims of this chapter are as follows: 
• Optimise mass spectrometric, and liquid chromatographic conditions for all 
available hepcidin isoforms 
• Investigate protein precipitation, immunocapture and solid phase extraction as 
suitable sample preparation techniques 




2.2 Materials and methods 
2.2.1 Materials 
Human hepcidin-20, -22, -24, -25, and isotopically labelled hepcidin-25 [(13C8,15N3)-hepcidin-25; 
hepcidin-ISTD] were from Peptides International (Kentucky, USA). Amino acid sequences 
(MWmonoisotopic) for hepcidin-20, -22, -24, and -25 were: ICIFCCGCCHRSKCGMCCKT 
(2189.771), FPICIFCCGCCHRSKCGMCCKT (2433.892), THFPICIFCCGCCHRSKCGMCCKT 
(2671.999), and DTHFPICIFCCGCCHRSKCGMCCKT (2787.026), respectively. The 
MWmonoisotopic for hepcidin-ISTD was 2813.114. The purity of all compounds was greater than 
95.9 %, however, the net peptide content ranged from 65.9–84.1 % (100 % for hepcidin-ISTD). 
All were supplied as trifluoroacetate salts. Heavy (quadruple) charcoal stripped human serum 
(SHS) was from Sera Laboratories Ltd (West Sussex, UK). All reagents used were from Sigma 
Aldrich (Poole, UK) and were of either ACS reagent or HPLC grade. Water was deionised (> 12 
mΩ, Elga, Marlow, UK). All analytical LC columns were purchased from Hichrom (Theale, UK). 
Disposal Automated Research Tips (D.A.R.T) were pre-bound with anti-hepcidin-25 polyclonal 
antibodies (Pierce, ThermoFisher Scientific, Rockford USA) by ThermoFisher Scientific (Tempe, 
USA). Protein LoBind 0.5 and 1.5 mL tubes, and 500 µL 96-deep-well plates were from 
Eppendorf (Stevenage, UK). pH testing strips were from VWR (Lutterworth, UK). HBS-EP buffer 
containing; 0.01 mol/L HEPES [4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid], 0.15 mol/L 
sodium chloride, 3 mmol/L EDTA, and 0.005 % (v/v) surfactant polysorbate20 (P20) was from 
GE Healthcare Life Sciences (Little Chalfont, UK). Polysorbate20, sodium dodecyl sulfate 
(SDS), and Triton X-100 (all > 99 %) were from Sigma Aldrich (Poole, UK). Oasis µElution 96-
well SPE plates (30 µm particle size, 2 mg packing per well) were obtained from Waters 
(Elstree, UK).  
Unless otherwise stated hepcidin-20, -22, -24, -25 and hepcidin-ISTD were added to 
SHS at a final concentration of 100 µg/L for developmental work. Portions (1.0 mL) were stored 
in 1.5 mL LoBind tubes at -20 °C until required. 
 
2.2.2 Instrumentation 
An Aria Transcend LX-II system (ThermoFisher Scientific, San Jose, CA) consisting of 4 Accela 
1250 high-pressure quaternary pumps, valve interface module, and CTC PAL autosampler was 
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used with a Q-Exactive Orbitrap high resolution MS (ThermoFisher Scientific, Bremen, 
Germany). The autosampler tray was maintained at 10 °C. Instrument control was performed 
using Xcalibur software (version 3.1; ThermoFisher Scientific). A Finnpipette Novus 12 channel 
pipette (Thermo Fisher Scientific, Bremen, Germany) was used for immunocapture. A Waters 
extraction manifold for 96-well plates was used for solid phase extraction. Theoretical isotope 
patterns, m/z, and product ions were calculated using Pinpoint software (v 1.1, ThermoFisher 
Scientific, San Jose, USA). Final MS conditions were as follows; spray voltage 4.0 kV; 
temperatures: vaporiser 150 ºC; capillary 350 ºC; auxiliary, sheath, and sweep gases 10, 35 
and 0 (arbitrary units) respectively, S-lens voltage 90 V. The C-trap capacity was set at 3 x 106 
charges, and maximum injection time was 200 ms. Full-scan MS data were acquired using a 
resolving power of 70,000, defined as full width at half maximum at m/z 200, with a scan range 
of 400–1,000 m/z.  
For all post-acquisition data processing, peak areas were generated by filtering full-scan 
data using a mass extraction window of ± 10 ppm based on theoretical m/z values of the five 
most abundant isotopes of the [M+3H]3+, [M+4H]4+, and [M+5H]5+ (Table 2.1). External mass 
calibration was carried out using a positive mass calibration solution (ThermoFisher Scientific, 
Bremen). Peak area ratios (hepcidin-20, -22, -24, and -25 to hepcidin-ISTD) were measured 
and used to construct calibration curves (1/x2 weighting, not forced through zero). 
 
2.2.3 Extraction yield, matrix effects, and process efficiency 
The extraction yield, matrix effects, and process efficiency were assessed per accepted 
strategies (Matuszewski et al., 2003). All hepcidins were added; (A) to the appropriate 
extraction solution at a concentration corrected for sample concentration, (B) after, or (C) before 
the extraction procedure to the appropriate biological matrix.  
This approach allows the matrix effect (ME), extraction recovery (RE) of the extraction 
procedure, and overall “process efficiency” (PE) to be calculated as follows: 
ME (%)  = B/A x 100 
RE (%)  = C/B x 100 
PE (%)  = C/A x 100 
For matrix effects a value greater than 100 % may suggest ion enhancement, whereas a value 
less than 100 % may suggest ion suppression.  Extraction recovery is the absolute amount 
(expressed as a percentage) of a compound that has been extracted from the sample using a 
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given procedure not taking into account matrix effects. Process efficiency is the overall 
percentage of compound that has been extracted and takes into account the degree of matrix 
effect. The ME, RE and PE, are in part calculated by comparison to a solution containing all the 
analytes that has not been through the extraction process, but directly injected onto the LC-HR-
MS. 
 
2.3 Optimising Mass Spectrometry Conditions 
In mass spectrometry, optimisation of the signal obtained for a given analyte is generally 
undertaken by direct infusion of the analyte via a syringe pump into the MS at a flow-rate and in 
a solution comparable to that used in the final LC method. From this, a mass spectrum is 
obtained, which is a plot of the relative abundances of ions as a function of their m/z. Due to the 
large size of peptides and proteins, when analysed using electrospray ionisation (ESI) they 
become multiply charged, and several protonated molecules of varying charge states are 
present in the mass spectrum. 
To investigate the mass spectrum of all hepcidins, separate 200 mg/L aqueous 
solutions containing 0.1 % (v/v) formic acid of each hepcidin was directly infused into the MS 
using heated electrospray ionisation (HESI) in positive mode and full scan data acquired (100–
1,500 m/z). Theoretical m/z values of the five most abundant isotopes of the [M+3H]3+, 
[M+4H]4+, and [M+5H]5+, are shown in Table 2.1.  
Hepcidin-20, and hepcidin-22 gave the greatest response, followed by hepcidin-24, and 
then hepcidin-25, and hepcidin-ISTD. The response of hepcidin-20 was some three times that 
of hepcidin-25 and hepcidin-ISTD at the concentration investigated. This may in part be due to 
poor ionisation of hepcidin-25 since the amino acid at the N-terminus of hepcidin-25 is aspartic 
acid, which is negatively charged and not able to accept a positive charge, whereas the amino 
acids at the N-terminus of hepcidin-20, -22, and-24 are isoleucine, phenylalanine, and tyrosine 
respectively, which are neutrally charged, hence may be able to accept some charge when 
positively ionised. For most analytes, [M+2H]2+ to [M+6H]6+ were present, and for all analytes 
except hepcidin-20, the most abundant ions observed were [M+4H]4+ and [M+5H]5+ (Figure 2-1, 
Figure 2-2). For hepcidin-20 however, the [M+3H]3+ and [M+4H]4+ were most abundant (Figure 
2-1). A magnified mass spectrum of the [M+5H]5+ of hepcidin-25, showing the theoretical m/z of 
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ten isotopes together with the contribution of each isotope to the overall charge state is given in 
Figure 2-3. When infusing each separate hepcidin isoform, neither hepcidin-20, -22, -24, or -25 
were present when they should not have been (which is in-keeping with the high purity stated 
on the analytical data sheets), and shows a lack of in-source molecular degradation. However, 
when reviewing the mass spectrum of hepcidin-20, ions corresponding to the theoretical 
masses of the [M+4H]4+ charge state of hepcidin-19 were observed (m/z 520.1790, 520.4300, 
520.6790), although the relative proportion of these ions to the corresponding charge state of 
hepcidin-20, were extremely low (< 1 %). 
 
Table 2.1. Theoretical masses of the top five isotopes of the [M+3]3+, [M+4]4+, and [M+5]5+ 
of hepcidin-20, -22, -24, -25, and hepcidin-ISTD.   
 Charge state 






















































































Figure 2-1. Mass spectra of (A) hepcidin-20, and (B) hepcidin-22 following direct infusion of separate 200 mg/L aqueous solutions containing 0.1 % 













































































Figure 2-2 Mass spectra of (A) hepcidin-24, and (B) hepcidin-25, following direct infusion of separate 200 mg/L aqueous solutions containing 0.1 % 
















































































Figure 2-3. Magnified mass spectrum of the [M+5H]5+ ion of hepcidin-25 (resolving power 
140,000 defined as FWHM at m/z 200; figure in parentheses: percentage contribution of 
isotope to total charge).  
 
When peptides are fragmented, the product ion scan contains ‘b’ and ‘y’ ions. Product ions that 
extend from the N-terminus are known as b ions, and those that extend from the C-terminus are 
known as y ions. These b and y ions can also be multiply charged, as can the precursor ion. 
Fragmentation of the [M+5H]5+ of hepcidin-25 was investigated at a collision energy of 
20 eV. The most abundant product ion was the y193+ (m/z 693.236) ion, with many other b and 
y ions present, but no product ion of any significant abundance (Figure 2-4). It is not surprising 
that some product ions of hepcidin-25 were hepcidin-20 (y203+), -21 (y213+), and -22 (y223+), which 
were themselves multiply charged. Increasing the collision energy to 30 eV completely 
fragmented the precursor ion, resulting in many small product ions of no significant abundance. 
The product ions of all hepcidin-20, -22, and -24 were also investigated following collision 























































































induced dissociation at 20 and 30 eV, the mass spectra obtained were all similar, with the y19 





Figure 2-4. (A) Product ion scan of the [M+5H]5+ of hepcidin-25 at 20 eV, and (B) amino 
acid sequence of hepcidin-25 indicating b and y ions. 
 
Modifying the charge state of peptides or proteins is undertaken in some instances to; (i) 
concentrate the signal into fewer charge states, (ii) simplify spectra, and (iii) to improve signal-
to-noise-ratios (Krusemark et al., 2009). To investigate this for those analytes studied here, 3–
nitrobenzyl alcohol (3-NBA), a common additive used to modify charge state, was added (0.1 % 
v/v) to the infusion solution of each analyte. Mass spectrums obtained are given in Figure 2-5 












































hepcidins. However, it did not concentrate the signal into a single charge state, which would be 
desirable as it may help to improve the LLoQ. Increasing the concentration of 3-NBA from 0.1 to 
1.0 % (v/v) did not alter the charge state further. The use of 3-NBA as an additive to modify the 
charge state of hepcidin-25 has been reported (Rochat et al., 2013) when using an Exactive 
Plus Orbitrap analyser (ThermoFisher Scientific, Bremen), where, a similar charge state 
distribution was reported to that identified here when using 0.1 % (v/v) 3-NBA. Since the 
addition of 3-NBA did not concentrate the signal of any analyte into a single charge state, it was 





Figure 2-5. Mass spectra of (A) hepcidin-20, and (B) hepcidin-22, following direct infusion of separate 200 mg/L aqueous solutions containing 0.1 % 













































































Figure 2-6. Mass spectra of (A) hepcidin-24, and (B) hepcidin-25, following direct infusion of separate 200 mg/L aqueous solutions containing 0.1 % 
(v/v) 3-NBA into the MS. Charge state and theoretical monoisotopic m/z are shown. 










































































As hepcidin-25 gave the least intense signal of all hepcidins following infusion into the MS, and 
because the [M+5H]5+ ion of hepcidin-25 was most intense, MS parameters were optimised 
using this ion, and the final MS conditions are presented in Chapter 2.2.2. 
 
2.4 Optimising Liquid Chromatography conditions 
LC columns investigated are listed in Table 2.2. For comparison of these columns, separate 
eluents consisting of 0.1 % (v/v) aqueous formic acid (eluent A), and 0.1 % (v/v) formic acid in 
acetonitrile (eluent B) were used with gradient elution. Starting condition; 5 % B, ramped to 100 
% B over 10 minutes, held for 4 minutes then returned to initial conditions for 1 minute. Flow-
rate was 0.40 mL/min, and column maintained at 60 ºC. Mass spectrometry conditions are as 
outlined above. 
 
Table 2.2. Summary of LC columns investigated.  
 Parameter 
Column Column length (mm) 
Column 





ACE  100 2.1 C18 2.0 100 
ACE  100 2.1 C18 3.0 100 
ACE 100 1.0 C18 3.0 100 
ACE 100 2.1 Ultracore SuperC18 2.5 100 
ACE 50 2.1 C18 3.0 100 
Accucore 100 2.1 Phenyl hexyl 2.6 100 
ProSwift 50 1.0 Phenyl Monolithic column 
 
With regards to peak asymmetry, chromatographic resolution, and retention of analytes, the 
ACE C18 (100 x 1.0 mm i.d., 3.0 µm a.p.s) column was found to give optimum performance. 
Using this column, parameters such as flow-rate, column temperature, and the LC gradient 
were optimised.  
The impact of changing eluent B from 100 % acetonitrile to 100 % methanol, and to a 
1:1 mix of acetonitrile+methanol was also investigated. However, these additional solvents had 
a negligible effect on the chromatographic resolution of analytes, and rather increased the 
retention of all analytes on the LC column.  
Final LC parameters are given in Table 2.3, and an extracted ion chromatogram is 
shown in Figure 2-7. There was a significant ‘dead volume’ in the LC system, calculated to be 
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approximately 0.35 mL; when taken into consideration it was calculated that hepcidins-20, -22, -
24, and -25, eluted in approximately 19–30 % eluent B. 
 
Table 2.3. Final LC parameters 
Parameter Condition 
Eluents A: 0.1 % (v/v) aqueous formic acid  
B: 0.1% (v/v) formic acid in acetonitrile  
Column temperature 60 ºC 
Flow-rate 0.1 mL/min during the 8 minute analysis time 
Gradient Starting condition 5 % B for 1 minute, ramped to 50 % B over 
8 minutes, held for 1.5 minutes (100 % B, 0.4 mL/min) then 
immediately returned to initial conditions for 1.5 minutes 
(0.4 mL/min) 




Figure 2-7. Extracted ion chromatograms for hepcidin-20, -22, -24, -25, and hepcidin-ISTD 
from the direct injection of an aqueous 100 µg/L solution. 









































2.5 Optimising Sample Preparation 
Appropriate sample preparation is essential for any analyses undertaken by LC-MS in order to 
minimise ion suppression/enhancement from matrix components, and therefore improve 
accuracy and precision, as well as to minimise contamination of the LC and MS system. 
Reported techniques for the measurement of hepcidin-25 have included protein precipitation, 
solid-phase extraction, and functionalised magnetic nanoparticles. Recently, antibodies raised 
against hepcidin-25 bound to disposable automated research tips (D.A.R.Ts) have become 
available. Due to available resources within the laboratory only protein precipitation, solid-phase 
extraction and disposable automated research tips were investigated. 
 
2.5.1 Protein precipitation 
Protein precipitation was investigated using a number of different solutions, in order to identify 
which solution gave the best process efficiency. Sample (100 µL), and chilled protein 
precipitation solution (stored at 2–8 °C) were added (300 µL) to a 0.5 mL LoBind tube, and 
vortex mixed for 5 minutes, followed by centrifugation for 5 minutes (16,060 x g). Supernatant 
(100 µL) was diluted with deionised water (400 µL), and 100 µL analysed by LC-HR-MS. 
Results are given in Figure 2-8. All analytes (100 µg/L) were also added to portions of each 
precipitation solution and directly injected onto the LC-HR-MS (Figure 2-9) to give an indication 
of: (i) the solubility of the analyte in the solution, and (ii) the effect of the solution on the 






Figure 2-8. Process efficiency of all analytes from stripped human serum (100 µg/L) 
extracted using several protein precipitation solutions. Mean of triplicates, error bars 




























Acetonitrile only 2 % formic acid (acetonitrile, v/v)
5 % ammonia (acetonitrile, v/v) Methanol only
2 % formic acid (methanol, v/v) 5 % TCA (water:acetonitrile: 4+1, w/v)





Figure 2-9. Peak areas of each hepcidin (100 µg/L) when added to individual portions of 
precipitation solution and directly injected onto the LC-HR-MS. Mean of triplicates, error 
bars represent ± standard deviation. 
 
An acidified (2 % v/v) organic precipitation solution gave the best process efficiency, with little 
difference between acidified methanol and acetonitrile, although for hepcidin-25 the use of 2 % 
(v/v) formic acid in methanol gave a marginally better process efficiency, and therefore this was 
used in future experiments. The addition of 2 % formic acid reduced the pH of the supernatant 
from approximately pH 6 to below 1; the addition of both 5 and 10 % (v/v) trichloroacetic acid 
(TCA) also reduced the pH of the supernatant to below 1. 
Comparing the results from Figure 2-8 and Figure 2-9, where the analytes were added 
to the precipitation solution and directly analysed, it is likely that acidification of the precipitation 
solution most likely displaces hepcidin from binding proteins during sample preparation. The 
poor process efficiency when using 5 and 10 % (v/v) TCA is likely due to protein bound analyte 
being precipitated (i.e. ‘dragged down’) together with the binding protein, combined with the 



























Acetonitrile only 2 % formic acid (acetonitrile, v/v)
5 % ammonia (acetonitrile, v/v) Methanol only
2 % formic acid (methanol, v/v) 5 % TCA (w/v) (water:acetonitrile: 4+1)
10 % TCA (w/v) (water:acetonitrile: 4+1)
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To ascertain process efficiency, matrix effects, and extraction recovery when using 2 % 
(v/v) formic acid in methanol as a protein precipitant, hepcidin-20, -22, and -25 were added to 
SHS (100 µg/L) and were calculated as described (Chapter 2.2.3). Due to a lack of hepcidin-24, 
and hepcidin-ISTD reference material at the time, these analytes were not investigated. 
Samples were prepared by addition of 2 % (v/v) formic acid in methanol (300 µL) to sample 
(100 µL) in a 0.5 mL LoBind tube, and vortex mixed for 5 minutes followed by centrifugation for 
5 minutes (16,060 x g). Supernatant (100 µL) was diluted with deionised water (400 µL), and 
100 µL analysed by LC-HR-MS. Results are given in Table 2.4. 
 
Table 2.4 Extraction recovery, matrix effect, and process efficiency of hepcidin-20, -22, 
and -25 added to stripped human serum (100 µg/L), following precipitation with methanol 
containing 2 % (v/v) formic acid. Mean of triplicates. (Hepcidin-24, and hepcidin-ISTD 
could not be investigated due to a lack of reference material) 
 
Extraction 
recovery, % (SD) 
Matrix 
effect, % (SD) 
Process 
efficiency, % (SD) 
Hepcidin-20 26.0 (0.9) 113.8 (1.8) 29.6 (1.5) 
Hepcidin-22 25.5 (0.4) 121.4 (1.3) 31.0 (0.9) 
Hepcidin-25 26.5 (0.8) 164.4 (0.1) 43.7 (1.3) 
 
Extraction recovery was low for all analytes, and there were significant matrix effects for 
hepcidin-25. It was not possible to identify the origin of this matrix effect, a co-eluting compound 
was not identified in the mass spectrum, and alterations to the LC gradient did not show 
improvement. 
Despite the presence of significant matrix effects, other parameters such as linearity 
and sensitivity were investigated. To ascertain these, hepcidin-20, -22, -24, and -25 were added 
to SHS (100 µg/L). This was serially diluted with SHS to produce further solutions of 1, 2, 5, 10, 
20, and 50 µg/L. Samples were analysed in triplicate as described above, using 2 % (v/v) formic 
acid in methanol as the precipitation solution. Calibration curves for all analytes were linear (R2 
> 0.90). However, the lowest concentration that could be detected was 20 µg/L. This is not 
surprising given the considerable dilution of the sample that was performed first with the 
precipitating solution, and then with deionised water. Significant dilution of the supernatant with 
water is required to minimise the final concentration of methanol present in the supernatant to 
ensure that all analytes are retained on the LC column. To improve sensitivity, the effect of 
57 
 
evaporating the supernatant (in borosilicate tubs) to dryness under nitrogen, at ambient room 
temperature was ascertained. Process efficiency was poor using this approach with 
approximately 20 % of all analytes being recovered following evaporation and reconstitution. 
Dimethyl sulfoxide (DMSO) was added to the supernatant prior to evaporation in order to 
prevent complete evaporation of the extract and to keep the analytes in solution. However, 
addition of DMSO [20 % (v/v)] to the supernatant had a negligible effect on analyte recovery, 
after evaporation and reconstitution. Time spent vortex mixing (5–60 minutes), and the ratio of 
sample to precipitating solution (1+1, and 1+2) was investigated, but neither improved process 
efficiency or sensitivity.  
Protein precipitation is a simple sample preparation technique that has been used for 
the measurement of hepcidin-25 prior to LC-MS/(MS) by several investigators (Murao et al., 
2007, Rochat et al., 2013). However, given the considerable matrix effects present, the lack of 
sensitivity, and instability of all analytes upon evaporation, this technique was not considered 
suitable and not investigated any further. 
 
2.5.2 Immunocapture 
In immunocapture, pipette tips are embedded with a monolithic microcolumn activated with an 
antibody. Sample is aspirated using these tips in repeated binding cycles, and finally the 
captured analyte is eluted and analysed by LC-MS(/MS). The process of capturing the analyte 
and analysis by mass spectrometry is known as mass spectrometric immunoassay (MSIA). 
MSIA has already been used for the measurement of several clinically important proteins in 
human plasma and has been shown to be selective and highly sensitive (Krastins et al., 2013). 
Recently, D.A.R.Ts bound with polyclonal, hepcidin-25 antibodies that have been raised against 
the C-terminus of hepcidin-25 (Figure 1-2) have become available. To assess the suitability of 
immunocapture, all hepcidins were added to deionised water (100 µg/L), and analysed 
according to the procedure in Table 2.5. Deionised water (65 µL) was added to the eluted 








Table 2.5. Immunocapture procedure. 
Step Solution Volume (µL) 
















































Process efficiency ranged from 67–103 % (SD range: 11–16) for all analytes, clearly indicating 
that the antibody bound to the tip can capture all hepcidins in the absence of plasma or serum. 
However, when attempted using a SHS sample (500 µL), the tips often blocked and process 
efficiency was poor (< 1 % all analytes). To minimise tip blockage, and to displace hepcidins 
from plasma protein, sample (500 µL) was diluted with a range of aqueous diluents (750 µL, 
Table 2.6) into 1.5 mL LoBind tubes and vortex mixed for 60 minutes, followed by 
immunocapture. Process efficiency was unacceptable for all procedures (Table 2.6). In order to 
ascertain whether the low process efficiency obtained was due to matrix effects or poor 
extraction efficiency, extraction recovery, and matrix effects, were also ascertained following 
dilution of the sample (500 µL) with deionised water (750 µL) prior to immunocapture (Table 
2.7).  
 
Table 2.6. Process efficiency of all analytes (100 µg/L) from stripped human serum (500 
µL), following dilution of the sample with several diluents prior to immunocapture. Mean 
of triplicates. 
 Hepcidin-20 Hepcidin-22 Hepcidin-24 Hepcidin-25 Hepcidin-ISTD 
PE (%) SD PE (%) SD PE (%) SD PE (%) SD PE (%) SD 
Deionised water 5.9 0.5 4.2 0.6 4.7 0.4 3.2 0.1 2.9 0.3 
Deionised water 
and sonication 5.9 0.6 4.6 0.8 4.5 0.5 3.6 0.4 3.3 0.5 
HBS-EP 1.6 0.1 2.2 0.3 2.3 0.2 1.2 0.4 1.2 0.3 
Aqueous P20, 
0.005 % (v/v) 4.9 0.4 2.7 0.3 4.0 0.4 2.4 0.4 2.4 0.2 
Aqueous SDS, 
0.3 % (v/v) 3.6 0.2 2.1 0.1 2.5 0.2 1.2 0.1 1.1 0.1 
Aqueous Triton 
X-100, 0.3 % v/v 
 






Table 2.7. Extraction yield, matrix effect, and process efficiency of all analytes (100 µg/L), 









Hepcidin-20 5.6 (2.4) 95.0 (3.9) 5.9 (0.5) 
Hepcidin-22 4.2 (1.5) 101.0 (1.7) 4.2 (0.6) 
Hepcidin-24 4.5 (1.2) 96.0 (5.7) 4.7 (0.4) 
Hepcidin-25 3.1 (7.1) 93.0 (10.1) 3.2 (0.1) 
Hepcidin-ISTD 2.9 (5.1) 102.0 (7.1) 2.9 (0.3) 
 
It is evident from the data in Table 2.7 that the poor process efficiency obtained when using 
immunocapture is due to low extraction recoveries as opposed to matrix effects. This may be 
due to unknown matrix components interfering with the binding of the analyte to the antibody, or 
because of significant analyte-protein binding, especially as the diluents used have a neutral 
pH, and therefore unlikely to displace protein bound hepcidins. Unfortunately, the use of 
diluents at extremes of pH (e.g. acidic) to disrupt protein binding is not feasible as this would 
denature the antibodies bound to the tips. Instead, to try and disrupt protein binding, protein 
precipitation with acetonitrile prior to immunocapture was undertaken. Acetonitrile (300 µL) was 
added to sample (100 µL), vortex mixed for 5 minutes and centrifuged for 5 minutes (16,060 x 
g). The supernatant was diluted with deionised water so that the acetonitrile content was < 5 % 
(v/v) prior to immunocapture. Process efficiency was still unacceptable (< 1 %, all analytes). 
Increasing the number of capture cycles from 500–1,500, and altering the ratio of sample to 
diluent did not improve process efficiency.  
Even though immunocapture produces extremely clean extracts, and has been shown 
to be useful for measuring some peptides and proteins in human plasma (Krastins et al., 2013), 
the extremely poor process efficiency of all hepcidins from SHS makes MSIA an unsuitable 
technique for the measurement of hepcidin-25 and N-truncated isoforms. 
 
2.5.3 Solid Phase Extraction 
SPE was investigated using Waters OASIS µElution plates. This is because: (i) these plates are 
available pre-prepared with a range of sorbents (Figure 2-10), (ii) allow the use of elution 







Figure 2-10. Surface-modification of the five SPE sorbents investigated; (A) hydrophilic 
lipophilic balanced (HLB); (B) maximum anion exchange (MAX); (C) weak anion exchange 
(WAX); (D) maximum cation exchange (MCX); and (E) weak cation exchange (WCX). 
 
2.5.3.1 Sorbent comparison 
The five sorbents shown in Figure 2-10, as well as the impact of loading and eluting the sample 
in an acidic, basic or neutral environment were investigated using a modified protocol available 
from Waters (Figure 2-11). Results are given in Figure 2-12, Figure 2-13, Figure 2-14, Figure 
























Figure 2-11. SPE procedure undertaken to compare 5 sorbents, and the effect of neutral, 
acidic, and basic loading and eluting conditions (prior to loading the sample, each well 












Sample ( 200 µL)
600 µL deionised water or
600 µL 4 % (v/v) phosphoric acid (aq) or 
600 µL 5 % (v/v) ammonia (aq) 
Vortex mix 10 min + 
centrifuge 5 min (16,060 x g)
Wash
200 µL 10 % (v/v) acetonitrile (aq) 
Elute
50 µL 70 % (v/v) acetonitrile (aq) or
50 µL 1 % (v/v) TFA in 70 % (v/v) acetonitrile (aq) or
50 µL 5 % (v/v) ammonia in 70 % (v/v) acetonitrile ( aq) 
Load sample under vacuum
Elute sample under vacuum
LC-HR-MS analysis





Figure 2-12. Process efficiency for hepcidin-20 following SPE using different sorbent chemistries and different loading and eluting conditions. Mean 











































Figure 2-13 Process efficiency for hepcidin-22 following SPE using different sorbent chemistries and different loading and eluting conditions. Mean 






































Figure 2-14 Process efficiency for hepcidin-24 following SPE using different sorbent chemistries and different loading and eluting conditions. Mean 




































Figure 2-15 Process efficiency for hepcidin-25 following SPE using different sorbent chemistries and different loading and eluting conditions. Mean 







































Figure 2-16 Process efficiency for hepcidin-ISTD following SPE using different sorbent chemistries and different loading and eluting conditions. 



































Loading pH   Eluting pH 
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For hepcidin-20, -22, and -24, and to a lesser extent hepcidin-25, the HLB sorbent provided the 
greatest process efficiency compared to the other sorbent chemistries, especially when used 
with acidic loading and acidic eluting conditions, and was far superior to the process efficiency 
obtained when using protein precipitation or immunocapture. 
To ascertain the cause of the low process efficiency for some of the sorbents, and to 
further compare all sorbents, the extraction recovery, matrix effects, and process efficiency were 
ascertained when the sample was loaded and eluted under acidic conditions. All analytes were 
also added to deionised water (100 µg/L) before extraction. Samples were prepared according 
to Figure 2-11, except that they were diluted with 4 % (v/v) aqueous phosphoric acid before 
loading, and eluted with 1 % (v/v) trifluoroacetic acid (TFA) in 70 % (v/v) aqueous acetonitrile. It 
was not possible to ascertain extraction recovery, matrix effects, and process efficiency using 
the WCX sorbent (all analytes), or the HLB sorbent for the hepcidin-ISTD due to limited 
resources. Results are given in Table 2.8. The HLB sorbent has the best process efficiency 
followed by the MAX sorbent. It is interesting to note that the process efficiency for all analytes 
in deionised water is far less than in SHS, this is likely due to poor solubility in a 100 % aqueous 
























Table 2.8. Extraction recovery, matrix effect, and process efficiency of hepcidins in SHS 
and deionised water at 100 µg/L following SPE. (HLB sorbent not investigated for 
hepcidin-ISTD due to limited resources)  Mean of triplicates. 
 
Extraction 
recovery, % (SD) 
Matrix 
effect, % (SD) 
Process 
efficiency, % (SD) 
SHS 
Process 
efficiency, % (SD) 
DEIONISED WATER 
Hepcidin-20 
    
HLB 64 (3) 64 (1) 100 (10) 33 (3) 
MCX 0 (0) 62 (15) 0 (0) 0 (0) 
WAX 7 (2) 99 (3) 7 (1) 11 (1) 
MAX 31 (3) 96 (5) 32 (4) 17 (6) 
Hepcidin-22 
    
HLB 91 (12) 101 (0) 92 (19) 30 (4) 
MCX 0 (0) 98 (24) 0 (0) 0 (0) 
WAX 18 (5) 138 (8) 25 (3) 22 (2) 
MAX 38 (2) 138 (1) 52 (6) 22 (7) 
Hepcidin-24 
    
HLB 81 (2) 115 (1) 93 (21) 30 (4) 
MCX 0 (0) 116 (27) 0 (0) 0 (0) 
WAX 10 (2) 165 (5) 17 (3) 18 (3) 
MAX 32 (3) 161 (5) 51 (8) 17 (6) 
Hepcidin-25 
    
HLB 82 (10) 129 (0) 106 (24) 33 (4) 
MCX 0 (0) 130 (31) 0 (0) 0 (0) 
WAX 13 (4) 187 (4) 24 (4) 19 (3) 
MAX 30 (4) 183 (4) 55 (8) 19 (7) 
Hepcidin-ISTD 
    
MCX 1 (2) 135 (33) 1 (0) 0 (0) 
WAX 14 (3) 187 (9) 26 (0) 24 (3) 
MAX 35 (3) 182 (2) 63 (10) 31 (13) 
 
As the use of a HLB sorbent with acidic loading and eluting conditions gave superior process 
efficiency compared to PPT and immunocapture, and because of other advantages of SPE (e.g. 
batch analysis on 96-well plates), SPE was further investigated and optimised as a suitable 




2.5.3.2 Optimisation of sample and diluent volume  
The impact of increasing sample volume on response was investigated by keeping the ratio of 
sample to 4 % (v/v) aqueous phosphoric acid constant (1+2), while the volume of sample was 
increased from 50–300 µL. The impact of increasing the volume of 4 % (v/v) aqueous 
phosphoric acid (100–400 µL) to a fixed volume of sample (100 µL), was also investigated using 
the procedure outlined in Figure 2-11.  
When the volume of sample loaded onto the HLB sorbent increased so did the area of 
each analyte (Figure 2-17). However, when the volume of sample was doubled, the area 
increased by only 35–50 % as opposed to an expected 100 % increase. This may be due to the 
poor disruption of hepcidins from proteins. Increasing the volume of 4 % (v/v) aqueous 
phosphoric acid to sample did not have any significant effect on analyte area (Figure 2-18). 
These investigations indicated that the volume of sample loaded onto the HLB sorbent could be 
increased if improvements in sensitivity are required, and a minimum ratio of 1 part sample to 1 










Figure 2-17. Effect of increasing the volume of sample (100 µg/L, all analytes) loaded 
onto the HLB sorbent, while keeping the ratio of sample to diluent (1+2) constant. 
Analysis undertaken in singlicate. 
 
 
Figure 2-18. Effect of increasing the volume of sample relative to buffer (100 µg/L, all 
analytes) loaded onto HLB sorbent, while keeping the volume of sample (100 µL) 































































2.5.3.3 Impact of sample preparation prior to loading 
To assess which acid to dilute the sample with prior to loading onto the HLB sorbent, 4 % (v/v) 
aqueous phosphoric acid, and 0.1 % (v/v) aqueous formic acid were compared as diluents. 
Phosphoric acid and formic acid were selected, as when prepared with these final percentages 
they do not precipitate out proteins, but still reduced the pH of the supernatant to below 1. A 
solution of 10 % (w/v) aqueous TCA, containing 20 % acetonitrile was also investigated as a 
diluent. Sample (200 µL) was added to the appropriate diluent (600 µL) in a 1.5 mL LoBind tube, 
vortex mixed for 10 minutes before centrifuging (5 minutes, 16,060 x g) and loading all of the 
supernatant onto the HLB sorbent. 
There was little difference in peak areas for all hepcidins between the use of 0.1 % (v/v) 
aqueous formic acid, and 4 % (v/v) aqueous phosphoric acid as diluents (Figure 2-19). 
However, precipitating out proteins using 10 % (v/v) aqueous TCA prior to loading onto the SPE 





Figure 2-19. Comparison of different diluents on peak areas. Mean of triplicates, error 

























10 % (w/v) aqueous TCA
0.1 % (v/v) aqueous formic acid




Although there was little difference between the use of phosphoric and formic acid, aqueous 
formic acid (0.1 %, v/v) as a diluent was marginally better for hepcidin-25, and is consistent with 
other investigators who have used this approach prior to loading onto the SPE sorbent (Li et al., 
2009; Wolff et al., 2013; Lefebvre et al., 2015). Increasing the percentage of formic acid from 
0.1–1.0 % (v/v) did not improve response, therefore a 0.1 % (v/v) aqueous formic acid solution 
was used to minimise protein precipitation and therefore reduce the chance of the analyte being 
‘dragged down’ by binding proteins. 
 
2.5.3.4 Optimisation of wash solution 
Wash solutions consisting of either 20 % (v/v) aqueous acetonitrile alone, 20 % (v/v) aqueous 
methanol alone, or either with 4 % (v/v) phosphoric acid or 5 % (v/v) ammonia added were 
compared. There was little difference in the area of all analytes (Figure 2-20) between wash 
solutions. However, a wash solution containing 20 % (v/v) aqueous acetonitrile alone gave a 
slightly better response for hepcidin-25.  
The use of acetonitrile in the wash solution was further optimised by comparing 
deionised water containing varying percentages (v/v) of acetonitrile (0–50 %) either alone, with 
4 % (v/v) phosphoric acid, or 5 % (v/v) ammonia (Figure 2-21). The optimum percentage of 
acetonitrile in the wash solution was considered to be 20 % (v/v), without the addition of 





Figure 2-20. Effect of different wash solutions on analyte peak areas. Analysis 















































20 % (v/v) methanol alone
20 % (v/v) acetonitrile alone
20 % (v/v) methanol containing 5 % (v/v) ammonia
20 % (v/v) acetonitrile containing 5 % (v/v) ammonia
20 % (v/v) methanol containing 4 % (v/v) phosphoric acid







Figure 2-21. Effect of varying concentrations of; (A) aqueous acetonitrile alone, (B) 
aqueous acetonitrile with 0.1 % (v/v) formic aid, and (C) aqueous acetonitrile containing 4 













































































































2.5.3.5 Optimisation of eluting solution  
The percentage of acetonitrile in the eluting solution was optimised over the range 30–90 % 
(v/v) while keeping the elution volume constant (50 µL). The elution volume was also 
investigated over the range 20–80 µL, while keeping the acetonitrile content constant (70 %, 
v/v). The optimum percentage of acetonitrile in the eluting solution was considered to be 60 %, 

































Figure 2-22. Effect of; (A) increasing the percentage of acetonitrile (v/v) in a constant 
elution volume (70 µL), and; (B) increasing the volume of elution solution, while keeping 
the percentage of (v/v) acetonitrile constant (70 %). Mean of triplicates, error bars 


































































2.5.3.6 Final SPE method  
Following much optimisation, the final SPE method was as follows:  
 
• Dilute sample (200 µL) with 0.1 % (v/v) aqueous formic acid (600 µL) 
• Vortex mix for 5 minutes, followed by centrifugation for 5 minutes (16,060 x g)  
• Load supernatant onto HLB sorbent under vacuum 
• Wash with 20 % (v/v) aqueous acetonitrile (200 µL) 
• Elute with 60 % (v/v) aqueous acetonitrile containing 1 % (v/v) TFA (70 µL)  
• Add 100 µL of deionised water to extract 
• Inject 100 µL onto LC-HR-MS 
Using the above method, a calibration curve over the range 1–200 µg/L (all analytes) was 
prepared in SHS, and extracted per the method described. The calibration was linear for all 
analytes (R2 > 0.90). Therefore, this method was considered suitable for the measurement of all 
hepcidins, and this optimised method was then ready for validation. 
 
2.6 Discussion 
Published mass spectrometry based methods for the measurement of hepcidin-25 broadly fall 
into 2 groups (i) SELDI- and MALDI-TOF-MS based, and (ii) LC-MS/(MS) based. No published 
method quantifies all commercially available isoforms of hepcidin-25 (i.e. hepcidin-20, -22, -24, 
and -25). SELDI- and MALDI-TOF-MS are widely used in research environments for qualitative 
analysis. When used for quantitative analysis, advantages include high-throughput of samples; 
some disadvantages, however, include poor reproducibility between samples in-part due to 
matrix effects, and relatively low mass resolution (Szájli et al., 2008). The use of a suitable 
internal standard can help to improve the precision of measurements, and if the assay has been 
thoroughly developed and evaluated SELDI and MALDI can be applicable to the measurement 
of hepcidin-25. Several such assays have been published (Ward et al., 2008; Laarakkers et al., 
2013). As SELDI/MALDI instruments are mainly located within research environments it is not 
surprising that the first published methods for hepcidin-25 quantitation used these techniques. 
However, published hepcidin-25 methods, have increasingly used LC-MS/MS, in-part because 
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this technique is widely used for quantitative analysis and that these instruments are more 
widely found in clinical chemistry laboratories.  However, LC-HR-MS is becoming increasingly 
popular in laboratories for the quantitative analysis of peptides/proteins and small molecules.  
The results from proficiency testing schemes can be useful to compare techniques, and 
this approach has been undertaken for vitamin D (Couchman et al., 2012). Unfortunately, no 
such scheme exists for hepcidin-25, and even though there have been several round-robins 
undertaken (Kroot et al., 2009, Kroot et al., 2012) participant’s assays are grouped into either 
immunochemical or mass spectrometric, and no further detail is given in-order to provide 
anonymity of each participant’s results. Therefore, the performance of different mass-
spectrometric techniques (i.e. MALDI vs SELDI, or vs LC-MS/MS) cannot be compared, and 
even if this information was available there would be too few assays per group to allow 
meaningful interpretation. 
 With regards to sample preparation published LC-MS based methods for hepcidin-25 
have used either protein precipitation (Murao et al., 2007; Rochat et al., 2013), ultrafiltration 
(Kobold et al., 2008), magnetic nanoparticles (Bansal et al., 2010) or solid phase extraction 
(Murphy et al., 2007; Wolff et al., 2013; Li et al., 2009; Li et al., 2015; Lefebvre et al., 2015). In 
the work undertaken here however, protein precipitation using an organic solvent (e.g. 
acetonitrile) or aqueous TCA, prior to analysis by LC-MS gave unacceptable process 
efficiencies and matrix effects. Instead, Waters Oasis µElution SPE plates were used as they 
are available in 96-well formats readily applicable to high-throughput analyses, come in a range 
of sorbent chemistries, and allow concentration of the analyte through the use of small elution 
volumes. The HLB sorbent provided optimum process efficiency with minimal matrix effects, as 
compared to other ion-exchange sorbents. This is in keeping with several other reported 
methods that have used Waters Oasis µElution SPE plates with the HLB sorbent (Murphy et al., 
2007; Li et al., 2009; Li et al., 2015; Wolff et al., 2013). A recently published method (Lefebvre 
et al., 2015) used Waters OASIS MAX µElution plates after mixing the sample with 0.1 % (v/v) 
aqueous formic acid, and eluting with 5 % (v/v) formic acid in 72.5 % (v/v) aqueous acetonitrile. 
However, this approach is counterintuitive as all hepcidins have an isoelectric point of 8.22–
8.53, and when loaded onto a MAX sorbent in an acidic environment the mechanism of 
retention would not be ion-exchange but rather reversed-phase. Furthermore, all hepcidins have 
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only 18 to 25 % of their amino acids ionisable, of which most are situated next to disulfide 
bridges and would be unlikely to interact with ion-exchange functions present on the sorbents.  
Despite immunocapture having been used a number of other clinically relevant proteins 
(Krastins et al., 2013); it was not suitable as a sample preparation technique for hepcidin 
primarily due to poor process efficiency. It is not clear why process efficiency was low when 
using this approach, but it is likely that other unknown endogenous compounds interfered with 
antibody binding.  
 With regards to chromatography, even though all hepcidins had similar retention times 
they were almost resolved at baseline, and the use of a microbore LC column (i.e. internal 
diameter 1 mm) allowed the use of a low flow-rate (0.1 mL/min) without an excessively long 
analysis time. Since ESI is concentration-dependent, a low flow-rate will not cause a reduction 
in sensitivity, but rather improve sensitivity as ionisation of the analyte is much improved at low 
flow flow-rates.   
Traditionally, triple quadrupole mass–analysers have been used for the quantitation of 
small molecules, including peptides and proteins. This is in part, due to the selectivity and 
sensitivity that can be obtained with these instruments. However, hepcidin-25 can absorb 
substantial fragmentation energies before fragmentation occurs, and when hepcidin-25 does 
fragment, there are many product ions of low or variable intensities (Bansal et al., 2009). Those 
methods that have used this approach, monitor product ions which are either of low abundance 
(Murphy et al., 2007) or of a low m/z (Murao et al., 2007), which lack specificity. Furthermore, 
these methods monitor only a single charge state, and a single isotope of that charge state, 
however there is the possibility that charge state distribution may differ from sample to sample. 
The method developed here, has the advantage that the top 5 most abundant isotopes (88 % of 
the theoretical charge) of the top 3 most predominant charge states are monitored and used for 
post-acquisition data processing, thereby ensuring that any charge state or isotope variability 
between samples is accounted for. By using high resolution-mass spectrometry, the method 
here resolves almost all precursor ions entering the mass spectrometer, which improves 
selectivity and aids accurate quantitation, especially when used with an appropriate mass 
extraction window. Also, by using high resolution-mass spectrometry and acquiring data in full 
scan mode across a broad mass range, post-acquisition interrogation of data for other isoforms 
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of hepcidin (i.e. hepcidin-19, -21, -23) is possible, as is presented in Chapter 3, when 
investigating the stability of hepcidin isoforms. 
 
2.7 Conclusions 
The proposed method allows the quantitation of all available hepcidin isoforms in a single 
analysis.  By acquiring data in full scan mode the top 5 isotopes of each charge state to be 
summed, ensuring that most of the analyte charge can be used in post-acquisition data 
processing. Despite the use of protein precipitation having been previously used for the 
measurement of hepcidin-25, neither this technique, nor immunocapture, was suitable for the 
work undertaken here due to poor process efficiencies. Solid Phase Extraction, although time-
consuming to optimise, gave superior process efficiency, and the use of 96-well plates has the 






















Method validation is a necessary process to demonstrate that an analytical method is suitable 
for its intended use. Parameters such as accuracy, precision, and ion suppression (if MS is 
being used) should be assessed, as should stability of the analyte in prepared extracts and in 
biological samples. Comparability between matrix types (i.e. plasma vs serum) should also be 
ascertained if the sample type may vary, and where possible the developed method should be 
compared against other appropriately validated methodologies. As significant variability 
between assays for hepcidin-25 has been reported (Kroot et al., 2009; Kroot et al., 2012; van 
der Vorm et al., 2016), a method-based reference range in healthy individuals should also be 
established. 
 
The aims of this chapter are as follows: 
 
• Validate the developed LC-HR-MS assay for serum/plasma hepcidin-25 and 
N-truncated isoforms 
• Compare hepcidin isoform concentrations in paired human plasma and serum samples 
• Investigate the stability of all hepcidin isoforms when added to stripped-human serum 
and in clinical samples 
• Measure all hepcidin isoforms in samples from healthy volunteers to create a 




3.2 Materials and methods 
All chemicals, reagents and consumables used are given in Section 2.2.  
 
3.2.1 Preparation of calibration and internal quality control solutions  
Stock solutions (100 mg/L, corrected for purity where required) of each individual hepcidin, 
including internal standard, were prepared in 30 % (v/v) aqueous acetonitrile containing 0.1 % 
(v/v) formic acid. Stripped human serum was analysed before use to prepare calibration and 
IQC solutions, and no analytes were detected (LLoQ 1 µg/L). Two calibration working solutions 
(1 mg/L and 4 mg/L, all analytes) were prepared by appropriate dilution of individual stock 
solutions with analyte-free stripped human serum into grade A volumetric glassware. A separate 
internal quality control (IQC) working solution was prepared (4 mg/L, all analytes) in analyte-free 
stripped human serum. 
To prepare calibration and IQC solutions (Table 3.1), appropriate volumes of working 
solutions were pipetted into grade A volumetric glassware and made up to volume with analyte-
free stripped human serum. After standing overnight (2–8 ºC) and after thorough mixing, 
portions of all solutions were transferred to 0.5 mL LoBind tubes and stored at -20 ºC until 
required.  
Working internal standard (IS) solution (1 mg/L) was prepared by dilution of the 
hepcidin-ISTD stock solution with 30 % (v/v) aqueous acetonitrile containing 0.1 % (v/v) formic 
acid, and portions stored at -20 °C in 0.5 mL LoBind tubes until required. 
 
Table 3.1 Nominal analyte concentrations: stripped human serum calibration and IQC 
solutions. 
Analyte 




1 2 3 4 5 6 7 A B C 
Hepcidin-20 1 2 5 10 25 50 100 4 8 25 
Hepcidin-22 1 2 5 10 25 50 100 4 8 25 
Hepcidin-24 1 2 5 10 25 50 100 4 8 25 




3.2.2 Instrumentation and conditions 
An Aria Transcend LX-II system (ThermoFisher Scientific, San Jose, USA) consisting of four 
Accela 600 high-pressure quaternary pumps, valve interface module, column oven and CTC 
PAL autosampler was used with a Q-Exactive mass spectrometer (ThermoFisher Scientific). 
Liquid chromatography and mass spectrometer instrument control was performed using Aria OS 
(version 2.0, ThermoFisher Scientific), and Xcalibur software (version 2.2, ThermoFisher 
Scientific), respectively. System eluents were: (A) 0.1% (v/v) aqueous formic acid, and (B) 0.1% 
(v/v) formic acid in acetonitrile. The total eluent flow rate was delivered at 0.1 mL/min, using the 
following step wise gradient; 5 % B for 1 minute, ramped to 50 % B over 8 minutes, then 
stepped to 100 % for 1.5 minutes (flow-rate 0.4 mL/min) before returning to starting conditions 
for 1.5 minutes (flow-rate 0.4 mL/min). Prepared samples (100 µL) were injected onto an ACE 
C18 modified silica column (100 x 1.0 mm i.d, 3 µm a.p.s) maintained at 60 ºC. MS detection 
was carried out in positive mode using heated electrospray ionization [spray voltage 4.0 kV; 
temperatures: vaporizer 150 ºC; capillary 350 ºC; auxiliary, sheath and sweep gases 10, 35 and 
0 (AU), respectively, S-lens voltage 90 V]. The total analysis time was 12 minutes. Full-scan MS 
data were acquired using a resolution setting of 70,000, defined as full width at half maximum at 
m/z 200, with a scan range of 400–1000 m/z (Orbitrap settings: maximum injection time 200 ms, 
automatic gain control [AGC] target 3 x 106 ions). Post-acquisition data processing used 
Xcalibur software, and peak areas were generated by filtering full scan data using a mass 
extraction window of ± 10 ppm based on theoretical monoisotopic m/z values of the five most 
abundant isotopes of the [M+3]3+, [M+4]4+, and [M+5]5+ charge states (Table 2.1).  
Peak area ratios (hepcidin-20, -22, -24, and -25 to hepcidin-ISTD) were measured and 
used to construct calibration curves (1/x2 weighting, not forced through zero). Qualitative analyte 
identification criteria were: (i) LC retention time within 10 s of that initially ascertained (including 
co-elution with the internal standard for hepcidin-25), and (ii) m/z value of the protonated pre-
cursor ion within ± 10 ppm. Samples where the analyte concentration measured was above the 





3.2.3 Sample preparation  
Sample (200 µL) was added to a 1.5 mL LoBind tube together with IS working solution (10 µL, 
1,000 mg/L), and 0.1 % (v/v) aqueous formic acid (600 µL), followed by vortex mixing for 5 
minutes, and centrifugation for 5 minutes (16,060 x g). An Oasis HLB µElution, 96-well, SPE 
plate was conditioned by addition of methanol (200 µL) followed by deionised water (200 µL) 
while under vacuum. The entire supernatant was loaded onto the conditioned 96-well SPE 
plate, and allowed to flow freely under gravity for 5 minutes after which vacuum was applied 
until no supernatant remained. The plate was washed sequentially with 20 % (v/v) aqueous 
acetonitrile (200 µL), and then deionised water (200 µL), both under vacuum. Analytes were 
eluted with 70 % (v/v) aqueous acetonitrile containing 1 % (v/v) TFA under vacuum (60 µL). 
After elution, 0.1 % (v/v) formic acid (70 µL) was added to each extract. The 96-well plate was 
then transferred to the autosampler, and 100 µL injected onto the LC-HR-MS. 
 
3.2.4 Method validation  
3.2.4.1 Mass accuracy 
To assess mass accuracy, mass error (m/z ∆) was calculated for each individual isotope (top 5) 
of the [M+3H]3+, [M+4H]4+, and [M+5H]5 ions of each calibration solution within one batch (intra-
assay) and between batches (inter-assay, N = 5). 
 
3.2.4.2 Intra-, inter-assay precision and accuracy, and LLoQ 
Intra- and inter-assay precision and accuracy were assessed by replicate analysis (N = 5) of 
IQC solutions on the same day and in duplicate on different days (N = 5), respectively. Lower 
limits of quantification (LLoQ) were assessed by dilution of calibration solution 3 with analyte-
free stripped human serum, and analysed in triplicate. The LLoQ was defined as the lowest 
concentration where inaccuracy and imprecision were < 20 %. 
 
3.2.4.3 Extraction recovery, matrix effects, and process efficiency 
To ascertain extraction recovery, matrix effect, and process efficiency (‘overall recovery’) the 
procedure suggested by Matuszewski et al (2003) was followed. All hepcidins (including internal 
standard) were added to analyte-free stripped human serum at the same concentration as IQCs 
A, B and C either before (A), or to analyte-free stripped human serum post extraction (B). All 
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hepcidins were also added to 35 % (v/v) aqueous acetonitrile containing 1 % (v/v) TFA (C). The 
peak area ratios (expressed as a percentage) of A to C, B to C, and B to A were calculated to 
ascertain process efficiency, matrix effects, and extraction recovery, retrospectively. Process 
efficiency was further ascertained by addition of all analytes (100 µg/L) to serum from 5 different 
sources (all analytes were below the LLoQ before fortification).  
As hepcidin-25 has been suggested to be largely protein bound to α-2-macroglobulin, 
changes in the concentration of this protein - especially in those individuals with reduced kidney 
function, may affect the extraction of hepcidin-25,. Therefore, to ascertain whether there is an 
effect of increasing α-2-macroglobulin concentrations on process efficiency, α-2-macroglobulin 
was added to phosphate buffered saline containing all hepcidins (100 µg/L) at 1, 2, 3, and 4 g/L, 
and were analysed (N = 3) according to the protocol described herein. These concentrations of 
α-2-macrogobulin were chosen as they cover the range than can be expected in both healthy 
individuals and those with reduced kidney function (de Sain-van der Velden et al., 1998). 
 
3.2.4.4 Carry-over 
Carry-over was assessed through consecutive analysis of prepared samples containing all 
analytes at low and high (L and H; 5 and 500 µg/L, respectively) concentrations in the order H, 
H, H, L, L, L.  
 
3.2.4.5 Stability 
3.2.4.5.1 Autosampler stability 
To investigate analyte stability in the autosampler tray (10 ºC), separate solutions of hepcidin-
20, -22, -24, and -25 were prepared in 20 % (v/v) aqueous acetonitrile containing 0.4 % TFA 
(v/v) at low (5 µg/L all analytes, except hepcidin-25: 10 µg/L), and high (50 µg/L all analytes, 
except hepcidin-25: 100 µg/L) concentrations. A portion of each sample was injected onto the 
LC-HR-MS every hour for up to 24 hours.   
 
3.2.4.5.2 Freeze-thaw 
Freeze–thaw stability was assessed by freezing (-20 ºC for 23 hours) and thawing (ambient 
room temperature, 1 hour) analyte-free stripped human serum containing individual hepcidins 
(50 µg/L). After thorough mixing, the solutions were analysed using freshly prepared calibration 
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solutions that had not undergone freeze-thawing. Portions of solutions that remained were 
returned to the freezer until the following day (3 freeze–thaw cycles in total).  
 
3.2.4.5.3 Fortified and Clinical samples 
To investigate analyte stability, all hepcidins were added to separate portions of analyte-free 
stripped human serum (final concentration 50 µg/L all analytes, except hepcidin-25 at 100 µg/L), 
and stored in the dark as approximately 500 µL portions in LoBind tubes at (i) -18 to -20 ºC, (ii) 
2–8 ºC, and (iii) at ambient room temperature (approximately 20 °C). Each solution was 
sampled at 0, 1, 2, 4, 8 hours, 1 to 5, 7, 14, 21, and 28 days. Serum from 5 separate patients 
were also stored at (i) 2–8 ºC, and (ii) at ambient room temperature for 28 days. Each solution 
was sampled at time 0, after 1 to 3, 5, 7, 14, 21, and 28 days.  
To ascertain whether there was degradation of any hepcidin isoform during the 
extraction process, each individual hepcidin was added to separate portions of analyte-free 
charcoal-stripped human serum (50 µg/L all analytes), and analysed in duplicate. 
 
3.2.4.6 LC-HR-MS vs ELISA/LC-MS/MS method comparison 
For method comparison purposes, 67, and 51 serum samples that had been previously 
analysed for hepcidin-25 using an ELISA, (Ganz et al., 2008), and a published LC-MS/MS 
method (Bansal et al., 2010), respectively were used for method comparison purposes. All 
samples were stored at -20° for up to 12 months prior to analysis by LC-HR-MS. 
 
3.2.4.7 Comparison of plasma and serum  
For the comparison of all analytes in human plasma and serum, excess serum [Beckton 
Dickson (BD) Vacutainer SST II Advance] and plasma (BD Vacutainer dipotassium EDTA) from 
the same patient (N = 47) that had been submitted for routine biochemical and haematological 
analyses were collected from the Blood Sciences Laboratory, KCH. Samples were stored at 2–8 
ºC for up to 4 hours before centrifugation (12,000 x g), and aliquots of the serum or plasma 
were stored in 0.5 mL LoBind tubes at -20 ºC until analysis. All aliquots were fully anonymised 




3.2.5 Investigation of other hepcidin isoforms and oxidation products 
Using Pinpoint software (ThermoFisher Scientific), theoretical m/z ratios and isotope patterns 
were generated for hepcidin-19, -21, and -23, and these were used to investigate whether other 
hepcidin isoforms maybe present in calibration/IQC solutions, or stability samples. 
 Hepcidin-24 and -25 both contain the amino acid methionine which is prone to oxidation 
to either a sulfone or sulfoxide. Theoretical m/z were generated using Pinpoint software and 
calibration solutions were retrospectively reviewed. 
 
3.2.6 Charge state distribution 
To investigate whether the distribution of charge state differs from sample-to-sample, data from 
serum samples used for comparison of plasma and serum were re-processed to provide peak 
areas of each individual charge state ([M+3H]3+, [M+4H]4+, and [M+5H]5+), for each individual 
hepcidin. 
 
3.2.7 Establishment of reference range 
To establish a reference range for all hepcidin isoforms in healthy individuals using the current 
method, volunteers from the Pathology Laboratory, King’s College Hospital, Denmark Hill, 
London, were requested to donate whole blood. All volunteers were given an information sheet 
and a consent form outlining the details of the request (Appendix A). After providing informed 
consent, sample was collected into BD Vacutainer SST II Advance blood collection tubes, and 
was fully anonymised by use of a participant identification number. Once collected, samples 
were immediately centrifuged (12,000 x g) and the serum separated. Serum ferritin, iron, c-
reactive protein (CRP), and total iron binding capacity were immediately measured. Serum 
ferritin (LLoQ: 1 µg/L) was measured using a direct chemiluminometric two-site immunoassay 
(Siemens Healthcare Diagnostics Ltd, UK). C-reactive protein (LLoQ: 2.0 mg/L) was measured 
with an ELISA (Wako Chemicals, Germany). Total iron binding capacity (TIBC, LLoQ: 1 µmol/L) 
was calculated indirectly by the unsaturated iron binding capacity method. Serum iron was 
measured using a colourimetric assay (LLoQ: 1 µmol/L). Normal reference ranges for these 
analytes used within KCH were as follows; ferritin 20–300 (males), 20–200 (females) µg/L, CRP 
< 5 mg/L, TIBC (males and females) 50–72 µmol/L, and TSAT (males and females) 20–50 %. 
Following analysis, serum was stored in separate 0.5 mL LoBind tubes at -20 ºC within 2 hours 
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of collection until analysis for hepcidin isoforms. Samples were analysed for all hepcidin 
isoforms within 1 week of storage. 
 
3.2.8 Statistical analysis 
Statistical analysis was performed using Analyse-it (Analyse-it Software Ltd, Leeds, UK) for 
Microsoft excel, and SPSS for Windows, version 23.0 (SPSS Incorporated, Chicago, USA). 
Normality of data distribution was assessed using the Shapiro–Wilk test. Relationships were 
explored using Spearman’s rank correlation (r), the Mann–Whitney U test or Kruskal-Wallis test. 
A p value < 0.05 was considered statistically significant. To determine predictors of serum 
hepcidin isoform concentrations, univariate regression analysis was first undertaken, and 
variables where p = > 0.1 were excluded from further multivariate regression analysis. To 
correct for skewness, hepcidin isoform concentrations were log transformed prior to univariate 
and multivariate regression analysis. 
 
3.3 Results  
3.3.1 Method validation 
3.3.1.1 Calibration and mass accuracy 
Calibration was linear (R2 > 0.94) for all analytes over the range studied (Figure 3-1). Extracted 
ion chromatograms together with analyte retention times, and mass spectrums are shown in  
Figure 3-2, Figure 3-3, and Figure 3-4, respectively. The LC peak width at half height for all 
analytes was approximately 3 seconds; with approximately 12 points under each peak 
(unsmoothed data, calibration solution 4). Mean (SD) intra- (N = 5), and inter-assay (N = 5) 







Figure 3-1 Calibration curves for hepcidin-20, hepcidin-22, hepcidin-24, and hepcidin-25. Samples extracted in duplicate from stripped human serum and 
analysed using developed LC-HR-MS method. 
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Figure 3-2 Typical extracted ion chromatogram showing analyte retention time. 
Extraction window ± 10 ppm based on theoretical m/z. Chromatograms: (A) calibration 














































































Figure 3-3. Mass spectrum of a calibration standard 4 (10 µg/L, all analytes), indicating 




Figure 3-4. Mass spectrum of the [M+3H]3+ of hepcidin-25, from a calibration solution 4 
(10 µg/L). The top 5 isotopes monitored are indicated together with a mass extraction 
window of ± 10 ppm (dashed line). The accurate mass, exact mass and the mass error 









































m/z accurate = 930.0176
m/z exact = 930.0159
m/z ∆ = 1.8700
m/z accurate = 930.3497
m/z exact = 930.3501
m/z ∆ = -0.4618
m/z accurate = 930.6828
m/z exact = 930.6835
m/z ∆ = -0.7518
m/z accurate = 931.0172
m/z exact = 930.0169
m/z ∆ = 0.3350
m/z accurate = 931.3521
m/z exact = 931.3503


















3.3.1.2 Intra-, inter-assay precision and accuracy, and LLoQ 
Intra- and inter-assay precision and accuracy are summarised in Table 3.2. The LLoQ was 1 
µg/L for all analytes. 
 
Table 3.2. Summary accuracy and precision data. 
 
Analyte 
Hepcidin-20 Hepcidin-22 Hepcidin-24 Hepcidin-25 
Intra-assay (N = 5) 
            
Nominal  
concentration (µg/L) 4 8 25 4 8 25 4 8 25 8 75 150 
Mean measured  
concentration (µg/L) 4 9 26 4 8 24 5 9 30 9 80 164 
RSD (%) 11 14 6 < 1 6 7 11 10 9 9 2 6 
Accuracy  
(% nominal) 100 113 104 100 100 96 125 113 120 113 107 109 
Inter-assay (N = 5)             
Nominal  
concentration (µg/L) 4 8 25 4 8 25 4 8 25 8 75 150 
Mean measured  
concentration (µg/L) 4 9 26 4 8 25 5 9 29 8 78 154 
RSD (%) 21 6 14 4 2 6 22 13 15 6 7 7 
Accuracy  
(% nominal) 100 113 104 100 100 100 125 113 116 100 100 103 
 
3.3.1.3 Extraction recovery, matrix effects, and process efficiency 
Extraction recovery, matrix effects, and process efficiency for all analytes are summarised in 
Table 3.3. Median (range) process efficiency for all analytes added to analyte-free serum from 5 
separate sources were; 36 (22–45), 25 (18–37), 23 (17–26), 24 (15–38), and 23 (15–32) % for 
hepcidin-20, -22, -24, -25, and -ISTD, respectively. Increasing the concentration of α-2-









Table 3.3. Extraction efficiency, matrix effects, and process efficiency for all analytes at 
low (hepcidin-20, -22, -24: 4 µg/L, hepcidin-25: 8 µg/L), medium (hepcidin-20, -22, -24:  
µg/L, hepcidin-25: 75 µg/L), and high (hepcidin-20, -22, -24: 25 µg/L, hepcidin-25: 150 





Hepcidin-20 Hepcidin-22 Hepcidin-24 Hepcidin-25 Hepcidin-ISTD 
Extraction  
efficiency 24 (11) 20 (7) 18 (7) 17 (6) 16 (6) 
Matrix  
effects 109 (22) 130 (25) 132 (27) 133 (26) 132 (25) 
Process  





Hepcidin-20 Hepcidin-22 Hepcidin-24 Hepcidin-25 Hepcidin-ISTD 
Extraction  
efficiency 49 (19) 53 (22) 40 (15) 50 (21) 49 (20) 
Matrix  
effects 69 (10) 83 (14) 104 (17) 95 (16) 96 (16) 
Process  





Hepcidin-20 Hepcidin-22 Hepcidin-24 Hepcidin-25 Hepcidin-ISTD 
Extraction  
efficiency 35 (13) 47 (12) 42 (8) 43 (10) 42 (10) 
Matrix  
effects 68 (6) 78 (8) 90 (8) 84 (7) 84 (8) 
Process  








Figure 3-5. Effect of increasing α-2-macroglobulin concentrations on peak areas of all 
hepcidins. Mean of triplicates, error bars represent ± standard deviation (Kruskal-Wallis; 
hepcidin-20, p = 0.46; hepcidin-22, p = 0.42; hepcidin-24, p = 0.52; hepcidin-25, p = 0.25; 
hepcidin-ISTD, p = 0.23).  
 
3.3.1.4 Carry-over 































3.3.1.5.1 Autosampler stability 
All analytes were stable in extracts on the autosampler at low and high concentrations 
respectively (Figure 3-6 and Figure 3-7). 
 
 
Figure 3-6 Stability of hepcidin-20, -22, -24 and, -25 in extracts on the autosampler at 10 





































Figure 3-7 Stability of (A) hepcidin-20, and -24, and (B) hepecidin-22, and -25 in extracts 




































All analytes were stable following 3-freeze thaw cycles 
 
3.3.1.5.3 Fortified samples 
When stored at ambient room temperature all analytes were stable (± 20 % of initial 
concentration) for 1 week, after which there was a steady decline until week 4 where the 
concentration of hepcidin-20 was only 15 % of that measured initially, and for hepcidin-22, 24, 
and -25; 40 % of that initially. All analytes were stable for up to 3 weeks at 2–8 ºC, after which 
concentrations began to decline (Table 3.4). Under all storage conditions the decline in 
hepcidin-20, -24, and -25 concentrations was not paralleled by an increase in the 
concentrations of other known hepcidin isoforms. However, the decline in hepcidin-22 when 
stored at room temperature was paralleled by the presence of increasing concentrations of 
hepcidin-20 (Figure 3-8). Hepcidin-20 was also detected after day 2 when hepcidin-22 was 
stored at 2–8 ºC, although measured concentrations were low (median 3, range 2–6 µg/L). 



















Table 3.4. Analyte stability when added to separate portions of stripped human serum, 
and stored at; (A) ambient room temperature in the dark, and; (B) 2–8 ºC. * Due to 
sampling error data not available. 
 (A) 
Time 
Analyte concentration (%a) after storage  
at ambient room temperature 
Hours Days Weeks Hepcidin-20 Hepcidin-22 Hepcidin-24 Hepcidin-25 
1 - - 84 95 96 91 
2 - - 80 101 102 98 
3 - - 93 96 100 106 
4 - - 90 * 84 * 
8 - - 86 * 91 94 
24 1 - 95 109 86 89 
48 2 - 126 98 69 90 
72 3 - 83 89 80 90 
96 4 - 76 93 91 86 
120 5 - 85 90 85 93 
168 7 1 77 81 82 89 
336 14 2 42 62 65 95 
504 21 3 32 51 49 * 




































Time Analyte concentration (%a) after storage  
at 2–8 ºC 
Hours Days Weeks Hepcidin-20 Hepcidin-22 Hepcidin-24 Hepcidin-25 
1 - - 74 100 96 93 
2 - - 98 101 95 97 
3 - - 80 101 71 94 
4 - - * 103 * 105 
8 - - 61 111 103 101 
24 1 - 91 97 95 97 
48 2 - 60 109 96 98 
72 3 - 59 99 86 99 
96 4 - 103 105 76 91 
120 5 - 60 93 84 92 
168 7 1 85 98 90 100 
336 14 2 81 99 82 93 
504 21 3 77 99 86 100 
672 28 4 69 * 70 74 




Figure 3-8. Stability of hepcidin-22 when added to stripped human serum, and stored at 
2–8 ºC, showing an increase in the presence of hepcidin-20. 
 
3.3.1.5.4 Clinical samples 
When stored at ambient temperature the concentration of all analytes steadily declined day-to-
day, by broadly the same amount (Figure 3-9). Although hepcidin-25 was stable (± 20 % of 
initial concentration) in samples 2 and 3 at the third day, in the remaining samples 
concentrations had declined to 70–80 % of those at day 1.  
When stored at 2–8 ºC all analytes were considerably more stable than at room 
temperature; hepcidin-25 was stable (± 20 % of initial concentration) for 5–7 days, however 
there was again much variability between samples (Figure 3-10).  
In all samples stored either at room temperature, or at 2–8 °C there was no evident 
























Figure 3-9 Stability of hepcidin isoforms in five serum patient samples when stored in the dark at ambient room temperature for up to 28 days. (A) 
Hepcidin-20, (B) hepcdidin-22, (C) hepcidin-24, and (D) hepcidin-25. Data expressed as a percentage of the concentration measured initially. Initial 
concentrations in samples 1–5 for hepcidin-20; 3, 9, 6, 1, 6 µg/L, hepcidin-22; 4, 16, 7, < 1, 4 µg/L, hepcidin-24; 17, 19, 12, 6, 19 µg/L, and hepcidin-25; 
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Figure 3-10. Stability of hepcidin isoforms in five patient samples when stored at 2–8 °C for up to 28 days. (A) Hepcidin-20, (B) hepcdidin-22, (C) 
hepcidin-24, and (D) hepcidin-25. Data expressed as a percentage of the concentration measured at time ‘0’. Concentrations at time 0 in samples 1–5 
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3.3.1.6 Method comparisons 
3.3.1.6.1 LC-HR-MS vs ELISA 
A scatterplot, and Bland-Altman plot of the sample comparison is shown in Figure 3-11. There 
was a positive and significant correlation (r = 0.79, p < 0.0001) for hepcidin-25 between the two 
methods used. However, the concentrations of hepcidin-25 measured by the developed 
LC-HR-MS method were approximately 13 % of those measured using the ELISA method, and 
with proportional (p < 0.0001) bias. In no sample was either hepcidin-20, or hepcidin-22 





Figure 3-11. Scatterplot (A), and Bland-Altman plot (B) showing the correlation between 
serum hepcidin-25, in samples when analysed using an ELISA and the developed 




























































Hepcidin-25 (µg/L) by ELISA
R2 = 0.64





3.3.1.6.2 LC-HR-MS vs LC-MS/MS 
A scatterplot, and Bland-Altman plot of the sample comparison is shown in Figure 3-12. There 
was a very good correlation between the two methods for hepcidin-25, although there was a 
bias that was proportional (p < 0.05).  
Hepcidin-20, -22, and -24 were detected in 86, 69, and 69 % of samples, respectively, 
and the median (range) hepcidin-20, -22, and -24 concentrations measured were 11 (1–91), 2 
(1–23), and 3 (1–62) µg/L, respectively. The published LC-MS/MS method used for comparison 
























Figure 3-12. Scatterplot (A), and Bland-Altman plot (B) showing the correlation between 
serum hepcidin-25 in samples (N = 45) when analysed using a published LC-MS/MS 
method, and the developed LC-HR-MS method. Solid line = simple linear regression, 
dashed lines = 95 % limits of agreement. 

































































3.3.1.7 Comparison between plasma and serum 
There was a strong and significant correlation (r = ≥ 0.95, p = < 0.05) between all analytes in 
paired plasma and serum (Figure 3-13). Hepcidin-20, -22, 24, and -25 were detected in 74 (N = 
35), 23 (N = 11), 53 (N = 25), and 89 (N = 42) % of serum samples. Median (range) serum 
hepcidin-20, -22, -24, and -25 concentrations measured were 4 (1—34), 6 (2—21), 8 (1—51), 




Figure 3-13. Scatterplots of (A) hepcidin-20 (N = 35); (B) hepcidin-22 (N = 11); (C) hepcidin-24 (N = 25); and (D) hepcidin-25 (N = 42) in human plasma 
and serum. Dashed line = 95 % confidence intervals, Solid line = simple linear regression. 
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3.3.2 Investigation of other hepcidin isoforms and oxidation products 
Neither hepcidin -21, or -23 were identified in any calibration or IQC solution, however, there 
was a small peak present at the same retention time as hepcidin-20 (8.18 min, area 0.4 % of 
the hepcidin-20 peak), in those samples fortified with hepcidin-20. Reviewing the mass 
spectrum of this peak identified ions corresponding to the theoretical masses of the [M+4H]4+ 
charge state of hepcidin-19 (m/z 520.1790, 520.4300, and 520.6790). This was also consistent 
with the tentative identification of hepcidin-19 in the hepcidin-20 tuning solution. 
Sulfone/sulfoxide products of hepcidin-24 and hepcidin-25 were not identified. 
 
3.3.3 Charge state distribution 
The contribution of each charge state to the sum of the [M+3H]3+, [M+4H]4+, and [M+5H]5+ 
charge states are shown in Table 3.5. 
 
Table 3.5. Percentage contribution of each individual charge state to the sum of [M+3H]3+, 
[M+4H]4+, and [M+5H]5+. Data shown as mean (SD). 
 
Charge state 
[M+3]3+ [M+4]4+ [M+5]5+ 
Hepcidin-20  65.4 (4.6) 31.2 (4.6) 3.2 (4.6) 
Hepcidin-22  44.7 (5.2) 47.8 (5.2) 6.5 (5.2) 
Hepcidin-24  44.9 (9.2) 42.5 (9.2) 9.8 (9.2) 
Hepcidin-25  33.4 (10.5) 52.7 (10.5) 13.0 (10.5) 
Hepcidin-ISTD  37.2 (12.3) 48.7 (12.3) 13.8 (12.3) 
 
For hepcidin-20, the [M+3H]3+ ion is most abundant, whereas for hepcidin-22, -24, -25 and the 
internal standard the charge is broadly shared between the [M+3H]3+ and [M+4H]4+ charge 
states. This distribution of charge state is very different to that obtained when each analyte was 
individually infused into the mass spectrometer (Figure 2-1, and Figure 2-2).  
 
3.3.4 Establishment of reference range 
Serum was collected from 59 volunteers, 21 were male [median (range) age; 39 (24–68) yr], 
and 38 female [median (range) age: 36 (21–61) yr]. Ethnicity was recorded as white 3(6 
individuals), black (11), mixed race (2), Asian (7), and 3 did not provide this information. Forty-
111 
 
six recorded no medication, 5 reported as being on the oral contraceptive pill, and the 
remainder were on miscellaneous drugs (e.g. omeprazole, insulin, tetracyclizine). No medical 
conditions were mentioned of any note, except for 2 females that had β-thalassemia. For 
comparison of data, and for assessment of reference ranges, individuals with β-thalassemia 
were excluded (N = 2), as were those with a ferritin concentration < 20 µg/L (N = 11), and those 
where hepcidin-25 was below the LLoQ (N = 5). 
Summary biochemical data and serum hepcidin-25 concentrations measured are given 
in Table 3.6. Ferritin, and transferrin saturation were significantly lower in females as compared 
to males (p = < 0.01, and < 0.05, respectively). The median (range) hepcidin-25 concentration 
measured was 8 (1–31 µg/L), and despite median hepcidin-25 concentrations being lower in 
females (6 µg/L) as opposed males (11 µg/L), this was not statistically significant (p = 0.22). 
There was no significant difference between males and female for CRP (p = 0.56), iron (p = 
0.12), TIBC (p = 0.08), ferritin:hepcidin-25 (p = 0.31), or TSAT:hepcidin-25 (p = 0.47). The 
median (range) hepcidin-25: ferritin ratio was 14.8 (3.9–75.7), and the TSAT:hepcidin-25 ratio 
was 3.0 (5.3–21.0). Of those samples where hepcidin-25 was not detected, ferritin, iron, TIBC, 
and TSAT were all within their reference ranges, and were not indicative of iron deficiency. 
















Table 3.6. Summary biochemical data from (A) male, and (B) female serum volunteer 
samples (N.B. hepcidin-20, -22, and -24 were < 1 µg/L in all samples analysed). 








Ferritin (µg/L) 133 51 55 101 222 348 
C-reactive  
protein (mg/L) 2.2 < 2.0 3.2 3.0 6.0 9.7 
Iron (µmol/L) 17.9 8.8 13.8 16.3 24.2 31.7 
Total iron binding  
capacity (µmol/L) 57 49 51 56 64 67 
Transferrin  
saturation (%) 32 16 22 31 43 63 
Hepcidin-25 (µg/L)1 10 2 2 11 17 20 
Ferritin:Hepcidin-25 18.7 3.8 5.9 14.3 29.6 82.9 
TSAT:Hepcidin-25 5.4 1.4 1.7 2.9 13.9 21.9 
       








Ferritin (µg/L) 83 20 24 61 193 311 
C-reactive  
protein (mg/L) 2.1 < 2.0 2.3 2.9 3.1 3.2 
Iron (µmol/L) 15.9 7.3 10.1 15.4 24.1 29.0 
Total iron binding  
capacity (µmol/L) 59 46 54 58 66 70 
Transferrin  
saturation (%) 27 12 17 27 41 44 
Hepcidin-25 (µg/L)2 8 1 1 6 16 31 
Ferritin:Hepcidin-25 14.9 3.1 4.6 9.7 29.4 69.3 
TSAT:Hepcidin-25 7.3 0.9 1.4 4.0 17.1 39.3 
1 Excludes 3 samples where hepcidin-25 < 1 µg/L 
2
 Excludes 2 samples where hepcidin-25 < 1 µg/L 
 
Hepcidin-25 was positively correlated with ferritin (r = 0.48, p = < 0.05, Figure 3-14), and 
negatively correlated with TIBC (r = -0.40, p = < 0.05, Figure 3-15). Hepcidin-25 was not 
correlated with serum iron (r = 0.05, p = 0.76, Figure 3-14) or transferrin saturation (r = 0.16, p = 
0.32, Figure 3-15). Multivariate regression analysis, including the predictors ferritin and TIBC, 
only explained 26 % of the variation in serum hepcidin-25 concentrations, and showed ferritin (p 





Figure 3-14. Scatterplots showing the correlation between serum hepcidin-25, and (A) ferritin, and (B) iron in healthy volunteers. Solid line = simple 



































































Figure 3-15. Scatterplots showing the correlation between serum hepcidin-25, and (A) TIBC ferritin, and (B) iron, (C) TIBC, and (D) transferrin 































































3.4.1 Method validation 
The method developed here has good sensitivity, and is selective, with acceptable accuracy 
and precision for all hepcidin isoforms. Although, for hepcidin-20, and -24 precision at the 
lowest IQC (4 µg/L) was marginally outside the acceptance criteria of 20 %, It was still 
acceptable. There were minimal matrix effects for all analytes, and process efficiency, whilst low 
(< 50 %, all analytes), was compensated for by the internal standard, and an LLoQ of 1.0 µg/L 
was still achieved for all analytes. 
 
3.4.1.1 Stability and oxidation products 
All hepcidins (except hepcidin-25) were stable at ambient room temperature for 5–7 days 
(hepcidin-25; 3 weeks) when added to stripped human serum. However, in patient samples 
stored at ambient room temperature, concentrations of all hepcidin isoforms had begun to 
decline by day 1. These latter findings are broadly in-keeping with published reports that have 
found hepcidin-25 to be stable for 16 h in patient samples, when stored at room temperature (Li 
et al., 2009). All hepcidin isoforms in both stripped human serum, and patient samples were 
more stable when stored at 2–8 °C.  
It is not clear why hepcidin isoforms appeared to be more stable at ambient room 
temperature when added to stripped human serum, as compared to patient samples. However, 
the process of charcoal stripping, that removes some hormones and steroids, may remove 
enzymes involved in the degradation of hepcidin isoforms. Certainly, the treatment of foetal 
bovine serum with charcoal has been shown to reduce enzyme activity, electrolytes, and certain 
enzymes (Cao et al., 2009).  
It is interesting to note that when added to stripped human serum, the decline in 
hepcidin-24, and -25 concentrations was not paralleled by measurable concentrations of the 
smaller N-truncated isoforms of these analytes. Whereas, the decline in hepcidin-22 was 
paralleled by an increase in hepcidin-20 when stored at ambient room temperature. In patient 
samples, there was also no evident increase in any hepcidin isoform concentration that 
coincided with the decline in hepcidin-25.  
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Hepcidin-19, -21, or -23 were also not identified as being formed during storage, 
although this can only be tentatively concluded as without a reference compound, the 
chromatographic retention time, nor whether these compounds are extracted under the current 
methodology cannot be elucidated. But as hepcidin-19, -21, and -23 have very similar 
physiochemical properties (Table 1.1) to those hepcidins investigated here, it would be feasible 
to assume that they would extract, and ionise in a similar way.  
Since there was no evident degradation of each hepcidin isoform to a smaller form, this 
would suggest that the decline during storage in hepcidin isoforms is likely attributable to 
adsorption onto the container wall or endogenous compounds, or due to peptide aggregation, 
which has been reported for hepcidin-25 (Malyszko, 2009).  
Hepcidin-24 and -25 both contain the amino acid methionine which is prone to oxidation 
to either a sulfone or sulfoxide, and the oxidation of both hepcidin-24 and -25 have been 
identified in urine samples (Swinkels et al., 2008). Oxidation of hepcidin-24 and -25 in serum 
has been reported to be minimal (Ward et al., 2008; Swinkels et al., 2008), and is supported by 
the findings here. 
 
3.4.1.2 Method comparison 
3.4.1.2.1 LC-HR-MS vs ELISA 
There was a positive and significant correlation for hepcidin-25 between the LC-HR-MS method 
developed here and a commercially available ELISA. However, concentrations of hepcidin-25 
measured using LC-HR-MS were some 10 fold lower than those obtained when using the 
ELISA. Variability between immunochemical and chromatographic techniques have been 
reported in a number of ‘round robins’ (Kroot et al., 2009; Kroot et al., 2012; van der Vorm et al., 
2016), and it has been suggested that part of this variability could be due to the presence of 
hepcidin isoforms other than hepcidin-25 present in samples, causing interference in 
immunochemical assays. However, this is certainly not the cause of the 10 fold difference in 
hepcidin-25 concentrations measured here, as all samples used in the comparison had non-
detectable or very low concentrations of hepcidin-20, -22, or -24. It is likely that the cause of this 
disparity is in the preparation of calibration solutions used in the ELISA assay, or that the 
antibody used in the ELISA is cross-reacting with an unknown endogenous compound. Another 
investigator (Itkonen et al., 2012) reported no correlation at all with the DRG ELISA used here 
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when comparing it to an LC-MS/MS based assay for hepcidin-25. Furthermore, a review by 
Kroot et al., (2011) states that “the bioactive hepcidin kit of DRG Instruments, (purchased 
October 2009) gave similar concentrations for all samples and could not discriminate between 
iron metabolism disorders (unpublished results)". It should be remembered though, that the 
samples used here for comparison purposes were stored for up to 12 months at -20 °C 
following initial analysis by ELISA and stability data covering this period is not available. 
Therefore, lack of analyte stability may compromise the data here. However, hepcidin-25 has 
been shown to be stable for up to 2 years following storage at -80 °C (Laarakkers et al., 2013). 
 
3.4.1.2.2 LC-HR-MS vs LC-MS/MS 
The excellent correlation between the method developed here and a previously published LC-
MS/MS assay helps support the assumption that the assay developed is fit for purpose. 
Furthermore, the LC-MS/MS assay used for comparison purposes has reported to perform well 
in previous round robins (Sukhi Bansal, personal communication). 
 
3.4.1.3 Comparison of plasma and serum 
There was an excellent correlation between EDTA plasma and serum for all analytes, which is 
in keeping with other reports for hepcidin-25 (Kobold et al., 2008; Butterfield et al., 2010). Other 
investigators have reported a bias of some 24 % for hepcidin-25 between human EDTA plasma 
and human serum (Lefebvre et al., 2015).  Lithium-heparin plasma and serum are reported to 
be comparable (Busbridge et al., 2009; Itkonen et al., 2012), although other investigators have 
reported marginally higher concentrations (8 %) of hepcidin-25 in EDTA plasma compared to 
heparinised plasma (Laarakers et al., 2013). There have been no reports as to the correlations 
of hepcidin-20, -22, or -24 between human plasma and serum, other than that described here, 
where there was a good correlation between these two matrices. This would indicate, certainly 
for the method developed here, that should serum not be available for hepcidin isoform 
quantitation, then EDTA plasma is a suitable alternative. However, since routine biochemical 
tests for assessing iron status (i.e. ferritin, TSAT) are undertaken on serum this maybe the most 
suitable sample type for hepcidin measurement, as it would allow all markers of iron status to be 




3.4.2 Charge state distribution 
Distribution of the charge state for all hepcidins was significantly different in patient samples as 
compared to that observed when each analyte was separately infused into the mass 
spectrometer. This may not be that surprising as unknown compounds (e.g. proteins, 
phospholipids, and drugs) present in human serum, which are not present in the infusion 
solution, are likely to affect ionisation of the analyte within the MS source. As the method 
developed here acquires data in full-scan mode, and the area of the three charge states are 
summed, any variability in isotope and/or charge state distribution is unlikely to affect accurate 
quantitation. A disadvantage to this approach is that monitoring a number of isotopes and 
charge states can reduce the signal to noise ratio, and therefore reduce sensitivity. However, a 
LLoQ of 1.0 µg/L was still achieved for all analytes, which is comparable to reported LC-MS/MS 
methods for hepcidin-25 (Murphy et al., 2007; Kobold et al., 2008; Wolff et al., 2013). Published 
LC-MS/MS methods for hepcidin-25 acquire data in SRM mode using triple quad mass-
spectrometers, monitoring a single charge state and there is no uniformity in the charge state 
being monitored, with some methods monitoring the [M+3H]3+ (Wolff et al., 2013; Kobbold et al., 
2008), [M+4H]4+ (Li et al., 2009; Hwang et al., 2011), or the [M+5H]5+ ion (Delaby et al., 2014). It 
is possible that the most appropriate pre-cursor and product ions of a given charge state are not 
being monitored in these methods, since the distribution of charge state may differ between that 
seen when infusing the solution into the MS and when analysing samples; this could affect 
accurate quantitation. It is advisable that if hepcidin isoforms are to be quantified by LC-MS/MS, 
at least two charge states, and ideally 3 should be monitored to account for variability between 
samples.  
 
3.4.3 Establishment of reference range 
The concentrations of hepcidin-25 measured here are broadly comparable with those reported 
by other investigators (Addo et al., 2016; Anderson et al., 2011; Bansal et al., 2010; Campostrini 
et al., 2012; Galesloot et al., 2011; Hwang et al., 2011; Kemna et al., 2007; Kroot et al., 2010). 
Although, significantly higher hepcidin-25 concentrations have been reported by some 
investigators (Ganz et al., 2008; Koliaraki et al., 2009). In these reports though, 
immunochemical assays have been used, and it is likely that there is some cross-reactivity of 
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hepcidin-20, -22, and -24 with the hepcidin-25 antibody used, thereby falsely elevating the 
reported hepcidin-25 concentration.  
Mean (95 % CI) serum hepcidin-20 concentrations of 7.24 (6.94–7.58) µg/L have been 
reported in one large study (N = 1,577) of the general population (Campostrini et al., 2012). 
However, in only half (54.2 %) of all samples was hepcidin-20 detected. In another study, mean 
serum hepcidin-20, and -22 concentrations of 2.6 and 0.97 µg/L were measured in 40 healthy 
volunteers (Addo et al., 2015). Hepcidin-24 concentrations in healthy controls have not been 
reported to date. Neither hepcidin-20, -22, or -24 were at detectable concentrations in the 
volunteer samples measured here, this may simply be because they are not present in the small 
number of samples analysed, or they may be present but below the detection limits of the 
assay. Certainly, the concentrations of hepcidin-22 reported by Addo et al., 2015, were below 
the LLoQ of the method developed here. It should also be noted in the report by Addo et al., 
2015, no details were given as to assay validation or the source of the reference compounds 
used, thereby raising concerns over the validity of the concentrations reported. 
For hepcidin-25, age and sex specific methodological reference ranges should always be 
established, as well as the ratio of transferrin saturation to hepcidin-25, and ferritin to hepcidin-
25. A limitation of the work undertaken here is the relatively small number of samples obtained 
for ascertaining method dependent reference ranges, and a lack of standardisation with regards 
to when the samples were taken. Be this as it may, a method based reference range for 
hepcidin-25 has been established.  
 
3.5 Conclusion 
Presented here is the appropriately validated LC-HR-MS method for the measurement of all 
commercially available hepcidin isoforms in human serum. There was a good correlation (R2 ≥ 
0.90) between dipotassium EDTA plasma and serum for all analytes, and a good correlation 
with a published LC-MS/MS method. In samples from healthy volunteers (N = 46), hepcidin-20, 
-22, and -24 were below the LLoQ (1 µg/L) in all samples, and a reference range for hepcidin-25 










Chapter 4 Hepcidin in Chronic 






Chronic kidney disease (CKD) is a term that refers to the progressive loss (over months or 
years) of renal function. CKD is contrary to acute kidney injury, which is sudden damage to the 
kidney, usually as a consequence of another serious illness (e.g. heart failure).  The severity of 
CKD is defined by the calculated estimated glomerular filtration rate (eGFR) (Table 4.1), with a 
normal eGFR being above 90 mL/min/1.73 m2. Using data from the combined 2009 and 2010 
Health Survey for England, it has been estimated that 6 % of men and 7 % of women have an 
eGFR below 60 mL/min/1.73 m2, and therefore reduced kidney function (Aitken et al., 2014).  
 
Table 4.1. Stages of CKD based on estimated glomerular filtration rate. 
Stage eGFR  (mL/min/1.73 m2) Description 
1 > 90 
Normal kidney function but urine findings  
or structural abnormalities  
or genetic trait point to kidney disease 
2 60–89 
Mildly reduced kidney function, and  
Other findings (as for stage 1) point  
to kidney disease 
3a 45–59 Moderately reduced kidney function 
3b 30–44 Moderately reduced kidney function 
4 15–29 Severely reduced kidney function 
5 < 15 or on dialysis Very severe, or end stage kidney failure  
 
Causes of CKD include the various types of glomerulonephritis, chronic tubulo-interstial disease 
such as chronic pyelonephritis, genetic disease such as polycystic kidney disease, immune-
mediated disease such as systemic lupus erythematosus or vasculitis, and long-term use of 
some medications (e.g. non-steroidal anti-inflammatory drugs, proton pump inhibitors, lithium, 
etc), however, high blood pressure or diabetes are the most common causes. Anaemia is a 
well-known complication of CKD, and estimates have suggested that some 12 % of patients 
with CKD in the UK have anaemia [defined as a haemoglobin concentrations ≤ 12 g/dL in 
women and ≤ 13 g/dL in men (Mikhail et al., 2012; WHO, 1968)]. The major cause of anaemia in 
these patients is reduced erythropoietin (EPO) production, which decreases with increasing 
severity of kidney damage. Therefore, treatment with erythropoiesis-stimulating agents (ESAs) 
is a common treatment strategy (NICE, 2015). However, in some 10–20 % of patients with 
anaemia, treatment with ESAs is ineffective, with one of the most common causes of ESA hypo-
responsiveness being iron deficiency (Babitt & Lin, 2012). Iron-deficiency may be ‘absolute’ (i.e. 
122 
 
when the total body iron stores are exhausted), or ‘functional’ (where there are ample iron 
stores but a failure to release iron rapidly enough to satisfy the demands of the bone marrow 
(Macdougall et al., 1989). Haemodialysis patients are particularly prone to absolute iron 
deficiency from chronic bleeding, frequent phlebotomy, or from blood trapping in the dialysis 
apparatus, and it has been estimated that patients can lose some 1–3 g of iron per year (Babitt 
& Lin, 2012).  
Treatment with iron supplementation is a recommended treatment in non-dialysing CKD 
patients. With the choice of either oral or intra-venous (IV) iron depending on the severity of iron 
deficiency, availability of preparations, and previous response to oral iron therapy (KDIGO, 
2012). Management of iron deficiency in patients with CKD is complicated by the poor response 
in some patients to oral iron, particularly those on haemodialysis with functional iron deficiency. 
Therefore, it is recommended that IV iron should be used in all patients with CKD undergoing 
dialysis (KDIGO, 2012). However, the use of IV iron is more costly than oral iron when 
accounting for drug, administration, and indirect costs to the patient for time and travel, and it 
can also cause rare but serious short-term effects including anaphylactic-type reactions, 
hypotension, and arthralgia (Liles, 2012). 
Hepcidin-25 has been recognised as having a key role in functional iron deficiency and 
anaemia in CKD (Macdougall et al., 2010). Poor gastro-intestinal absorption of 
dietary/supplementary oral iron is proposed to be due to raised plasma concentrations of 
hepcidin-25 as a result of inflammatory cytokines (e.g. IL-6, known inducers of hepcidin-25 
transcription), although reduced eGFR, and therefore reduced excretion may be a contributing 
factor. Inappropriately raised plasma hepcidin-25 concentrations are also believed to be a 
contributing factor to the persistent anaemia present in those patients treated with ESAs, and as 
such, therapeutics targeting the hepcidin-25-ferroportin axis are currently being investigated. 
One such therapeutic, Lexaptepid pegol, a pegylated structured L-oligoribonucleotide that binds 
and inactivates hepcidin-25, has been shown to inhibit hepcidin-25, and raise serum iron 
concentrations and TSAT in patients with anaemia of chronic disease (Boyce et al., 2016). It is 
feasible that this compound may work in patients with anaemia of CKD. It is also interesting to 
note that in cell-lines, vitamin D directly inhibits hepcidin-25 transcription, and a pilot study in 
healthy human volunteers showed a decrease in serum hepcidin-25 within 24 hours of a single 
dose of 25D-hydroxyvitamin D (Bacchetta et al., 2014). 
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Measuring hepcidin-25 concentrations may be of use in the clinical assessment of 
anaemia in CKD patients, and in guiding the selection of which therapy is most likely to be 
successful in individual patients. Additionally, since patients with CKD have raised hepcidin-25 
concentrations, it is likely that N-truncated isoforms of hepcidin-25 are also present, although 
few studies have measured hepcidin-20, and -22 in patients with CKD, and no studies to date 
have reported concentrations of hepcidin-24. This is of particular concern since hepcidin-25 
‘specific’ immunoassays are still being widely used for hepcidin-25 measurement in these 
patients, and it is likely that there is cross-reactivity of hepcidin-20, -22, and -24 with the 
hepcidin-25 antibody used, hence reported hepcidin-25 concentrations may be misleading. 
Furthermore, even though N-truncated isoforms of hepcidin-25 have been shown to have little if 
any activity at the FP-1 receptor, they may have a role as a biomarker for various diseases, and 
they may have some antimicrobial activity (Ho et al., 2013).  
 
The aims of this chapter are as follows: 
• Measure hepcidin isoforms in serum samples from patients with CKD not undergoing 
haemodialysis, as well as those individuals undergoing haemodialysis. 
• Investigate the impact of haemodialysis on the concentrations of hepcidin isoforms. 
• Investigate relationships of hepcidin isoform concentrations with demographic and 
clinical variables using univariate and multivariate regression analysis 




4.2.1 Patient samples 
Patients with varying stages of CKD (not requiring dialysis) attended a renal clinic at King’s 
College Hospital, London for routine monitoring. A whole blood sample (BD Vacutainer 
dipotassium EDTA), and a serum (BD Vacutainer SST II Advance) sample was taken for routine 
biochemical and haematological tests (including ferritin, CRP, TIBC, iron, creatinine, and 
haemoglobin) as part of their on-going care. Patients with CKD undergoing haemodialysis had a 
serum sample taken immediately before the procedure, and again directly afterwards, for 
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routine biochemical tests as part of their on-going care. Full blood count and biochemical tests 
were undertaken within the Blood Sciences Laboratory of King’s College Hospital, in 
accordance with local procedures (Chapter 3.2.7).  
After completion of all biochemical tests, excess serum was stored into 1.5 mL protein 
LoBind tubes at -20 ºC for up to one month until analysis for hepcidin isoforms. All samples 
were taken as a part of routine care, excess sample was fully anonymised, and all linkages with 
the sample to the patient removed, therefore review by a research ethics committee was not 
required, in accordance with Royal College of Pathologists, and Human Tissue Act Guidelines 
(Marks, 2012, Human Tissue Authority, 2017). Time taken between collection of the sample and 
storage for hepcidin measurement was approximately 6 hours, during this time the sample was 
stored at 2–8 ºC. 
Samples obtained from healthy volunteers that were used to establish a reference 
range for hepcidin isoforms (Chapter 3.3.4) were used as controls for comparison purposes. 
 
4.2.2 Analytical methods 
Hepcidin isoforms were measured in singlicate, with a set of calibration and IQC solutions at the 
beginning and end of each assay and an IQC every 10 samples using the LC-HR-MS method 
previously described.  
 
4.2.3 Statistical analysis 
Statistical analysis was performed using Analyse-it (Analyse-it Software Ltd, Leeds, UK) for 
Microsoft excel, and SPSS for Windows, version 23.0 (SPSS Incorporated, Chicago, USA). 
Normality of data distribution was assessed using the Shapiro–Wilk test. Relationships were 
explored using Spearman’s rank correlation (r), the Mann–Whitney U (grouped data), or the 
Wilcoxon signed-rank (matched pairs) test. A p-value < 0.05 was considered statistically 
significant. To determine predictors of serum hepcidin isoform concentrations, univariate 
regression analysis was first undertaken, and variables where p = > 0.1 were excluded from 
further multivariate regression analysis. To correct for skewness, concentrations were log 





Samples were obtained from 71 patients with CKD not undergoing haemodialysis, and an 
additional 34 patients pre- and post-haemodialysis; demographics are shown in Table 4.2 and 
Table 4.3. Unfortunately, samples were not available from individuals with stage 5 CKD, not 
requiring haemodialysis. 
Patients with CKD and those on haemodialysis were significantly older than the control 
group. The ratio of males to females was comparable for the control group and those patients 
with CKD requiring haemodialysis. However, there were more males with CKD not requiring 
haemodialysis as compared to the control group and those patients requiring haemodialysis. 
Patients with CKD not requiring dialysis, and those requiring dialysis had significantly higher 
serum CRP and ferritin, and significantly lower serum iron, TIBC, and TSAT, as compared to the 
control group. Some 57 % of CKD patient’s not requiring dialysis had a raised CRP, as 
compared to 74 % of patients on haemodialysis. The proportion of patients with a raised CRP 
did not differ markedly between stages of CKD (stage 1: 63 %, stage 2: 50 %, stage 3: 44 %, 
and stage 4: 69 %). 
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Table 4.2. Clinical and demographic data for controls and patients with CKD not undergoing haemodialysis. Data shown as median (range), hepcidin-22 







































Key ND = not detected (LLoQ 1 µg/L) 1. Hepcidin-20 detected in 73 % of samples, 2. Hepcidin-24 detected in 20 % of samples, 3. Hepcidin-25 detected in 87 % of samples. 
 Controls 
(N = 41) 
Stage 1 
(N = 8) 
Stage 2 
(N = 14) 
Stage 3 
(N = 27) 
Stage 4 
(N = 22) 
All CKD 
(N = 71) 
Controls vs.  
all CKD p-value 
Male (%) 44 38 57 74 50 59 - 










(20–90) < 0.001 





































(2.1–123.2) < 0.05 










(13–1495) < 0.001 










(3.9–43) < 0.001 










(29–79) < 0.001 










(7–84) < 0.01 









Hepcidin-24 (µg/L) ND ND ND ND ND 3 (2–14)2 - 










(2–134)3 < 0.01 










(1–134) < 0.01 
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Table 4.3. Clinical and demographic data for controls, and samples from patients pre-, and post-haemodialysis. Data shown as median (range). 
Insufficient numbers to report median (range) hepcidin-24 concentrations for samples taken post-haemodialysis. 
 Demographics and analytical results Significance testing between data sets (p-value) 
 Controls  
(N = 41) 
Pre-haemodialysis 
(N = 34) 
Post-haemodialysis 
(N = 34) 
Controls vs.  
pre-HD 
Controls vs.  
post-HD 
Pre-HD vs.  
post-HD  
All CKD vs. 
Pre-HD  
Male (%) 44 44 - - - - - 
Age (years) 37 (24–68) 
59 
(27–87) - < 0.001 - - 0.33 
Haemoglobin (g/dL) - 103 (56–137) - - - - < 0.001 
CRP (mg/dL) 3.0 (< 2.0–10.0) 
10.6 
(2.6–124.3) - < 0.001 - - < 0.05 




(28–5044) < 0.001 < 0.001 < 0.05 < 0.001 




(4.8–38.5) < 0.001 < 0.01 < 0.001 < 0.001 




(21–57) < 0.001 < 0.001 < 0.001 < 0.001 




(8–93) < 0.001 0.39 < 0.05 0.35 
Hepcidin-20 (µg/L) ND 18 (5–129)1 
10 
(5–73) - - < 0.05 < 0.001 
Hepcidin-22 (µg/L) ND 19 (9–32)2 
15 
(10–19) - - - - 
Hepcidin-24 (µg/L) ND 9 (5–51)3 ND - - - < 0.05 




(4–143) < 0.001 < 0.001 < 0.05 < 0.001 




(4–228) < 0.001 < 0.001 < 0.05 < 0.001 
Key 1. Hepcidin-20 detected in 71 % of samples, 2. Hepcidin-22 detected in 9 % of samples, 3. Hepcidin-24 detected in 26 % of samples, 4. Hepcidin-25 detected in 88 % of samples. ‘Total’ hepcidin = sum 




4.3.1 Hepcidin in CKD patients not requiring haemodialysis 
Hepcidin-25 (median, range) was significantly raised in samples from patients with CKD not 
requiring haemodialysis (14, 2–134 µg/L) as compared to the control group (8, 1–31 µg/L, p = < 
0.01), although some 61 % of samples had a hepcidin-25 concentration that was within the 
range of concentrations measured in the control group (Figure 4-1). Overall, hepcidin-25 was 
positively correlated with ferritin (r = 0.55, p = < 0.001), and negatively correlated with TIBC (r = 
-0.45, p = < 0.01), haemoglobin (r = -0.34, p = < 0.01), and eGFR (r = -0.33, p = < 0.01), Figure 
4-2, and Figure 4-3. There was no statistically significant correlation of hepcidin-25 to iron, 




Figure 4-1. Concentrations of hepcidin-25 in controls, CKD patients not undergoing 
haemodialysis and in samples taken pre, post-haemodialysis (hepcidin-25 on logarithmic 
































Table 4.4. Correlation of hepcidin isoforms with haematological and biochemical indices 
in serum samples from patients with CKD not requiring haemodialysis. Hepcidin-22 not 
detected (LLoQ 1 µg/L) in any sample. 
 Parameter 
 Haemoglobin CRP Ferritin Iron TIBC TSAT eGFR 
Hepcidin-20        
r -0.40 0.24 0.44 -0.03 -0.58 0.12 -0.60 
p < 0.01 0.17 < 0.001 0.83 < 0.001 0.40 < 0.001 
Hepcidin-24        
r -0.49 0.50 0.51 -0.62 -0.75 -0.35 -0.04 
p 0.07 0.17 0.06 < 0.05 < 0.01 0.22 0.89 
Hepcidin-25        
r -0.34 0.24 0.55 -0.21 -0.45 -0.10 -0.33 







Figure 4-2. Scatterplots of hepcidin-25 with (A) eGFR, and (B) ferritin in patients with CKD not requiring dialysis. Solid line = simple linear regression, 
dashed lines = 95 % confidence intervals. 
 





















































































Figure 4-3. Scatterplots of hepcidin-25 with (A) TIBC, and (B) haemoglobin in patients with CKD not requiring dialysis. Solid line = simple linear 
regression, dashed lines = 95 % confidence intervals. 
 





























































Multivariate regression analysis, including the predictors eGFR, ferritin, TIBC, and haemoglobin 
only explained 30 % of the variation in serum hepcidin-25 concentrations; TIBC (p = < 0.05) was 
the only significant predictor of hepcidin-25 concentrations.  
Hepcidin-20 was similarly correlated to haemoglobin (r = -0.40, p = < 0.01), ferritin (r = 
0.44, p = < 0.001), TIBC (r = -0.58, p = < 0.001), and eGFR (r = -0.60, p = < 0.001) (Figure 4-4, 
and Figure 4-5, Table 4.4). Multivariate regression analysis, including the predictors 
haemoglobin, ferritin, TIBC and eGFR, showed TIBC (p = < 0.001), and eGFR  (p < 0.01), to be 
significant predictors of hepcidin-20. Hepcidin-24 was negatively correlated with iron (r = -0.62, 
p = < 0.05), and TIBC (r = -0.75, p = < 0.01), but was not correlated to haemoglobin, CRP, 







Figure 4-4. Scatterplots of hepcidin-20 with (A) eGFR, and (B) ferritin in patients with CKD not requiring dialysis. Solid line = simple linear regression, 







































































Figure 4-5. Scatterplots of hepcidin-20 with (A) TIBC, and (B) haemoglobin in patients with CKD not requiring dialysis. Solid line = simple linear 
regression, dashed lines = 95 % confidence intervals. 































































Figure 4-6. Scatterplots of hepcidin-24 with (A) iron, and (B) TIBC. Solid line = simple 
linear regression, dashed lines = 95 % confidence intervals. 
 











































In all samples from patients with CKD not requiring dialysis, hepcidin-25 was the most prevalent 
isoform of hepcidin detected (Figure 4-7), and was the only hepcidin isoform detected in 14 % of 




Figure 4-7. Prevalence of hepcidin isoforms in samples from (A) patients with CKD not 
requiring dialysis (N = 72), and (B) samples from haemodialysis patients taken pre-
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Hepcidin-25, was not detected in 10 samples, and of these, 8 had a low haemoglobin (median 
109, 68–114 g/dL), 6 had a low ferritin concentration (median 19, range 13–27 µg/L), and 9 had 
a low TSAT (median 17, range 5–26 %), suggesting that these patients had absolute iron-
deficiency that would explain an undetectable hepcidin-25 concentration.  
Besides hepcidin-25, hepcidin-20 was the most prevalent hepcidin isoform (72 % of 
samples), and its contribution to the ‘total’ hepcidin concentration (i.e. the sum of hepcidin-20, -
22, -24, and -25 isoforms where measured) increased with declining kidney function (Figure 4-8 
and Figure 4-9).  
Hepcidin-24 was detected in 19 % of samples, but the proportion of hepcidin-24 to the 
total hepcidin concentration measured was consistent across all samples irrespective of kidney 
function. Hepcidin-22 was not detected in any sample, and in no sample was hepcidin-20, -22, 


















Figure 4-9. Concentrations of hepcidin-20 in CKD patients not undergoing haemodialysis by stage of disease and in samples taken pre-, and 






































4.3.2 Hepcidin in CKD patients requiring haemodialysis 
Hepcidin-25 was significantly raised in samples taken pre-dialysis (median 54, range 11–234 
µg/L) as compared to both the control group (median 8, range 1–31 µg/L) and patients with 
CKD not requiring haemodialysis (median 8, range 1–134 µg/L). Although, 28 % of samples had 
a measurable hepcidin-25 concentration that was within the range found in healthy controls. 
Hepcidin-25 was only correlated to TIBC (r = -0.38, p = < 0.05), with no significant correlation to 
CRP, ferritin, iron, or TSAT (Table 4.5).  
 
Table 4.5. Correlation of hepcidin isoforms with biochemical tests in serum samples 
taken pre-haemodialysis. 
 CRP Ferritin Iron TIBC TSAT 
Hepcidin-20      
r 0.03 0.14 -0.11 -0.35 -0.16 
p 0.92 0.50 0.60 0.09 0.44 
Hepcidin-24      
r 0.51 0.79 -0.37 -0.34 -0.47 
p 0.19 < 0.05 0.33 0.36 0.20 
Hepcidin-25      
r 0.24 0.30 (0.42)1 -0.27 -0.38 -0.28 
p 0.28 0.11 (< 0.05)1 0.16 < 0.05 0.14 
Insufficient number of hepcidin-22 concentrations (9, 19, and 32 µg/L) to calculate correlation.  
Key. 1. Excludes outlier (hepcidin-25 = 16 µg/L, ferritin = 3,834 µg/L).  
 
However, excluding an outlier (hepcidin = 16 µg/L, ferritin = 3,834 µg/L) improved the correlation 
of hepcidin-25 to ferritin (r = 0.42, p = < 0.05). Multivariate regression analysis, including the 
predictors CRP, iron, and TIBC, only explained 31 % of the variation in serum hepcidin-25 
concentrations, and none were significant predictors of hepcidin-25. Hepcidin-20 was not 
correlated to any variable investigated, and hepcidin-24, was only correlated with ferritin (r = 
0.79, p = < 0.05, Table 4.5).  
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Hepcidin-25 was the most prevalent isoform of hepcidin detected in samples taken pre-
dialysis (Figure 4-7). Hepcidin-25, was not detected in 4 samples, and in these, 2 had a low 
haemoglobin concentration (65 and 96 g/dL), 1 had a ferritin concentration that was low (23 
µg/L), and 3 had a low TSAT (median 16, range 6–16 %). As with samples from patients with 
CKD not requiring haemodialysis, besides hepcidin-25, hepcidin-20 was the most prevalent 
isoform (76 % of samples). Hepcidin-22 and 24 were detected in 8 and 25 % of samples 
respectively. Hepcidin-25 was the only hepcidin detected in 11 % of samples (median 19, range 
11–152 µg/L), and in no sample were hepcidin-20, -22 or -24 detected in the absence of 
hepcidin-25. 
Following haemodialysis, median (range), hepcidin-20, -22, -24, and -25 concentrations 
had declined by some 38 (1–55), 44 (41–47), 34 (33–35), and 35 (6–71) %, respectively (Figure 
4-10). In all patients, hepcidin-20, -22, -24, and -25 had declined after dialysis, except in one 
patient where hepcidin-20 had increased from 7 µg/L (pre-dialysis) to 17 µg/L (post-dialysis). In 
one patient, hepcidin-22 was below the LLoQ post-dialysis (pre-dialysis: 9 µg/L), and in a further 




















































4.3.3 Hepcidin isoform correlations in CKD patients 
Correlations of hepcidin-25 to hepcidin-20, and -24 are shown in Figure 4-11. In patients with 
CKD not requiring haemodialysis, serum hepcidin-25 was strongly correlated to hepcidin-24 (N 
= 14, r = 0.82, p = < 0.05), and to a lesser extent with hepcidin-20 (N = 52, r = 0.52, p = < 0.05). 
Hepcidin-24 was also moderately correlated with hepcidin-20 (N = 13, r = 0.64, p = < 0.05). In 
samples taken pre-dialysis, there was a likewise strong correlation of hepcidin-25 with hepcidin-
24 (N = 9, r = 0.85, p = < 0.05), and again to a lesser extent with hepcidin-20 (N = 26, r = 0.70, 
p = < 0.05). There was no statistically significant correlation of hepcidin-24 with hepcidin-20 (N = 
7, r = 0.34, p = 0.45). There were an insufficient number of samples (N = 3) to investigate 





Figure 4-11. Correlation of serum hepcidin-25 with (A) hepcidin-20, and (B) hepcidin-24. 
Two samples excluded from graph A for clarity (hepcidin-20: 70 & 129 µg/L, and 


































































In the work undertaken here, all commercially available hepcidin isoforms have been measured 
in individuals with CKD not undergoing haemodialysis, and in samples from individuals 
undergoing haemodialysis both before and after the dialysis session. Hepcidin-25, and 
hepcidin-20 were found to be the most prevalent forms of hepcidin present in samples, and the 
concentrations of hepcidin-24 present have been ascertained, which have not been reported to 
date.  
 
4.4.1 Hepcidin isoforms in CKD not requiring haemodialysis  
A number of studies have reported concentrations of hepcidin-25 in patients with CKD (both not 
requiring and requiring haemodialysis) using either mass spectrometry (Weiss et al., 2009; 
Peters et al., 2010; Tessitore et al., 2010; Kuragano  et al., 2010; Rumjon et al., 2012; Uehata 
et al., 2012; Pelusi et al., 2013; van der Weerd et al., 2012; Chand et al., 2015; Addo et al., 
2016) or immunochemical assays (Malyszko et al., 2006; Ford et al., 2010; Troutt et al., 2013; 
Xu et al., 2011; Zaritsky et al., 2011; Mercadel L et al., 2014; Mogadam et al., 2015; Taheri et 
al., 2015; Wagner et al., 2015).  
Concentrations of hepcidin-25 measured here in patients with CKD not undergoing 
haemodialysis are broadly comparable to those reported by other investigators (Peters et al., 
2010; Rumjon et al., 2012; Uehata et al., 2012), except in one report where the concentrations 
of hepcidin-25 measured using an ELISA were 4-fold greater than those reported here 
(Mogadam et al., 2015). It is likely that the cause of this disparity is due to the different 
methodology used to quantify hepcidin-25, and a lack of assay standardisation as reported in 
round robins (Kroot et al., 2009; Kroot et al., 2012; van der Vorm et al., 2016).  
There are conflicting results as to whether patients with CKD not undergoing dialysis 
have raised hepcidin-25 as compared to healthy controls. In the samples measured here, 
hepcidin-25 was significantly raised as compared to healthy controls, although there was much 
overlap, with over half of these samples having a hepcidin-25 concentration that was within the 
range measured in healthy controls. One published study reported there to be no significant 
difference in hepcidin-25 concentrations between healthy controls and in patients with CKD not 
undergoing haemodialysis when using an MS based method (Peters et al., 2010). In contrast, 
other investigators have reported hepcidin-25 to be significantly raised (2-, 3 to 6-, and 20-fold 
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respectively) in non-dialysing CKD patients as compared to healthy controls (Malyszko et al., 
2006; Uehata et al., 2012; Troutt et al., 2013). It should be borne in mind though that the study 
that reported hepcidin-25 to be 20-fold higher in CKD patients compared to controls used an 
immunoassay for hepcidin measurement, and it is likely that other hepcidin isoforms cross-
reacted with the assay (Troutt et al., 2013). In this work, N-truncated isoforms of hepcidin-25, 
predominantly hepcidin-20, were found to be raised in patients with CKD. It could therefore be 
possible that the immunoassay method used by Troutt et al. (2013) could have reported falsely 
elevated ‘hepcidin-25’ concentrations, although this is unlikely to be the sole cause of the 
disparity in this case since, in the samples here, the median hepcidin-20 concentration (the 
most prevalent hepcidin isoform, besides hepcidin-25) measured was only 36 % of the 
measured hepcidin-25 concentration. 
In one study using mass spectrometry (Peters et al., 2010), hepcidin-20 and -22 were 
present in 81 % and 34 % of samples respectively, and the concentrations of hepcidin-20 
measured (median: 3.6, range: 1.2–12.8 µg/L) were broadly comparable to those reported here 
(median: 5, range: 1–31 µg/L), although the ratio of hepcidin-25 to -20 reported was higher (4.6) 
than in the samples in this study (2.8). Only three other studies have reported concentrations of 
hepcidin isoforms (hepcidin-20 and hepcidin-22 alongside hepcidin-25) in patients with CKD 
(Tessitore et al., 2010; van der Weerd et al., 2012; Addo et al., 2016). The method used in all 
four of these reports, however, used hepcidin-24 as an internal standard, thereby compromising 
accurate hepcidin-20, -22, and -25 determination. To date no studies have reported 
concentrations of hepcidin-24 in patients with CKD.  
The in-vitro stability studies undertaken in Chapter 3 identified that when hepcidin-25 
was added to stripped human serum, neither hepcidin-20, -22, or -24 were detected. There was 
also no degradation to a smaller hepcidin isoform when either hepcidin-20, -22, or -24 were 
added to separate portions of stripped human serum. Similarly, there was no evident increase in 
hepcidin-20, -22, or -24 as hepcidin-25 concentrations decreased when clinical samples were 
stored at ambient room temperature or at 2–8 °C. Also, when each individual isoform was 
added to separate portions of stripped human serum, concentrations of all hepcidin isoforms 
declined at comparable rates. This data needs to be interpreted with caution, especially when 
trying to extrapolate to the in-vivo formation of hepcidin isoforms in patients with CKD. However, 
what the stability studies undertaken and the data from patients here do suggest, is that N-
truncated isoforms of hepcidin-25 are unlikely to be formed in-vivo and are not artefacts of 
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sample preparation or storage. It is likely that in individuals with CKD, based on the correlations 
between the isoforms, hepcidin-25 is not metabolised sequentially (i.e. hepcidin-25, to hepcidin-
24, to hepcidin-22 etc), but instead hepcidin-25 could form hepcidin-22, and then hepcidin-20, 
or even directly from hepcidin-25 to hepcidin-20. Furthermore, hepcidin-25 may not undergo 
any metabolism before being eliminated from the body or it may just be degraded to hepcidin-24 
for example, and then eliminated, without being degraded to hepcidin-20, or -22 . There are still 
conflicting results as to whether hepcidin-25 is largely protein bound, and whether being bound 
impedes degradation. For example, it may be possible that only non-protein bound hepcidin-25 
is degraded, therefore in conditions where the plasma protein concentrations change, so would 
the degree of binding, and therefore the available ‘non-protein’ bound hepcidin-25 available for 
degradation.  
It is not clear if concentrations of the N-truncated isoforms of hepcidin-25 are raised as 
a result of reduced eGFR, or simply because these patients have raised hepcidin-25 
concentrations and there is then increased analyte available for degradation to smaller 
isoforms. In the samples analysed here from patients with CKD not requiring dialysis, hepcidin-
20 was more strongly correlated to eGFR than hepcidin-25 was to eGFR, suggesting that 
hepcidin-20 concentrations are more dependent on eGFR than those of hepcidin-25. As 
hepcidin-20 concentrations increase with the severity of kidney dysfunction (Figure 4-9), 
hepcidin-20 may be almost entirely renally cleared, and therefore it may be a suitable biomarker 
for kidney function, as has been suggested in a recent study (Addo et al., 2015). However, 
further work of a larger cohort of patients under controlled conditions is required to investigate 
the relationship between eGFR and isoforms of hepcidin, and their concentrations in other 
disease states (i.e. sepsis or ACD). In the meantime, however, hepcidin-20 is unlikely to be a 
suitable biomarker alone for renal function, as hepcidin-20 (and other isoforms of hepcidin-25) 
maybe increased in other conditions besides CKD (e.g. sepsis, Laarakkers et al., 2013). In-vitro 
studies have shown hepcidin-20 to have little, if any, activity at the FP-1 receptor (Laarakkers et 
al., 2013), but given the relatively high concentrations measured here to those of hepcidin-25, 
any biological function identified in the future may be clinically significant in patients with CKD. 
 
4.4.1.1 Predictors of hepcidin concentrations 
In patients with CKD not undergoing dialysis, TIBC was the only significant predictor of 
hepcidin-25 concentration in multivariate regression analysis. Although there were moderate 
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correlations with ferritin, haemoglobin, and eGFR in univariate analysis, reviewing the 
scatterplots of these data, however, do not suggest a particularly convincing relationship. These 
findings are comparable to reported studies that have found both ferritin and TIBC to be 
correlated with hepcidin-25 (Ashby et al., 2009; Peters et al., 2010; Uehata et al., 2012; Chand 
et al., 2013; Troutt et al., 2013), and those identified in healthy volunteers reported in Chapter 3. 
These correlations may not be surprising as a raised ferritin concentration would suggest 
adequate iron stores (in the absence of inflammation), and a reduced need for dietary iron 
uptake, and therefore raised serum hepcidin-25. Conversely, TIBC is raised in iron-deficiency, 
and lower when iron stores are normal to raised. Patients with iron deficiency in the absence of 
any confounders (e.g. inflammation), therefore, would be expected to have a low ferritin, low 
hepcidin-25 concentration, and a raised TIBC; patients with adequate iron stores would be 
expected to have a raised ferritin and hepcidin-25 concentration, but a low TIBC. 
There are conflicting results as to whether hepcidin-25 is correlated with eGFR. In one 
study using an ELISA (Zaritsky et al., 2009), ‘total hepcidin’ was correlated with eGFR. 
However, in studies using mass-spectrometry (Peters et al., 2010; Uehata et al., 2012) this 
correlation was not present. In the samples analysed here, hepcidin-25 was negatively, though 
weakly, correlated with eGFR in univariate analysis, but eGFR was found not to be a significant 
predictor of hepcidin-25 concentrations in multivariate regression. The relationship between 
hepcidin-25 and eGFR has clearly not been resolved; however, since there is no conclusive 
evidence, it is likely that concentrations of circulating hepcidin-25 are not predominantly 
dependent on glomerular filtration. It is possible that the raised hepcidin-25 concentrations 
present in some patients with CKD may be due to the up-regulation of synthesis from 
inflammatory cytokines that are present from the inflammation which is common in these 
patients, as opposed to reduced renal clearance. Certainly, over half of the patients with CKD 
not requiring dialysis had a raised CRP (median 6.1, range 2.1–123.2 mg/dL), as compared to 
only 4 % (N = 2) of samples in the control group, who only had marginally raised CRP 
concentrations (6.3, and 9.7 mg/L). 
Hepcidin-25 was found to be significantly correlated to haemoglobin in univariate 
analysis but not in multivariate analysis. As with eGFR, there are conflicting data as to whether 
hepcidin-25 is correlated with haemoglobin; some studies have reported a correlation between 
haemoglobin and hepcidin-25 concentrations (Maruyama et al., 2012; van der Putten et al., 
2010; Uehata et al., 2012), whereas others have reported no such correlation (Peters et al., 
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2010). The reason of this disparity could be due to differences in the underlying cause of 
anaemia (e.g. IDA or ACD) or inflammatory status of the populations studied, or because of 
different sample sizes. 
Hepcidin-20 was correlated with haemoglobin, ferritin, TIBC and eGFR; these results 
were similar to hepcidin-25 which would be expected given that there was a correlation, albeit 
weak, (r = 0.52, p = < 0.05) between hepcidin-25 and -20. The correlation of hepcidin-24 with 
the measured biochemical and haematological indices was not possible to interpret fully as 
there were too few samples containing this analyte (N = 14), although there was a significant 
and strong correlation of hepcidin-24 with TIBC, again which may not be surprising as there was 
good agreement between hepcidin-24 and hepcidin-25 concentrations (r = 0.82, p = < 0.05).   
   
4.4.2 Effect of haemodialysis on hepcidin concentrations 
Concentrations of hepcidin-25 were significantly raised in CKD patients requiring dialysis as 
compared to both healthy controls and in those patients with CKD not undergoing dialysis, 
consistent with previous reports (Peters et al., 2010; Ashby et al., 2009). Furthermore, in 
univariate regression there was a significant correlation of hepcidin-25 with TIBC and ferritin 
when an outlier was excluded, and again these findings are comparable to those reported by 
other investigators (Peters et al., 2010; Costa et al., 2009; Kato et al., 2008; Kuranagano, et al., 
2010; Tomosugi et al., 2006; Valenti et al., 2009; van der Weerd et al., 2012). However, in 
multivariate regression analysis, none were significant predictors of serum hepcidin-25.  
Following dialysis, serum hepcidin-25 concentrations declined by some 35 %, although 
there was much variation between individuals. A slightly lower clearance of 10–15 % (Peters et 
al., 2010), and 27 % (Kuragano et al., 2010) has previously been reported, whereas other 
investigators have reported higher clearances of 45 % (Zaritsky et al., 2010), and 51 % 
(Campostrini et al., 2010).  
Haemodialysis was also found to significantly reduce the concentrations of hepcidin-20, 
-22, and -24, which may not be surprising given their very similar molecular weights to hepcidin-
25, and that they also have an amphipathic structure, which is known to make these analytes 
prone to adsorption to surfaces that they come into contact with. It is not clear whether hepcidin 
isoforms are cleared during the dialysis procedure directly, or whether they adhere to the 
dialysis membrane. It is likely, however, that both contribute to the decline, since hepcidin-25 
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has been identified in both the ultrafiltrate and on the dialysis membrane post-haemodialysis 
(Malyszko et al., 2009; Peters et al., 2010).  
The finding that haemodialysis significantly reduces concentrations of hepcidin-25 
would suggest that immediately post-haemodialysis is the most appropriate time for 
administration of oral iron to maximise absorption; however, the median hepcidin-25 
concentration in samples post-dialysis was still some 6-fold greater than those measured in 
samples from healthy volunteers, and may therefore still be too high to allow maximal iron 
absorption.  
 
4.4.3 Utility of hepcidin measurement in patients with CKD                                                                                                                                          
In most patients with CKD, measurement of hepcidin-25 will provide little additional information 
as to an individual’s irons stores, or the amount of iron in circulation, when compared to 
traditional markers of iron status such as ferritin, TIBC, and TSAT. This is because hepcidin-25 
concentrations are not determined purely by renal function, but also affected by other factors 
including inflammation. Since hepcidin-25 is an acute phase response protein it is raised in 
response to inflammation as is ferritin and, in the absence of inflammation, patients that have 
low iron stores will have a low plasma ferritin as well as a likely low hepcidin-25 concentration. 
Furthermore, measurement of hepcidin-25 as a predictor of haemoglobin response to 
intravenous iron in patients with CKD on haemodialysis performed no better than traditional 
markers of irons status such as ferritin or TSAT in one study (Tessitore et al., 2010). 
However, hepcidin-25 measurement does provide an almost direct indication as to 
whether iron would be absorbed if given orally, something which no current marker of iron 
status can provide. Therefore, it could be helpful in deciding whether oral or IV iron would be 
most successful in the treatment of anaemia in CKD, although there have been no clinical trials 
undertaken to prove this theory. Of course, hepcidin-25 measurement would only give an 
indication as to an individual’s ability to absorb iron at the time of when the sample is taken, and 
its usefulness would therefore be based upon the ease at which hepcidin-25 could be 
measured, and the speed at which the results are available. It is interesting that in several 
samples from patients with CKD, undetectable concentrations of hepcidin-25 were found; this 
would suggest that in these patients, were oral iron supplementation to be given, there could be 





As regards to limitations of the work undertaken here, samples were from a naturalistic group of 
patients diagnosed with CKD. Some of these individuals may be being treated with ESAs, IV or 
oral iron, or be receiving no treatment for anaemia if present. Furthermore, the time of sampling 
was not kept constant, and hepcidin-25 has been shown to have a diurnal rhythm. However, the 
work here does give an indication as to the concentrations of hepcidin isoforms to be expected 
in this group of patients in a realistic, routine clinical setting.  
 
4.5 Conclusion 
Hepcidin-20 was found to increase with a decrease in kidney function, and only in samples from 
individuals with CKD undergoing haemodialysis were all hepcidin isoforms present. 
Furthermore, all hepcidin isoforms in serum were found to be significantly reduced by the 
haemodialysis procedure, a finding which is novel to the work undertaken here. Currently there 
is no conclusive evidence as to the value of measuring hepcidin-25 in individuals with CKD, 
although it may be useful in deciding whether to administer oral or IV iron. Due to the proven 
presence of hepcidin isoforms as renal function declines, any future studies investigating 
hepcidin-25 concentrations in CKD patients should use a very selective (i.e. mass-spectrometry) 
assay to ensure accurate quantitation of hepcidin-25, or if an immunoassay is used, at the very 














Both inappropriately low and raised hepcidin-25 concentrations have been implicated in 
disorders of iron deficiency and excess (Kroot et al., 2011). As hepcidin-25 directly controls the 
presence of FP-1 (Nemeth et al., 2004), and therefore the absorption and cellular release of 
iron, it is hoped that measurement of hepcidin-25 may be useful for the clinical management of 
iron disorders. Furthermore, even though N-truncated isoforms of hepcidin-25 have been shown 
to have little or no activity at the FP-1 receptor, they may still have an as yet unidentified 
physiological role, and may prove useful in interpreting hepcidin-25 concentrations.  
In this chapter, concentrations of hepcidin isoforms will be investigated in samples from 
individuals with iron overload [e.g. haemochromatosis, congenital dyserythropoietic anaemia 
(CDA II), non-alcoholic fatty liver disease], and iron deficiency (e.g. IDA, ACD). Hepcidin 
isoforms will also be investigated in samples from individuals known to have sepsis, which is 
known to induce hepcidin-25 synthesis through inflammatory cytokine activity. Furthermore, the 
correlation between individual hepcidin isoforms will be explored to identify if this changes 
between disease states. 
 
The aims of this chapter are as follows: 
• Investigate the concentration of hepcidin isoforms in individuals with IDA, ACD, ID, and 
Sickle Cell Anaemia. 
• Investigate the concentration of hepcidin isoforms in individuals with hereditary 
haemochromatosis of varying genotypes, non-alcoholic fatty liver disease, and non-HFE 
iron overload. 




5.2 Materials and Methods 
Iron-deficient anaemia (IDA) was defined as a low haemoglobin (normal range, males; 130–
165, females; 115–155 g/dL), a low TSAT [normal range (males & females); 20–50 %], a raised 
TIBC [normal range (males & females); 50–72 µmol/L] and a low ferritin (normal range, males; 
20–300, females; 20–200 µg/L). Anaemia of Chronic Disease (ACD) was defined as a low 
haemoglobin, a raised ferritin, a low TSAT, and a low TIBC. Iron-deficiency without anaemia 
was identified as a low ferritin concentration but a normal haemoglobin concentration.  
5.2.1 Patient samples 
Patients with hereditary haemochromatosis and non-haemochromatosis related iron overload 
attended a liver outpatient’s clinic at King’s College Hospital, London for routine monitoring. 
Patients with sickle cell anaemia, and CDA attended a haematology outpatient’s clinic, also at 
King’s College Hospital again for routine monitoring. During the clinics a serum (BD Vacutainer 
SST II Advance) sample was taken for routine biochemical tests (including ferritin, CRP, TIBC, 
iron, creatinine) as part of their on-going care. Biochemical tests were undertaken within the 
Blood Sciences Laboratory of King’s College Hospital, in accordance with local procedures 
(Chapter 3.2.7). The soluble transferrin receptor (STfR, LLoQ: 3 nmol/L) was measured by 
ELISA (R&D Systems, Minneapolis, USA). The manufacturer suggested target range for STfR is 
(males and females) is 8.7–28.1 mol/L. 
After completion of all biochemical tests excess serum was stored into 1.5 mL protein 
LoBind tubes at -20 ºC, for up to six months until analysis for hepcidin isoforms. All samples 
were taken as a part of routine care, excess sample was fully anonymised, and all linkages with 
the sample to the patient removed, therefore review by a research ethics committee was not 
required, in accordance with Royal College of Pathologists, and Human Tissue Act Guidelines 
(Marks, 2012, Human Tissue Authority, 2017). Time taken between collection of the sample and 
storage for hepcidin measurement was approximately 6 hours, during this time the sample was 
stored at 2–8 ºC. 
Samples obtained from healthy volunteers that were used to establish a reference 




5.2.2 Analytical methods 
Hepcidin isoforms were measured in singlicate, with a set of calibration solutions and IQCs at 
the beginning and end of each assay, and an IQC every batch of 10 samples using the LC-HR-
MS method previously described (Section 3.2). Biochemical tests were undertaken within the 
Blood Sciences Laboratory of King’s College Hospital, in accordance with local procedures 
(details Chapter 3.2.5). The soluble transferrin receptor (STfR, LLoQ: 3 nmol/L) was measured 
by ELISA (R&D Systems, Minneapolis, USA). The manufacturer suggested target range for 
STfR is (males and females) is 8.7–28.1 mol/L.  
 
5.2.3 Statistical analysis 
Statistical analysis was performed using Analyse-it (Analyse-it Software Ltd, Leeds, UK) for 
Microsoft excel, and SPSS for Windows, version 23.0 (SPSS Incorporated, Chicago, USA). 
Normality of data distribution was assessed using the Shapiro–Wilk test. Relationships were 
explored using Spearman’s rank correlation (r), simple linear regression analysis (R2), the 
Mann–Whitney U (grouped data), or the Wilcoxon signed-rank (matched pairs) test. A p-value < 
0.05 was considered statistically significant. Where more than 1 sample from a patient was 




Demographics of samples analysed are given in Table 5.1, and statistical significance between 
groups compared to controls is given in Table 5.2. Ten samples were obtained from individuals 
that had IDA, 10 samples from individuals with ID, 18 samples from individuals with ACD, 12 
samples from individuals with SCA (7 HbSS, and 5 HbSC), and 4 samples from an individual 
with CDA II. A single sample was obtained from each individual, except for 1 individual that had 
CDA II where 4 samples were obtained. A further 9 samples were received from individuals that 
had a low TSAT and haemoglobin consistent with IDA, but a ferritin concentration that was 
within the normal range, CRP was also raised in these 9 samples (Table 5.1).  
Hepcidin-25 was significantly lower (p = < 0.0001) in all groups as compared to 
controls, except in patients with ACD where hepcidin-25 was significantly compared to all other 
groups (p = < 0.0001) (Figure 5-1). Hepcidin-25 was detected in all samples from individuals 
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with ACD, but it was only detected in 1 (10 %), 1 (10 %), 1 (25 %), and 4 (33 %) samples from 
individuals with IDA, ID, CDA II, and SCA, respectively. In samples from individuals with IDA 
with a ferritin concentration within the normal range, hepcidin-25 was only detected in 3 (33 %) 
samples, and there was no significant difference in the hepcidin-25 concentration measured in 
this group and in samples from individuals with IDA but a low ferritin concentration (p = 0.40).  
Hepcidin isoforms other than hepcidin-25 were only detected in patients with ACD. 
Hepcidin-20, -22, and -24 were detected in 18 (100 %), 6 (33 %), and 15 (83 %) of these 
samples respectively (Figure 5-2). In samples from patients with ACD, hepcidin-25 was strongly 
correlated to hepcidin-24 (N = 15, r = 0.83, p = < 0.0001), and hepcidin-22 (N = 6, r = 0.83, p = 
< 0.05), but less so to hepcidin-20 (N = 18, r = 0.52, p = < 0.05). Hepcidin-24 was likewise 
strongly correlated to hepcidin-22 (N = 6, r = 0.83, p = < 0.05), and hepcidin-20 (N = 15, r = 
0.87, p = < 0.0001). Hepcidin-22 was not correlated with hepcidin-20 (N = 6, r = 0.54, p = 0.27). 
With regards to the correlation of hepcidin isoforms with biochemical parameters, hepcidin-25 
was only correlated to ferritin (r = 0.85, p = < 0.0001), as was hepcidin-24 (r = 0.72, p = < 0.05), 
and hepcidin-20 (r = 0.57, p = < 0.05). 
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Table 5.1. Clinical and demographic data for controls and samples from individuals with IDA, ACD, ID, SCA and CDA II. Data shown as median (range), 
ND = Not detected (< 1 µg/L). 
 
Controls 
(N = 41) 
IDA 
(N = 10) 
IDA  
(normal ferritin, N = 9) 
ACD 
(N = 18) 
ID 
(N = 10) 
SCA 
(N = 12) 
CDA II 
(N = 4) 
Male (%) 44 40 100 6 10 67 100 






























(< 2–13) < 2 
































































Soluble transferrin receptor 
(nmol/L) - - - - - 
65.5 
(32.5–142.0) - 
Hepcidin-20 (µg/L) ND ND ND 8 (2–72) ND ND ND 
Hepcidin-22 (µg/L) ND ND ND 9 (3–88) ND ND ND 
Hepcidin-24 (µg/L) ND ND ND 8 (4–45) ND ND ND 
















Table 5.2. Statistical significance between groups by variable using the Mann–Whitney U 
test (statistically significant, p = < 0.05). 
 p-value 
Controls vs.  
IDA 
Controls vs.  
ACD 
Controls vs.  
ID 
Controls vs.  
SCA 
Age  0.49 < 0.0001 0.27 0.05 
CRP  0.28 < 0.0001 0.06 0.79 
Ferritin  < 0.0001 < 0.0001 < 0.0001 0.52 
Iron  < 0.0001 < 0.0001 < 0.0001 < 0.05 
TIBC  < 0.001 < 0.0001 0.11 0.59 
TSAT < 0.0001 < 0.0001 < 0.0001 < 0.05 
Hepcidin-20  - - - - 
Hepcidin-22  - - - - 
Hepcidin-24 - - - - 






Figure 5-1. Concentrations of hepcidin-25 in controls, and samples from individuals with IDA, IDA (normal ferritin), ID, CDA II, and SCA (number of 
































Figure 5-2. Concentrations of hepcidin-20, hepcidin- 22, hepcidin-24, and hepcidin-25 in 
samples from individuals with ACD (number of samples in parentheses). 
 
5.3.2 HFE-related and non-HFE related iron overload 
In total, 86 samples were received from patients with HFE-related iron overload; of these sixty 
samples were obtained from 33 individuals that were HFE C282Y homozygotes 
(C282Y/C282Y), 6 samples from 4 individuals that were HFE C282Y heterozygotes (C282Y), 11 
samples from 5 individuals that were HFE C282Y compound heterozygotes (C282Y/H63D), and 
9 samples from 7 individuals that were HFE H63D heterozygotes (H63D). In addition, 12 
samples were received from 10 individuals with NAFLD, and 11 samples from 5 individuals that 
had non-HFE iron overload. Demographics of samples analysed are given in Table 5.3, and 
statistical significance between groups and controls is given in Table 5.4.  
 Hepcidin-25 was not detected in 42 and 17 % of samples from HFE C282Y 
homozygotes and HFE C282Y heterozygotes, retrospectively. However, hepcidin-25 was 
detected in all samples from the other groups analysed. Hepcidin-25 was significantly lower in 
HFE C282Y homozygotes as compared to controls, and was significantly higher in HFE H63D 
















5.4). There was no significant difference in concentrations of hepcidin-25 between controls, 
HFE C282Y heterozygotes, and HFE C282Y compound heterozygotes (Table 5.4). Hepcidin-25 
was significantly higher (p < 0.05) in all groups as compared to HFE C282Y homozygotes, and 
HFE H63D heterozygotes. Individuals with non-HFE iron overload, and NAFLD had significantly 
higher (p < 0.05) hepcidin-25 concentrations as compared to HFE C282Y heterozygotes, and 
HFE C282Y compound heterozygotes. Hepcidin-25 was significantly higher in individuals with 
non-HFE iron overload as compared to individuals with NAFLD (p < 0.05), but not compared to 
HFE C282Y compound heterozygotes (p = 0.76). There was no significant difference (p = 0.38) 
in hepcidin-25 between HFE C282Y compound heterozygotes and those individuals with 




Table 5.3. Clinical and demographic data for controls and patients with haemochromatosis of different genotypes, NAFLD, and in patients with non-HFE 
iron overload. Data shown as median (range), ND = Not detected (1 µg/L). 
 
Controls 
(N = 41) 
C282Y/C282Y 
(N = 33) 
C282Y 
(N = 4) 
C282Y/H63D 





(N = 5) 
NAFLD 
(N = 10) 
Male (%) 44 75 30 100 89 82 83 













CRP (mg/dL) 3 (< 2–10) - - - - - 
3 
(< 2–14) 




















































Hepcidin-20 (µg/L) ND ND ND ND ND 1 (1–2) ND 
Hepcidin-22 (µg/L) ND ND ND ND ND ND ND 
Hepcidin-24 (µg/L) ND ND ND ND ND 4 (3–4) ND 


























%age of samples with 




Table 5.4. Statistical significance between groups by variable using the Mann–Whitney U 


























































































Ferritin  < 0.05 0.07 < 0.01 < 0.001 < 0.05 < 0.05 
Iron  < 0.0001 0.15 < 0.05 < 0.05 0.09 0.33 
TIBC  < 0.0001 0.73 0.39 0.39 0.09 < 0.05 
TSAT < 0.0001 0.19 0.23 0.10 < 0.05 0.94 





Figure 5-3. Concentrations of hepcidin-25 in controls, in individuals with hereditary haemochromatosis of various genotypes, individuals with non-HFE 
































Fourteen samples were obtained from individuals with sepsis; demographics are given in Table 
5.5. Hepcidin-20, -22, -24, and -25 were detected in 9 (64 %), 8 (57 %), 12 (86), and 14 (100 %) 
samples. Hepcidin-25 was significantly (p = < 0.0001) raised as compared to controls (Figure 
5-4).  
 
Table 5.5. Clinical and demographic data for controls and patients with sepsis. Data 
shown as median (range). 
 
Controls 
(N = 41) 
Sepsis 
(N = 14) p-value 
Male (%) 44 36 - 
CRP (mg/dL) 3 (< 2–10) 
189 
(28–562) < 0.0001 
eGFR (mL/min/1.73 m2) - 56 (6–173) - 
Ferritin (µg/L) 66 (20–348) 
307 
(36–1343) < 0.0001 
Iron (µmol/L) 16.4 (7.3–31.7) 
2.0 
(1.0–9.7) < 0.0001 
TIBC (µmol/L) 57 (46–70) 
37 
(23–80) < 0.0001 
TSAT (%) 29 (12–63) 
5 
(1–13) < 0.0001 
Haemoglobin (g/dL) - 93  (64–140) - 
Hepcidin-20 (µg/L) ND 2 (<1–45) - 
Hepcidin-22 (µg/L) ND 3 (<1–18) - 
Hepcidin-24 (µg/L) ND 9 (<1–30) - 
Hepcidin-25 (µg/L) 8 (1–31) 
92 























































5.3.4 Relationship of hepcidin isoforms between disease states 
The correlations of each hepcidin isoform (concentrations from each disease state grouped, not 
analysed separately) to each other are given in Figure 5-5, Figure 5-6, and Figure 5-7. 
Hepcidin-25 was strongly correlated with hepcidin-24 (N = 50, r = 0.890, p = < 0.0001), but less 
so with hepcidin-22 (N = 17, r = 0.62, p = < 0.001), and hepcidin-20 (N = 103, r = 0.62, p = < 
0.0001). Hepcidin-24 was also strongly correlated with hepcidin-22 (N = 16, r = 0.85, p = < 
0.0001), but less so with hepcidin-20 (N = 44, r = 0.73, p = < 0.0001). Hepcidin-22 was strongly 
correlated with hepcidin-20 (N = 14, r = 0.87, p = < 0.0001).  
There was no statistically significant difference (p = 0.89) in the hepcidin-25:hepcidin-24 
ratio between samples from individuals with ACD, sepsis, CKD, and samples from individuals 
pre-haemodialysis (Figure 5-8). However, samples from individuals with sepsis had a 
statistically significant raised median hepcidin-25:hepcidin-20 ratio  as compared to individuals 
with CKD (p = < 0.05), and pre-haemodialysis (p = < 0.001). With regards to the ratio of 
hepcidin-24:hepcidin-20, samples from individuals with ACD had a significantly raised ratio as 
compared to those samples taken pre-haemodialysis (p = < 0.05). Also samples from 
individuals with sepsis had a significantly raised hepcidin-24:hepcidin-20 ratio as compared to 
samples from individuals with CKD (p = < 0.05), and those samples taken from individuals pre-






Figure 5-5. Scatterplots of hepcidin-25 with (A) hepcidin-20, (B) hepcidin-22, and (C) 
hepcidin-24. Solid line = simple linear regression, dashed lines = 95 % confidence 
intervals. 
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Figure 5-6. Scatterplots of hepcidin-24 with (A) hepcidin-20, and (B) hepcidin-22. Solid 
line = simple linear regression, dashed lines = 95 % confidence intervals. 
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Figure 5-7. Scatterplot of hepcidin-22 with hepcidin-20. Solid line = simple linear 
regression, dashed lines = 95 % confidence intervals. 
 












































































































































5.4.1 Hepcidin in iron deficiency anaemia (IDA) and iron deficiency (ID) 
Individuals with ‘true’ IDA (i.e. iron-deficient anaemia, without inflammation or other confounding 
factors) would be expected to have low hepcidin-25 concentrations to ensure maximal iron 
absorption. Certainly, this is what is shown in the samples analysed here, where individuals with 
IDA had significantly lower hepcidin-25 concentrations as compared to controls, and in most 
cases hepcidin-25 was below the LLoQ of the assay. This finding has also been reported by 
other investigators (Ganz et al., 2008; Kroot et al., 2010; Bregman et al., 2013).  
A sub-set of samples analysed were from individuals with IDA that had a ferritin within 
the reference range, and a markedly raised CRP. The median hepcidin-25 concentration from 
this subset was comparable to those with true IDA, but the range of hepcidin-25 concentrations 
measured were slightly broader. The broader range of hepcidin-25 concentrations measured 
most likely reflects the up-regulation of hepcidin-25 synthesis due to inflammation and raised 
circulating cytokines (e.g. IL-6), as identified by a raised CRP. Furthermore, these individuals 
also had significant renal impairment as indicated by a low eGFR, again possibly contributing to 
the raised hepcidin-25 as compared to samples from those with ‘true’ IDA. It is interesting that 
despite the markedly raised concentrations of CRP present in these individuals, hepcidin-25 
was still low and even non-detectable in some samples. Clearly, in these individuals, the down-
regulation of hepcidin-25 from reduced iron stores via the BMP-6-HJV-SMAD pathway takes 
precedence over the stimuli obtained from likely increased concentrations of circulating IL-6 
acting on the JAK/STAT pathway. Hepcidin-20, -22, nor -24 were present in any sample from 
individuals with IDA, which would be expected if they were degradation products of hepcidin-25 
since there was little to no hepcidin-25 detected.  
In samples from individuals with ID, hepcidin-25 was low, and in many samples, non-
detectable. Given that the life span of erythrocytes is approximately 120 days, this finding 
reflects that hepcidin-25 reacts more rapidly to changes in iron status than haemoglobin 
content. 
 
5.4.2 Hepcidin in anaemia of chronic disease (ACD) 
In ACD, plasma cytokines, particularly IL-6 are elevated, which in-turn induce hepcidin-25 
synthesis (Raj, 2009). Therefore, it is not surprising that in samples analysed here from 
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individuals with ACD, hepcidin-25 was significantly raised (some 6-fold) as compared to the 
control group and individuals with IDA. This finding has also been reported by other 
investigators (Kroot et al., 2010; Lasocki et al., 2010; Bergamaschi et al., 2013). Unlike samples 
from individuals with IDA or ID, N-truncated isoforms of hepcidin-25 were present in almost all 
samples, in-particular hepcidin-20 that was present in every sample. A likely reason for the 
presence of these isoforms is degradation of hepcidin-25 concentrations in-vitro, which is itself 
present in these samples at raised concentrations due to an increase of synthesis. Of course, 
ACD has a complicated pathogenesis, and patients with ACD will likely have other co-
morbidities that may also cause increases in plasma hepcidin-25 concentrations, such as 
reduced kidney function.  
 
5.4.3 Hepcidin as a tool to distinguish between IDA and ACD 
It has been hoped that measurement of hepcidin-25 may be a useful tool in helping to 
distinguishing IDA from ACD. In the samples measured here, a low or non-detectable 
hepcidin-25 concentration would suggest IDA, and a raised hepcidin-25 concentration would 
suggest ACD. However, there were still samples from individuals with IDA and ACD where 
hepcidin-25 was within the range measured in controls.  
When measured in isolation (without other markers of irons status) hepcidin-25 offers 
no real benefit compared to other markers of iron status in individuals with IDA, simply because 
in the samples analysed here all had a low ferritin and TSAT, and a raised TIBC, which are all 
consistent with IDA, and are well known, and well used criterion for diagnosing IDA (Goodnough 
et al., 2010). Hepcidin-25 measurement does have potential in the diagnosis of IDA from ACD, 
when interpreted together with other markers of iron status (e.g. ferritin), and this approach has 
proved successful in patients with inflammatory bowel disease (Bergamaschi et al., 2013), 
critical illness (Lasocki et al., 2010), rheumatoid arthritis (van Santen et al., 2011), and cancer 
related anaemia (Shu et al., 2014). However, there were still samples from individuals with ACD 
that had a hepcidin-25 that was within the ‘normal’ range. Given hepcidin-20 was detected in all 
samples from individuals with ACD, it is interesting to consider that if ACD is suspected, and 
hepcidin-25 is within the reference range, presence of hepcidin-20 could be used as a marker 
for ACD. However, much larger studies are required to fully evaluate this hypothesis, but it does 
suggest a possible role for hepcidin-20 measurement in clinical practice. 
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Isolated hepcidin-25 measurement has the advantage that it would indicate the ability 
for iron to be absorbed. For example, if hepcidin-25 was found to be significantly raised, oral 
iron may not be effectively absorbed, but treatment with IV iron could be administered 
immediately, preventing the adverse effects of oral iron (e.g. gastrointestinal upset), and 
reducing delays in treatment. Certainly, the usefulness of measuring hepcidin-25 to personalise 
the optimal route of iron (i.e. oral or IV) has been indicated in patients with IDA (Bregman et al., 
2013). Furthermore, a significantly elevated hepcidin-25 concentration in an individual with IDA 
is almost diagnostic of Iron Refractory Iron Deficient Anaemia, which is caused by a mutation in 
the TMPRSS6 gene, although confirmation by gene sequencing is recommended (Girelli et al., 
2016). 
Diagnosing ACD with concomitant ID is difficult. For example, inflammatory bowel 
disease is associated with frequent blood loss and iron-deficiency. Detection of ID is difficult 
using currently available markers of iron-status, such as ferritin, in part, because ferritin, is an 
acute-phase protein, and is elevated during infection/inflammation, even when iron deficiency is 
present. An algorithm including the soluble transferrin receptor is available (Goodnough et al., 
2010), however, measurement of the soluble transferrin receptor is not widely available, and 
reference ranges are method dependent. In such complicated situations, measurement of 
hepcidin-25 has shown to be useful in differentiating between ACD, IDA and those individuals 
with both ACD and ID. Individuals with ACD and concomitant ID have a hepcidin-25 
concentration that is lower than those with ‘pure’ ACD, but raised compared to those with IDA. 
This approach has been used successfully in patients with rheumatoid arthritis (van Santen et 
al., 2011). Unfortunately, samples were not available to investigate this in the work undertaken 
here. 
 
5.4.4 Hepcidin in Sickle Cell Anaemia and Congenital Dyserythropoietic Anaemia 
The samples analysed here were from individuals who were not known to be undergoing a 
crisis, and the hepcidin-25 concentration was significantly lower than those measured in 
controls. This would be expected as almost all (92 %) samples had a low haemoglobin, and 
therefore hepcidin-25 synthesis would be suppressed to ensure maximal iron absorption for 
effective erythropoiesis. Furthermore, concentrations of the soluble transferrin receptor were 
raised as compared to the manufacturer’s suggested reference range (8.7–28.1 nmol/L), which 
is consistent with increased erythropoiesis. This increased erythropoiesis would further drive the 
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suppression of hepcidin-25 synthesis. Although only a small number of samples were analysed, 
the data generated does confirm findings from other investigators that in individuals with SCA, 
hepcidin-25 production is suppressed in line with increased erythropoiesis (Kroot et al., 2009b; 
El Beshlawy et al., 2012; Karafin et al., 2015). As in individuals with IDA or ID, there were no N-
truncated isoforms of hepcidin-25 present, which would be expected if they are degradation 
products of hepcidin-25. The clinical usefulness of hepcidin-25 measurement in individuals 
specifically with SCA is currently limited. However, hepcidin-25 measurement has been 
suggested as a diagnostic marker of severe iron overload in patients with β-thalassemia major, 
although larger studies are required to confirm this finding (Kaddah et al., 2017). 
In the four CDA II samples analysed here, hepcidin-25 was below the LLoQ in all except 
1 sample where it was 3 µg/L. These findings are in-keeping with other published results, in that 
hepcidin-25 is inappropriately low given the degree of iron overload, and the ineffective 
erythropoiesis down regulates hepcidin-25 expression in these individuals (Casanovas et al., 
2011). Further studies are required to identify, what, if any role measurement of hepcidin-25 has 
in management of patients with CDA II.  
 
5.4.5 Hepcidin in HFE-related iron overload 
Given the samples analysed were from individuals known to have mutations in the HFE gene, 
and who were being treated for iron overload by regular venesection, therefore it is not 
surprising that many had non-detectable or low serum concentrations of hepcidin-25. Individuals 
that were C282Y homozygous had hepcidin-25 concentrations which were inappropriately low 
for the iron load present, as indicated by the low ferritin:hepcidin-25 ratio, and support findings 
reported by other investigators (van Dijk et al., 2008; Piperno et al., 2007). Hepcidin-25 
concentrations measured in C282Y homozygotes were broad, with some samples having non-
detectable concentrations of hepcidin-25, whereas others had concentrations of hepcidin-25 
that were within the range measured in controls. This most likely reflects the varying periods of 
time these individuals have been undergoing venesection. For example, it has been shown by 
other investigators that in untreated C282Y homozygotes, hepcidin-25 declines over time from 
when they are first diagnosed (i.e. untreated) to when undergoing regular (i.e. maintenance) 
venesection (van Dijk et al., 2008), most likely due to suppression of hepcidin-25 synthesis in 




The hepcidin-25 concentration in C282Y heterozygotes was not found to be significantly 
different from the control group, but was significantly raised as compared to individuals with the 
C282Y/C282Y genotype. The H63D polymorphism (either heterozygote or homozygote) is 
generally considered to have little clinical significance (Kelley et al., 2014). This may explain 
why there was no significant difference in concentrations of hepcidin-25 between C282Y 
heterozygotes, and C282Y/H63D compound heterozygotes (i.e. they have the same functional 
phenotype). Given the H63D mutation has no effect on HFE protein function, and has little 
clinical significance with regards to iron overload, the significantly raised concentrations of 
hepcidin-25 in samples from H63D heterozygotes, and H63D homozygotes compared to 
controls and the other HFE mutations studied, reflects increased hepcidin-25 synthesis in 
response to iron overload, which is likely due to other reasons and not the H63D mutation. 
Although specific clinical details are not available for the individuals studied here, all are known 
to have diabetes, dysmetabolic iron overload syndrome or other co-morbidities that could 
account for the iron overload present. 
 Overall, the concentrations of hepcidin-25 measured in individuals with various HFE 
genotypes are as would be expected. It should be remembered that all samples were from 
individuals undergoing regular venesection to deplete iron stores or for maintenance purposes. 
Therefore, comparison could not be made between concentrations of hepcidin-25 in recently 
diagnosed individuals and those undergoing venesection for maintenance purposes. The 
usefulness of hepcidin-25 measurement in individuals with HFE-related haemochromatosis has 
not been ascertained, but is likely to be limited. For example, ferritin, TIBC, and TSAT are all 
available in most general hospitals, and are well established markers of iron status and iron 
overload. Furthermore, genetic sequencing of the HFE gene is available and would provide a 
100 % confirmation of the presence of a HFE mutation. Hepcidin-25 has been suggested as 
being a useful tool for monitoring the effectiveness of treatment with venesection, to ensure that 
hepcidin-25 synthesis is not fully suppressed, which would exacerbate iron absorption and 
overload (van Dijk et al., 2008). However, larger clinical studies are required to fully investigate 
this proposal.  
 
5.4.6 Hepcidin in non-HFE related iron overload, and non-alcoholic fatty liver disease 
The samples analysed here were from individuals with non-HFE related iron overload that had 
been previously screened and found not to have any genetic mutations in the HFE, TfR2, HJV, 
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or SLC40A1 genes that are known to cause haemochromatosis, and had no evident reason for 
iron overload. In these samples hepcidin-25 was raised in response to increased iron stores, 
and therefore iron absorption should be suppressed, but this was not the case. These 
individuals have a phenotype like that of ‘ferroportin disease’, whereby hepcidin-25 is raised but 
there is ‘hepcidin resistance’ (Mayr et al., 2010), yet no known mutation in the FP-1 gene were 
found. This would suggest that there may be dysregulation between hepcidin-25 and FP-1, or 
that there is an unidentified mutation in FP-1 within these individuals. It has been reported that 
hepcidin-25 mediated ferroportin internalisation requires activation of the Janus Kinase2 protein 
for phosphorylation of FP-1 tyrosine residues 302 and 303 (De Domenico et al., 2009). 
However, another study has found this not to be the case and instead hepcidin-25 mediated 
ubiquitination of ferroportin involving lysine amino acids present between residues 229 and 269 
in the third cytoplasmic loop of ferroportin are required (Ross et al., 2012; Qiao et al., 2012). 
Currently, work is on-going to identify the cause of iron overload present in these individuals, 
and full genetic sequencing of the ferroportin gene and other iron-related genes is it be 
undertaken. In the samples analysed from individuals with NAFLD, hepcidin-25 was significantly 
(although only marginally) raised as compared to controls, which supports findings from other 
investigators (Boga et al., 2015; Senates et al., 2011). 
 
5.4.7 Hepcidin in sepsis 
Hepcidin-25 synthesis is known to be induced by cytokines, in particular IL-6, which are raised 
in the acute phase response (Damas et al., 1992; Nemeth et al., 2004). Therefore, it is not 
surprising that in these samples, hepcidin-25 was significantly raised as compared to controls, 
although there were still some samples where hepcidin-25 was within the range measured in 
controls. Almost all individuals had a low haemoglobin, and iron indices (e.g. ferritin, TIBC) that 
are consistent with ACD, although it is not possible to identify whether these individuals had 
concomitant iron deficiency. It is interesting that hepcidin-20, -22, and -24 were detected in 
many samples, and besides hepcidin-25, hepcidin-24 was the most abundant isoform of 
hepcidin in the samples analysed.  
 
5.4.8 Relationship of hepcidin isoforms  
One possible theory on the formation of each N-truncated isoform of hepcidin-25 is that each is 
sequentially degraded to a smaller form. If this were the case then there should be a good 
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correlation between each isoform. In part, this is reflected in the data here, especially for 
hepcidin-25 and hepcidin-24 for which there was a strong and significant correlation in all 
disease states investigated, and when results from all samples were combined. There was also 
a strong correlation of hepcidin-24 to hepcidin-22, but a weaker correlation of hepcidin-22 to 
hepcidin-20. There were generally poor correlations between non-adjacent hepcidin isoforms 
(i.e. between hepcidin-25 and hepcidin-20, hepcidin-24 and hepcidin-20). These data would 
suggest that each hepcidin isoform is sequentially degraded to each other. In no sample was 
hepcidin-19, 21, or -23 identified by retrospective data interrogation; of course, without a 
reference compound to confirm whether these isoforms are extracted or retained on the LC 
column this can only be tentatively concluded. 
  There was little difference in the ratio of hepcidin isoforms between the 
conditions investigated. This may be because of relatively low sample numbers or that the 
conditions investigated are all similar to each other in terms of CRP concentrations – a factor 
known to influence hepcidin-25 concentrations through up-regulation of synthesis. Certainly, 
sepsis is an extreme version of ACD and these two groups had raised CRP concentrations. The 
ratio of hepcidin-25 to hepcidin-20, and hepcidin-24 to hepcidin-20, however, were significantly 
lower in samples taken pre-haemodialysis compared to other groups; this is reflective of the 




The LC-HR-MS method developed here has shown to be capable of measuring hepcidin 
isoform concentrations in samples from a wide range of iron disorders. Hepcidin-20, -22, and -
24 were only present when hepcidin-25 was significantly raised, and hepcidin-25 was strongly 
correlated to hepcidin-24. The clinical importance of this finding requires further investigation, 
but measurement of hepcidin-25 may have a role in the differential diagnosis of IDA from ACD, 
and in assessing treatment with either oral or IV iron. The role of measuring hepcidin-25 in 
















Chapter 6 General Discussion 




The discovery of hepcidin-25 in 2001 has considerably advanced our understanding of iron 
metabolism, and the mechanisms involved in some disorders of iron deficiency or excess (e.g. 
IDA, haemochromatosis). Furthermore, novel therapies are being developed for the treatment of 
iron-overload and iron deficiency such as hepcidin-25 agonists, antagonists, and ‘mini-
hepcidins’ that mimic the actions of endogenous hepcidin-25. It has been, and still is, hoped that 
hepcidin-25 may be an additional tool in assessing and treating iron status in a clinical setting, 
and may even replace traditional markers of iron status (e.g. ferritin, TIBC, TSAT). 
 
6.2 Analytical aspects of hepcidin measurement  
Despite hepcidin-25 having been first identified in 2001, there is no ‘gold-standard’ assay 
available, and there is a lack of continuity between assays, which hampers the use of hepcidin-
25 measurement in a clinical setting (Kroot et al., 2009; Kroot et al., 2012; van der Vorm et al., 
2016). One area of confusion is over the term ‘hepcidin’. This term is used to refer to hepcidin-
25 specifically, or used to refer to all known and commercially available isoforms of hepcidin 
together, i.e. hepcidin-20, -22, -24 and -25. It may also be used to include other potential, non-
commercially available isoforms of hepcidin-25; hepcidin-19, -21, and -23. This means, 
especially for immunoassays where cross-reactivity between these isoforms may exist, it is not 
clear exactly what is being measured. Additionally, despite hepcidin-20, -22, and -24 having 
been identified, these additional hepcidin-25 isoforms are rarely measured and, until the work 
undertaken here, no full validated method for the quantitation of all commercially available 
hepcidin isoforms has been published (Handley et al., 2017, Appendix B). 
 
6.2.1 Reference compounds 
To date, there is still no fully traceable certified standard available for hepcidin-25. Availability of 
a certified reference compound enables full traceability of the specified concentration. During 
the work herein, hepcidin-25 used for the initial work showed on the analytical data sheet an 
HPLC purity of 98.4 %. However, some months later, a revised analytical data sheet was 
published adding an additional statement that there was a peptide content of 68.8 % (Figure 
6-1. In essence, the HPLC purity defines that 1.6 % of the compound is comprised of impurities, 
but of the 98.4 % that is ‘pure’ there is only 68.8 % that is hepcidin-25 itself. As such, when 
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producing calibration solutions from this solid, only 67.7 % of that which is weighed is actually 
hepcidin-25 (68.8 % of the 98.4 %); any investigators that made calibrations solutions or 
validated prior to this revised data-sheet, or that did not acknowledge the relevance of the 
peptide content could be inaccurate by 30 %.  
Indeed, this realisation was made by investigators in a round robin for hepcidin-25, 
whereby hepcidin-25 purchased from Bachem (Torrance, USA) was assumed to be 100 % 
pure, but the net peptide content was actually 68.8 % (Kroot et al., 2012). These findings raise 









Published assays for hepcidin-25 measurement broadly fall into 2 main groups: immunoassay 
and mass-spectrometry based. Advantages of immunoassays for hepcidin-25 are that minimal 
specialised equipment is required, kits are commercially available, relatively high-throughput is 
obtainable, and the assay has already been validated by the manufacturer (although in-house 
validation of the assay is always recommended). The main disadvantage however, is that 
isoforms of hepcidin-25 may cross react with the ‘specific’ hepcidin-25 antibodies falsely 
elevating the ‘measured’ hepcidin-25 concentration. Certainly, the comparison of the LC-HR-MS 
assay developed here to a commercially available ELISA showed concentrations of hepcidin-25 
were some 10-fold higher measured using the ELISA. It is interesting to note that the N-
truncated hepcidin isoforms were not detected in any of these comparison samples, therefore 
cross-reactivity with these isoforms was not the cause of the discrepancy, and it may be 
attributed to other endogenous compounds present in the sample or an issue with calibration.  
Mass spectrometry has the potential to be more selective than immunoassays for hepcidin-25 
measurement, and has the advantage that each hepcidin-25 isoform can be separately 
quantified. However, this does not mean that MS based assays are more accurate than 
immunoassays, as was certainly shown in round robins for hepcidin-25 (Kroot et al., 2009; Kroot 
et al., 2012; van der Vorm et al., 2016). Additional complications can arise from an inappropriate 
selection of internal standard; some published MS based methods used hepcidin-24 as an 
internal standard (Swinkels et al., 2008; Tessitore et al., 2010; van der Weerd et al., 2012; Addo 
et al., 2016), until it was recently identified as being present in-vivo. The introduction of a 
commercially available isotopically labelled hepcidin-25, however, will do much to improve MS 
based assays (Ward et al., 2008). 
Mass spectrometry assays for hepcidin-25 can be broadly divided into SELDI/MALDI 
based methods, and LC-MS(/MS) based methods. SELDI/MALDI-TOF-MS based methods were 
some of the first assays published for hepcidin-25 (Tomosugi et al., 2006), likely due to these 
being ‘soft’ ionisation techniques enabling identification of a compound from its molecular ion, 
and analysis is rapid as there is no chromatography. However, because sample pre-treatment 
can be limiting, and there is no further separation of analyte from potential interfering 
compounds (such as liquid chromatography) accurate quantitation may be compromised, 
although the limitations can be reduced by thorough method validation and use of an 
appropriate internal standard. Some thoroughly validated methods have been published that 
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have shown these techniques to be applicable for the measurement of hepcidin-25 (Ward et al., 
2008; Kroot et al., 2010).  
SELDI/MALDI instruments are primarily based in academic and research laboratories, 
whereas in clinical laboratories LC-MS/MS instruments are common place, and it is these 
instruments that would be used for the quantitation of hepcidin-25 should the assay become 
used routinely within a clinical setting. Certainly, LC-MS/MS based methods for hepcidin-25 are 
becoming widely published (Wolff et al., 2013; Delaby et al., 2014; Lefebvre et al., 2015). The 
advantage of LC-MS/MS is that through sample preparation can be undertaken prior to analysis 
that, together with LC, helps to reduce the effect of interfering compounds on accurate 
quantitation. A consideration with this technique, however, is that when ESI is used, hepcidin-25 
(and N-truncated isoforms) has several charge states (primarily [M+3H]3+, [M+4H]4+, and 
[M+5H]5+), and in all published LC-MS/MS methodologies only a single charge state is 
monitored that is not consistent between methods; there may be sample-to-sample variability in 
isotope and charge state distribution, which would not be corrected for should only a single 
charge state be monitored. In the work undertaken here it was found that, although the charge 
state distribution did not vary significantly between samples it was very different in extracted 
samples to those observed when each individual hepcidin was infused separately into the MS 
(Figure 2-1 and Figure 2-2). This has implications in LC-MS/MS methodology as there is 
potential for an inappropriate charge state to be chosen during method development. When the 
method developed here was compared to an LC-MS/MS based assay that detected only a 
single charge state, there was a good correlation between results. Be this as it may, monitoring 
a minimum of 2 charge states per analyte would minimise the effect of this potential variable.  
An advantage of the method developed here is that by using LC-HR-MS, and acquiring data in 
full scan mode, all charge states and isotopes can be selected for post-acquisition data 
processing. Furthermore, data can be interrogated post-acquisition for analytes not initially 
targeted, as was undertaken here when investigating analyte stability and whether hepcidin-19, 
-21, or -23 were also present. 
 
6.2.3 Sample preparation 
LC-MS(/MS) methods published for hepcidin-25 primarily use solid phase extraction, although a 
few methods using protein precipitation have been reported. In the work undertaken here, 
protein precipitation was found to be an unsuitable sample preparation technique due to poor 
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process efficiency and inadequate sensitivity. Immunocapture was likewise not successful, most 
likely due to endogenous compounds found in serum interfering with antibody binding. Instead, 
after extensive development, solid phase extraction was considered the most suitable sample 
preparation technique. Certainly, the use of solid phase extraction is widely reported in the 
literature for hepcidin-25 measurement (Li et al., 2009; Wolff et al., 2013; Lefbevere et al., 
2015). Advantages of this technique, and the method developed here, are that: (i) 96-well plates 
are used to aid throughput, and (ii) the supernatant does not require evaporation and re-
constitution, either to improve sensitivity or to make it appropriate for injection into the LC 
system. The whole sample preparation time for 96 samples (including calibrators/IQCs) was 
approximately 2 to 2.5 hours, prior to analysis by LC-HR-MS - therefore quite applicable to 
batch analysis in a clinical setting. 
 
6.2.4 Analyte stability and hepcidin isoforms 
In clinical samples, all analytes were relatively stable for a few days when stored at 2–8 °C, but 
all had limited stability when stored at ambient room temperature. Therefore, in a clinical setting 
samples should either be frozen immediately if analysis is to be delayed, or stored at 2–8 °C 
should analysis be undertaken in the proceeding days after collection. If measurement of 
hepcidin isoforms is requested as an additional test, i.e. after all tests have been undertaken on 
a sample, this should be possible if the sample is refrigerated or frozen. 
It is interesting that when each individual hepcidin was added to stripped human serum, 
a decline in the concentration of an individual hepcidin (e.g. hepcidin-25) was not matched by a 
corresponding increase in another (e.g. hepcidin-24); except for hepcidin-22, where a decline in 
concentration was paralleled by an increase in hepcicin-20. A similar picture was present in 
clinical samples. Yet, all isoforms of hepcidin have been measured in patient samples, 
particularly those samples from individuals with ACD or sepsis, or where hepcidin-25 is raised. 
These findings are of interest as it not only strongly suggests that N-truncated isoforms of 
hepcidin-25 are not an artefact formed only upon storage or processing of samples, but that 
they do exist in-vivo. Since there was no concurrent increase in alternative isoforms, the decline 
in hepcidin concentrations measured during storage may be due to aggregation, or adsorption 
to the container wall or other endogenous compounds.  
It was interesting that all hepcidins were more stable in stripped human serum than in 
clinical samples; a possible explanation is that the process of ‘stripping’ human serum with 
 187 
 
charcoal may reduce enzyme activity as has been shown with bovine serum (Cao et al., 2009). 
Therefore, both enzyme activity and adsorption may both contribute to the decline in hepcidin 
concentrations during storage. This is further supported by a report where addition of protease 
inhibitors to the plasma from individuals in intensive care (e.g. individuals with raised hepcidin-
25 concentrations) minimised the decline in hepcidin-25, but did not completely inhibit it 
(Laarakkers et al., 2013). In-vivo, hepcidin-20, -22, and -24 are most likely formed by enzymatic 
cleavage of hepcidin-25, although it is not clear which enzymes are involved, nor whether each 
hepcidin isoform is sequentially degraded. Unfortunately, there has been little research into the 
enzymes responsible for the degradation of hepcidin isoforms. Dipeptidylpeptidase-4 has been 
suggested as being responsible for degradation of hepcidin-22 to hepcidin-20 as proline is 
present at the cleavage site of hepcidin-22, whereas the difference between hepcidin -25 and -
24 is the loss of an aspartic acid therefore an aspartic acid protease is most likely involved.  
 
6.3 Application of hepcidin measurement 
To date there is no firm evidence to support the clinical use for hepcidin-25 measurement in the 
diagnosis and management of disorders of iron metabolism. However, this is in-part due to the 
variability between currently available assays, and a lack of established reference range for 
various disorders (e.g. ID, ACD, SCA). 
 
6.3.1 Clinical usefulness of hepcidin-25 measurement  
Many clinically relevant conditions are known to influence hepcidin-25 (e.g. alcohol abuse, 
anaemia, severely reduced kidney function), therefore hepcidin-25 concentrations should be 
interpreted in conjunction with other established markers of iron status (e.g. ferritin, TIBC, 
TSAT), and the clinical details available. Ferritin is a well-known and used marker of iron stores, 
it is relatively inexpensive and widely available within hospital laboratories, even though it has 
several limitations (e.g. an acute phase reactant). Given hepcidin-25 is generally well correlated 
with ferritin, hepcidin-25 would be unlikely to replace ferritin as a marker of iron stores, nor 
would it replace TIBC/TSAT as a marker of circulating iron availability. It does, however, provide 
an indication of potential iron absorption from the gut, and iron release from macrophages, 
something which no currently available marker of iron status can. Ferroportin controls iron 
absorption and release, however since it is present in the cell membranes, rather than 
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circulating in plasma, direct measurement of this protein is not practical, although ferroportin 
activity can be quantified (Ward & Kaplan, 2012). Hepcidin-25 concentrations can be used as 
an indirect marker of ferroportin activity in a way that no other marker can. 
 Hepcidin-25 measurement has been shown to be valuable in the differential diagnosis 
of IDA from ACD, and may also prove useful in identifying ACD with concomitant ID 
(Bergamaschi et al., 2013; Lasocki et al., 2010; van Santen et al., 2011; Shu et al., 2014). 
Certainly, while undertaking the work here, several requests were received from clinicians 
requesting hepcidin-25 measurement in samples from individuals that have had long term IDA 
that has not responded to iron therapy in order to explain this clinical situation. Hepcidin-25 was 
below 1 µg/L in all cases indicating that the individuals should be able to appropriately absorb 
iron. In these cases, measurement of hepcidin-25 was not able to directly identify the cause of 
anaemia, but it was able to rule out an inappropriately raised hepcidin-25 as a factor in the IDA 
present. Monitoring hepcidin-25 in hereditary haemochromatosis to avoid complete suppression 
of its synthesis (via excessive phlebotomy), and iron hyperabsorption has been suggested 
(Girelli et al., 2016). However, whilst preliminary work suggests a value of hepcidin-25 in these 
situations, larger studies are required to assess the clinical effectiveness of this.  
 
6.3.2 Clinical usefulness of hepcidin-20, -22, and -24 measurement  
Very few studies have reported concentrations of hepcidin-20, and -22 in both healthy 
individual’s and those with disorders of iron metabolism, and besides the work published here 
(Handley et al., 2017) no studies have reported concentrations of hepcidin-24. In part, this is 
because (i) assays developed largely only include hepcidin-25, and (ii) as N-truncated isoforms 
of hepcidin-25 have shown to have little or no activity at the FP-1 receptor (Laarakkers et al., 
2013) they are considered of no benefit to be measured. However, hepcidin-20, -22 may have 
some antimicrobial activity (Ho et al., 2013), and measurement of hepcidin-20, rather than 
hepcidin-25, has been suggested to be helpful in the diagnosis of acute myocardial infarction 
(Suzuki et al., 2009).  
In the work undertaken here, hepcidin-20 would seem to have the potential to be a 
marker of kidney function as well as for ACD, although much larger studies are required to 
ascertain the clinical relevance of this finding. Even though hepcidin-20, -22, and -24 have little 
activity at the ferroportin receptor, given the considerable contribution of hepcidin-20, -22, and -
24 to the ‘total’ hepcidin concentration measured in patients with ACD, sepsis, and CKD in the 
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work here and in reports by another investigator (Campostrini et al, 2012), they should not be 
dismissed as ‘degradation products’ of no clinical use. It has been hypothesised that hepcidin-
20 is not simply a non-regulated degradation product of hepcidin-25, but instead it is degraded 
by yet unidentified enzymes in response to iron-deficiency or iron-overload; in a healthy 
population the ratio of hepcidin-25:hepcidin-20 increased with increasing ferritin concentrations 
(Campostrini et al., 2012). This is an interesting hypothesis, which in-part maybe supported by 
the finding here that in conditions where hepcidin-25 is raised (ACD, sepsis, CKD), generally 
hepcidin-20 is present, and so are hepcidin-22, and -24. Although, without a clear mechanistic 
explanation for the formation of hepcidin-20, -22, or -24, these may simply be formed via non-
regulated degradation.  
 
6.4 Further work 
Future work on hepcidin isoforms should first concentrate on the harmonisation of assays. 
Although a few round robins have been distributed, a formal scheme should be initiated to 
provide ongoing confidence into the comparability of published ranges from different 
methodologies. Limitations to this are that there is no traceable reference compound for 
hepcidin isoforms, and a potential lack of sample stability when samples are sent worldwide. 
However, the benefit of such a scheme is that comparison between assays, both between 
methodologies (i.e. immunoassay vs MS), and within methods (i.e. MS) can be undertaken. 
Such a scheme should include all isoforms of hepcidin currently available (hepcidin-20, -22, -24, 
and -25) since, even if they cannot be separately quantified by some methods, the effect of their 
presence on assay accuracy can be ascertained. Any newly developed assays should, where 
possible, include all available isoforms of hepcidin.  
Furthermore, larger studies should be undertaken in individuals with CKD, IDA and ACD 
to assess the concentrations of all hepcidins (including hepcidin-20, -22, -24, and -25) present, 
and whether measurement of hepcidin-20 is useful in determining kidney function and the 
diagnosis of ACD, as indicated in the preliminary work undertaken here. Again, further work on 
the formation of hepcidin-20, -22, and -24 would be of value, for example trying to identify the 





The measurement of hepcidin-25, and possibly other N-truncated isoforms are promising tools 
for the diagnosis and management of disorders of iron metabolism. Especially as hepcidin-25 
has been shown to be able to differentiate IDA from ACD, identify ID in ACD, and it can provide 
an indication as to an individual’s response to oral iron. The clinical role of hepcidin-20, -22, and 
-24 has not been ascertained, although the work here does suggest that hepcidin-20 maybe of 
use in determining kidney function and in the diagnosis of ACD, although larger trials are 
required to fully investigate this. Be this as it may, all hepcidin isoforms should always be 
measured where possible, and for these analytes to be used in routine clinical practice; (i) 
harmonisation of assays needs to be undertaken, (ii) the importance of hepcidin-20, -22, and -
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Background: Hepcidin-25 is the master regulator of iron homeostasis. N-truncated isoforms of 
hepcidin-25 have been identified (hepcidin-20, -22, -24), although data on the concentrations of 
these isoforms is sparse. 
Methodology: Serum was mixed with aqueous formic acid, and the supernatant loaded onto a 
96-well-SPE-plate. Eluted analytes were analysed using LC-HR-MS. Forty-seven paired 
dipotassium-EDTA human plasma and serum samples were analysed.   
Results: The LLoQ was 1 µg/L (all analytes). Accuracy and precision was acceptable. There 
was a good correlation (R2 > 0.90, all analytes) between matrices. The median (range) serum 
hepcidin-20, -22, -24, and-25 concentrations measured were 4 (1–40), 8 (2–20), 8 (1–50), and 
39 (1–334) µg/L, respectively. 
Conclusion: LC-HR-MS is widely applicable to the measurement of hepcidin-25, and truncated 
isoforms. 
 
